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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of liver disease 
globally, affecting approximately 88% of obese individuals. It is characterised by 
hepatic lipid accumulation >5%, which can lead to inflammation and the development 
of non-alcoholic steatohepatitis (NASH), but this process is not well understood. 
NASH can, in turn, progress to cirrhosis and hepatocellular carcinoma. Observational 
studies in rodents and humans suggest that NAFLD is associated with dysfunctional 
mitochondrial metabolism, namely increased levels of TCA cycle activity. However, it 
is unclear if/how this is linked to lipid accumulation in hepatocytes.  
 
To overcome the limitations of studying mitochondrial metabolism in currently used 
models, I utilised a human pluripotent stem cell (hPSC) model of NAFLD. These 
hPSCs were differentiated to hepatocyte-like cells (HLCs) and challenged with a 
cocktail of high energy substrates: lactate, pyruvate and octanoic acid (LPO). To 
determine the extent to which this model is representative of human NAFLD, I 
characterised patterns of lipid accumulation, and showed the presence of 
macrovesicular steatosis following challenge with LPO, which was associated with 
increased expression of lipid droplet associated PLIN2. In humans presenting with 
NAFLD ~90% develop macrovesicular steatosis, demonstrating the utility of this 
system in modelling NAFLD. Further, I performed a transcriptomic analysis and 
identified dysregulation of a number of NAFLD-associated genes, including CYP7A1, 
HMGCS2, SLC2A4, PLIN2, PPARA, PPARG, PPARGC1A and FASN. Pathway 
enrichment analyses revealed dysregulation of genes associated with the TCA cycle 
and oxidative phosphorylation.  
 
Analysis of respiration in steatotic HLCs revealed decreased maximal respiratory 
capacity in steatotic HLCs, indicating dysfunction in the electron transport chain 
(ETC), between respiratory complexes I-III. Stable isotopic tracing of TCA cycle-
associated metabolites revealed a truncation of the cycle, with inhibited conversion of 
succinate to fumarate, confirming dysfunction of succinate dehydrogenase 
(respiratory complex II in the ETC). Mitochondria were able to bypass this truncation 
 
  iii 
by increasing purine nucleotide cycle (PNC) activity, leading to replenishment of 
fumarate. Experimental depletion of fumarate in steatotic cells reversed the 
macrovesicular steatosis observed in LPO-challenged HLCs, with addition of 
exogenous fumarate leading to partial reversal of the phenotype. This demonstrates, 
for the first time, that fumarate is a driver of macrovesicular steatosis.  
 
Fumarate is also a negative regulator of dioxygenases, which include the ten-eleven 
translocation (TET) enzymes. The TETs oxidise 5-methylcytosine (5hmC) to 5-
hydroxymethylcytosine (5hmC). To determine whether TET activity was impacted by 
fumarate accumulation, I performed DNA immunoprecipitation sequencing to 
measure 5hmC. This revealed global changes in 5hmC in steatotic HLCs but only 
showed a limited of number of changes in protein coding and promoter regions. 
Changes in promoter regions displayed a moderate negative correlation with gene 
transcription. To determine whether fumarate impacted on gene transcription more 
broadly, further RNA sequencing analysis was performed, following inhibition of the 
purine nucleotide cycle. This showed decreased expression of lipid droplet associated 
PLIN2, and pathway enrichment analyses revealed disruption of pathways associated 
with cellular response to oxidative stress and iron ion homeostasis.  
 
Taken together, these studies provide evidence that in NAFLD, exposure to high 
energy substrates results in TCA cycle truncation, leading to compensatory rewiring 
of mitochondrial metabolism through increased purine nucleotide cycle activity. This 
compensatory rewiring, however, leads to the development of macrovesicular 
steatosis. Thus, using this model, I show for the first time that fumarate is a driver of 
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Lay Abstract 
Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease 
around the world, affecting almost 9 out of 10 people who are obese. The disease 
begins when the liver accumulates too much fat and stores this in structures called 
lipid droplets. Although high levels of fat in a cell can be toxic, storing fats in lipid 
droplets can protect the cell. However, having too much fat in the liver can lead to the 
development of inflammation. People with this inflammation are more likely to develop 
cirrhosis, where the liver becomes excessively scarred, and have an increased risk of 
developing liver cancer or needing a transplant. Currently, NAFLD can only be 
reversed through diet and exercise, or by having weight-loss surgery.  
 
To study NAFLD, I used a cell-based model by using human liver cells treated with a 
combination of chemicals to make them accumulate fat. DNA is found in all cells and 
is made up of small subunits called genes. These genes act as instructions for making 
proteins, which are the building blocks of cells. The genes can be turned on or off but, 
like the volume dial on a stereo, they can also be turned up or down, telling a cell to 
make more or less of a protein. I found that when liver cells accumulate fat, they 
change which genes are turned up or down. Some of the genes that were turned up 
are used by cells to make lipid droplets.  
 
I also found that a lot of genes were turned down. A lot of these genes provide 
instructions to make proteins for structures called mitochondria. Mitochondria are 
found in all cells in the body and use sugars and fats to generate most of the energy 
that the body needs, leading to them being called the “powerhouses of the cell”. When 
people develop NAFLD, mitochondria do not work as well and cannot use sugars and 
fats properly, but it is unclear how this is linked to disease. I used the cell model of 
NAFLD to study whether mitochondria in liver cells with excess fat stop working 
properly. I found that mitochondria in these cells use sugar differently to healthy cells 
and this leads them to make more of a chemical called fumarate. I found that when 
mitochondria make too much fumarate, this leads them to make bigger lipid droplets.  
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Fumarate is also important because it can directly affect the DNA in the cell. Genes 
sometimes have extra chemicals (methyl groups) attached to them at specific 
locations. The methyl group (5mC) can be converted to a hydroxymethyl (5hmC) 
group by a group of proteins called the ten-eleven translocation (TET) enzymes. In 
specific circumstances, these chemical groups can be used to instruct the gene to 
make a protein, stop making a protein, or to make more or less of it. Fumarate can 
prevent the TET enzymes from working, which also interferes with the conversion of 
5mC to 5hmC. However, I did not find evidence that the TET enzymes are responsible 
for turning up genes related to making proteins associated with lipid droplets. This 
indicates that, in NAFLD, fumarate affects proteins other than the TET enzymes, 
which can also influence how genes are turned on, off, up or down. This information 
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Chapter 1: Introduction 
1.1 The pathogenesis of non-alcoholic fatty liver 
disease (NAFLD) 
1.1.1 Background of NAFLD 
In 2016 The Lancet published a survey of 19.2 million people, which revealed that, for 
the first time in history, the number of overweight people around the world outnumbers 
those who are malnourished [1]. This global obesity epidemic contributes to an 
approximated 2.8 million deaths per year [2], and is associated with the development 
of numerous diseases, including hypertension, type 2 diabetes (T2D), coronary heart 
disease, and NAFLD [3]. In line with the growing obesity epidemic, NAFLD has 
become the most common form of hepatic disease globally [4]. Whilst the association 
between obesity and NAFLD has been recognised since the 1960s [5], the functional 
link between these two disorders was not identified until the late 1970s and early 
1980s [6–9]. In 1979, histology analysis revealed a range of distinct subtypes in the 
livers of obese patients, from simple lipid accumulation (benign steatosis), to 
inflammatory hepatitis, fibrosis and cirrhosis (Figure 1.1) [6]. It was later revealed that 
the development of NAFLD is an independent risk factor for the development of 
hepatocellular carcinoma (HCC), the second most common cause of cancer-related 
death [10]. Together, these findings demonstrated that NAFLD has the potential to 
progress to life-threatening disease. At present, the only way to reverse the 
development of benign steatosis or non-alcoholic steatohepatitis (NASH) is through 
diet and exercise [11]. As the obesity epidemic continues, the number of people living 
with NAFLD will continue to grow, increasing the economic burden on healthcare 
systems globally [12], making it critical that new strategies for the treatment of the 
disease are developed. 
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Figure 1.1 Progression of NAFLD and associated risk factors in adult 
populations. Arrows indicate direction of disease progression and whether disease 
is reversible following intervention. Data are from Marengo et al (2016) [13].  
 
1.1.2 Histopathology of NAFLD 
As stated above, NAFLD comprises a spectrum of pathologies, from benign hepatic 
steatosis, to inflammatory NASH, liver cirrhosis, and HCC [14]. Histological analysis 
of NAFLD remains the gold standard for the diagnosis of NAFLD, whether this is 
benign steatosis or NASH [15]. Since histological analysis requires the collection of 
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biopsies, which is invasive and carries a risk, there is a need to develop new methods 
of diagnosis and study [16].  
 
1.1.2.1 Benign Steatosis 
Benign steatosis is characterised by hepatic fat content greater than 5% of total liver 
weight [17]. In adults, steatosis is normally characterised by macrovesicular lipid 
droplets, referring to a single large cytoplasmic lipid droplet, which can displace the 
nucleus to the periphery of the cell [18]. Less commonly, steatotic hepatocytes may 
contain multiple smaller lipid droplets (microvesicular steatosis), which do not displace 
the nucleus (Figure 1.2A) [18]. These lipid droplets are composed of multiple lipid 
species, including triglycerides (TGs), ceramides, diacylglycerides, cholesterol esters 
and free fatty acids (FFAs) [19]. In adults, steatotic cells are generally scattered 
around the small branches of the hepatic vein (acinar zone 3) [16]. This is in contrast 
to obese adolescents, where steatotic hepatocytes are more likely to be located in the 
periportal region [20]. In more extensive cases, distribution of steatotic hepatocytes 
can become random, occurring throughout the liver [21].  
 
1.1.2.2 NASH 
Approximately 37% of adult patients with benign steatosis will progress to develop 
NASH, which is strongly associated with hepatic inflammation, insulin resistance (IR), 
and T2D [22]. The development of NASH is characterised by hepatic inflammation 
and hepatocyte ballooning (Figure 1.2B), leading to tissue injury and remodelling 
[23]. As inflammation develops, the liver is infiltrated by a range of immune cells, 
including macrophages, natural killer (NK) cells, eosinophils, and type 1 helper T 
(Th1) cells [24]. Eosinophils deposit protein aggregates, termed Mallory-Denk bodies 
(Figure 1.2C), which are used in histology to identify NASH [25]. NASH is also linked 
to the development of megamitochondria (Figure 1.2D), but the contribution of these 
enlarged organelles to NASH pathology remains unclear [26].   
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Figure 1.2 Histopathological analysis of NAFLD and NASH. (A) Steatotic 
hepatocytes are characterised by macrovesicular lipid droplet accumulation (blue 
arrows). (B) NASH is characterised by development of hepatocyte ballooning (green 
arrows). (C) Mallory-Denk bodies (black arrow) are a sign of hepatocyte injury. (D) 
Development of megamitochondria (black arrowhead) is associated with NASH. 
Figure adapted from Brown & Kleiner, 2016 [25]. 
 
1.1.2.3 Cirrhosis 
Cirrhosis is the endpoint of the majority of chronic liver diseases and is characterised 
by the extensive deposition of collagen by fibroblasts, leading to a loss of tissue 
function [13]. Approximately 11% of patients with NASH-associated fibrosis will go on 
to develop cirrhosis [13]. This causes the irreversible loss of the liver parenchyma, 
limiting the ability of the organ to synthesise coagulation factors and albumin, as well 
as impairing blood flow and detoxification capacity. The development of this 
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phenotype limits the ability of the liver to function effectively, preventing it from 
excreting bilirubin, and resulting in jaundice and eventual organ failure [27].  
 
1.1.3 Progression of NAFLD to NASH and development of 
fibrosis  
1.1.3.1 From the two-hit to multiple hit model of NAFLD 
A major hurdle in the development of therapeutics for NAFLD is that the cause is 
multi-factorial [28]. In 1998, Day and James proposed the two-hit model, whereby 
benign steatosis represents the first “hit”, characterised by the accumulation of 
intracellular TGs. The second “hit” is characterised by the development of an 
inflammatory phenotype, associated with the production of inflammatory cytokines, 
oxidative stress, and mitochondrial dysfunction, triggering the development of NASH 
[29]. In this thesis, mitochondrial dysfunction is defined as alterations in mitochondrial 
function associated with pathogenesis. This has developed into a multiple-hit model, 
which considers numerous other factors driving pathology, including diet and genetic 
predisposition [30]. There is increasing evidence that dysfunctional mitochondrial 
metabolism may impact on epigenetic modifications of DNA and chromatin, and may 
also play a role in the development of this disease [31–33]. In particular, studies in 
humans and mice indicate that mitochondrial tricarboxylic acid (TCA) cycle disruption 
plays a central role in the pathogenesis of NAFLD [34,35]. These points will be 
discussed later in the introduction.  
 
1.1.3.2 The role of lipid species in progression from benign steatosis to 
NASH 
The development of lipid droplets during NAFLD pathogenesis may represent a 
protective mechanism employed by hepatocytes that are overloaded with fatty acids 
(FAs) [36]. This is supported by mouse studies of diacylglycerol acetyltransferase 2 
(DGAT2), which catalyses the final step in TG synthesis. Knockdown of DGAT2 
reduced accumulation of hepatic TGs but was associated with exacerbation of 
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hepatocellular injury [37]. If sequestration of TGs is protective, then this suggests that 
the generation of non-TG lipids plays a role in hepatocellular injury, progression to 
NASH, and development of fibrosis. The harmful effect of non-TG lipids is termed 
lipotoxicity, and in hepatocytes this is understood to contribute to the conversion of 
benign steatosis to NASH [36]. These non-TG lipids include diacylglycerol, 
acylcarnitines, FAs, cholesterol and ceramides, all of which are known to induce 
hepatocellular injury [38] and are also elevated in NASH patients [39,40]. Induction of 
hepatocellular injury by these non-TG lipids occurs through a number of pathways. 
For example, high levels of FA clearance by microsomal, peroxisomal and beta-
oxidation generates reactive oxygen species (ROS), causing oxidative stress and 
cellular injury [41]. High levels of intracellular FAs and cholesterol also induce 
endoplasmic reticulum (ER) stress and activation of the unfolded protein response 
(UPR) [42,43], a known contributor to NASH [44,45]. This is thought to impact on 
mitochondrial function too due to disruption of Ca2+ transfer between the mitochondria 
and ER [46]. The UPR is also known to induce ceramide synthesis [47], with high 
levels of ceramides inducing excessive ROS generation and apoptosis in steatotic 
hepatocytes [40,48]. Taken together, these combined findings support the protective 
role of TG sequestration in lipid droplets and the importance of non-TG lipids in the 
transition from benign steatosis to NASH.   
 
1.1.3.3 Inflammation  
Progression of benign steatosis to NASH is accompanied by infiltration of the hepatic 
parenchyma by innate and adaptive immune cells [49]. Lipotoxicity-induced 
hepatocellular injury and apoptosis triggers the release of danger-associated 
molecular pattern (DAMP) molecules, which bind to pattern recognition receptors 
(PRRs), including Toll-like receptor 4 (TLR4) [50]. Binding of DAMPs to TLR4 on 
Kupffer cells (KCs) activates nuclear factor kappa B (NF-kB) signalling, leading to 
secretion of cytokines such as interleukin 6 (IL-6) and tumour necrosis factor alpha 
(TNF-a). Whole-body knockout of TLR4 in mice attenuates the development of NASH, 
indicating its central role in the transition from NAFLD to NASH [50]. Activated KCs 
begin secreting transforming growth factor beta (TGF-b) and recruit other immune 
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cells, including neutrophils and natural killer cells, which infiltrate the liver parenchyma 
and promote inflammation [51].  
 
1.1.3.4 Fibrosis 
Hepatic inflammation and secretion of TGF-b leads to activation of liver-resident 
hepatic stellate cells (HSCs), which are normally quiescent, leading them to 
transdifferentiate to a myofibroblast phenotype [52]. Following transdifferentiation, 
HSCs become proliferative and chemotactic, and begin secreting extracellular matrix 
(ECM) proteins [53], including type I and type III collagens, laminin, and 
proteoglycans, leading to development of fibrosis [54–56]. Although hepatic fibrosis 
is not used as a diagnostic feature of NASH, its presence is a predictor of mortality 
and whether patients will require a liver transplant [57]. Where NASH-associated 
inflammation is not resolved, this can lead to excessive fibrosis and, ultimately, 
cirrhosis [58], but it is unclear why some patients develop this feature of NAFLD and 
others do not.   
 
1.2 Molecular basis of NAFLD 
1.2.1 The thrifty gene hypothesis 
NAFLD comprises part of the metabolic syndrome, a cluster of interconnected 
conditions including obesity and IR, which increase the risk of developing 
cardiovascular disease and T2D [59]. In 1962, the “thrifty gene hypothesis” was 
formulated, and posited an evolutionary selection of genes that contribute to 
increased lipid storage, to use as an energy source in times of food scarcity [60]. In 
modern society, where humans have access to abundant quantities of food, the 
prevalence of these genes increases the risk of developing disease, rather than being 
protective and providing an evolutionary advantage. Whilst there are undoubtedly 
genes that contribute to the development of components of the metabolic syndrome, 
there is some dispute over whether these genes provide an evolutionary advantage 
in times of food scarcity [61]. However, identification of “thrifty” genes may aid in the 
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search for therapeutic targets for the treatment of components of the metabolic 
syndrome.  
 
1.2.2 Genetics of NAFLD 
There have been a number of genome-wide association studies (GWAS) identifying 
alleles associated with increased risk of developing NAFLD [62–65]. These studies 
identified multiple single nucleotide polymorphisms (SNPs) associated with NAFLD, 
including PNPLA3 [62–65]. PNPLA3 is a membrane-associated TG hydrolase, 
involved in the packaging of TGs into very low-density lipoproteins (VLDLs) prior to 
export [66]. Pirazzi et al (2012) studied a mixed ethnicity population with increased 
hepatic lipid levels and found an isoleucine to methionine amino acid substitution that 
was independently associated with the NAFLD phenotype [66]. Further studies 
demonstrated that the I148M SNP in PNPLA3 is strongly associated with more 
extensive steatosis, lobular inflammation and development of fibrosis [67], but not with 
hepatic IR [68]. Furthermore, this SNP was associated with reduced VLDL export in 
steatotic livers [66,69–71]. There are also studies indicating that SNPs in genes 
associated with one-carbon metabolism may also correlate with severity of steatosis 
in NAFLD [72]. Unlike PNPLA3, this was observed in a single study, but as 
perturbation of one-carbon metabolism is associated with NAFLD [73], the association 
may be relevant. Recently, a GWAS of a European cohort identified the Pygopus 
family PHD finger 1 (PYGO1) gene as a novel modifier of steatosis, suggesting that 
the Wnt signalling pathway is also relevant to NAFLD pathogenesis [74].     
 
1.2.3 Insulin resistance 
IR is a hallmark of NAFLD and is tightly linked to the pathogenesis of the disease 
when associated with obesity [75]. Although GWAS studies have shown no 
association between any SNP and hepatic IR, NAFLD is associated both with hepatic 
and systemic IR [68]. However, the molecular basis of this association is not well 
understood. What is known, however, is that in obesity, the excess accumulation of 
lipids in visceral adipose tissue results in an increased release of FFAs into the 
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circulation [76]. In the steady state, stimulation of hepatic insulin receptors activates 
the PI3K/AKT pathway, inducing phosphorylation of the fork-head box protein FOXO1 
transcription factor [77] and glycogen synthase kinase-3b (GSK3b) [78]. 
Phosphorylation of FOXO1 prevents it from entering the nucleus [77]. However, 
disruption of the insulin signalling pathway can prevent the phosphorylation of 
FOXO1, allowing it to translocate to the nucleus, where it stimulates expression of 
genes associated with gluconeogenesis and de novo lipogenesis [79]. This leads to 
hepatic intracellular lipid accumulation, and development of large lipid droplets within 
the cytoplasm [16]. Lipid droplet accumulation is associated with increased 
expression of perilipin 2 (PLIN2), which regulates GSK3b activation through direct 
interaction with the enzyme [80]. This indicates that as well as mediating IR, GSK3b 
is responsive to intracellular lipid accumulation, and may be a key link between lipid 
accumulation and hepatic IR. Involvement of GSK3b in NAFLD was further 
demonstrated using a GSK3b knockout mouse, which failed to develop hepatic 
steatosis when fed a high fat diet, due to altered activity of adiponectin [81].   
 
1.2.4 Mechanisms of lipid accumulation in NAFLD 
The classic feature of NAFLD is the accumulation of intracellular lipid droplets within 
hepatocytes, which is associated with increased mitochondrial β-oxidation, and 
reactive oxygen species (ROS) generation [82–84]. This occurs as a result of 
imbalances in lipid uptake and synthesis compared to lipid export [85]. Whilst lipid 
uptake by hepatocytes is most likely a normal physiological process, the pathological 
accumulation of lipid droplets in steatotic livers is a consequence of chronic energy 
imbalance [85].   
 
1.2.4.1 Adipose tissue dysfunction causes excess fatty acid delivery to 
hepatocytes 
In normal weight adults, in the fed state, insulin secretion inhibits hydrolysis of TGs, 
but where patients are insulin resistant this causes a state of chronic inflammation. In 
turn, this leads to excess lipolysis within adipocytes, and subsequent release of FFAs 
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into the serum, which are taken up by the liver [85]. Patients with NAFLD display 
elevated serum FFA levels, induced by increased adipose tissue lipolysis [82,86]. 
Studies estimate that ~60% of TGs in steatotic lipids are derived from these serum 
FAs, with a minority generated by de novo lipogenesis (DNL) [83]. In the same study, 
radiolabelling of non-esterified fatty acids (NEFAs) revealed a small contribution of 
lipids in steatotic livers from dietary fats. Elevation of the fatty acid (FA) transporter 
CD36 was also identified in human steatotic livers, indicating an adaptation to enable 
increased FA sequestration from serum [87,88].  
 
As well as its role in IR and release of FFAs, adipose tissue also promotes lipid 
accumulation through secretion of adipose tissue hormones (adipokines) and 
inflammatory mediators. The adipokine adiponectin is secreted in multiple isoforms of 
varying molecular weight. Low level adipocyte secretion of the high molecular weight 
(HMW) isoform of adiponectin is observed in patients with IR, obesity, and NAFLD 
[89,90]. During fasting, high levels of circulating HMW adiponectin bind to hepatocyte 
receptors, increasing peroxisome proliferator-activated receptor alpha (PPARa) and 
5’ AMP-activated kinase (AMPK) activity [91]. In turn, increased PPARa and AMPK 
activity inhibit lipogenesis, promoting FA oxidation, providing substrates for the TCA 
cycle. In contrast to obesogenic conditions, this process in fasting promotes lipid 
clearance [91]. NAFLD and obesity are also associated with high levels of circulating 
IL-6 and TNFa. IL-6 is a pleiotropic cytokine, which has both inflammatory and anti-
inflammatory roles [92]. In mouse studies of obesity, IL-6 appears to promote lipolysis 
and protect against obesity [93]. However, in contradiction to this, increased levels of 
IL-6 are associated with the development of IR, which, in turn, is associated with the 
development of obesity and NAFLD [94], demonstrating the complexity of unpicking 
the role of this cytokine. TNFa is a pro-inflammatory cytokine, predominantly secreted 
by macrophages. In morbidly obese humans with NAFLD, circulating TNFa levels are 
elevated [95], suggesting that it plays a role in obesity-related systemic inflammation. 
Mouse studies show that inhibition of TNFa signalling protects against the 
development of steatosis, indicating that it plays a key role in the pathogenesis of 
these conditions [96]. Furthermore, both IL-6 and TNFa suppress insulin signalling by 
promoting the upregulation of suppressor of cytokine signalling 3 (SOCS3), further 
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contributing to lipid release from adipocytes [97]. The accumulation of hepatic lipids 
is associated with the development of mitochondrial dysfunction, but the mechanism 
linking these two disease features is unclear [98].   
 
1.2.4.2 Contribution of DNL to intracellular lipid accumulation in 
hepatocytes 
Whilst DNL contributes less to the TG pool than FAs, it is still a major source of lipids 
contributing to NAFLD [83]. This process synthesises FAs from acetyl-CoA subunits. 
These subunits are converted to malonyl-CoA by acetyl-CoA carboxylase (ACACA) 
[99]. Elevation of liver malonyl-CoA inhibits the rate-limiting enzyme of beta-oxidation, 
carnitine palmitoyltransferase 1 (CPT1), inhibiting, in turn, FA oxidation [100]. Fatty 
acid synthase (FASN) then converts malonyl-CoA to the long-chain saturated fatty 
acid palmitate [99]. This process is tightly regulated at the transcriptional level, with 
glucose and insulin activating the carbohydrate-responsive element-binding protein 
(ChREBP) and sterol regulatory element-binding protein (SREBP-1c), respectively 
[101,102]. In response to glucose and insulin, ChREBP and SREBP-1c are able to 
modulate the expression of  genes required for DNL [103,104]. The overexpression 
of SREBP-1c, FASN and ACACA has been observed in NAFLD patients, further 
supporting that DNL plays a role in human disease [105].  
 
1.2.4.3 Impaired lipid export 
In addition to increased levels of TG synthesis, NAFLD is associated with impaired 
export of lipids. Under homeostatic conditions, lipid export functions to deliver TGs 
and cholesterol to other tissues in the body, including cardiac and skeletal muscle 
[106]. These are transported in the form of VLDLs, which are lipoprotein particles 
composed of a lipid bilayer containing TGs and cholesterol esters, and stabilised by 
a single apolipoprotein B-100 molecule [106]. Assembly of VLDLs occurs in the lumen 
of the ER, before transport to the Golgi body. Following modification in the Golgi body, 
VLDLs are trafficked to the cell membrane and exported from the cell [107]. Assembly 
in the ER is facilitated by a range of hydrolase enzymes, including triglyceride 
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hydroxylase (TGH), microsomal transfer protein (MTP), carboxylesterase enzymes, 
and PNPLA3. As discussed previously in this chapter, PNPLA3 was identified in a 
number of GWAS studies as a high-risk allele for developing hepatic steatosis [63–
65]. Whilst the export process of VLDLs continues to function in the steatotic liver, 
excretion of these particles increases, plateauing once hepatic fat content reaches 
~10% [82]. This indicates that under steatotic conditions, the liver continues to export 
lipids as far as possible but is unable to do so once this limit is reached. Increased 
export of VLDLs increases ER stress, suggesting that increased assembly and export 
of these proteins may also impact on mitochondrial function [46].  
 
1.3 The role of mitochondria in NAFLD 
Mitochondria are organelles found in eukaryotic cells and are often termed the 
“powerhouse of the cell”, due to their central role in regulating energy homeostasis 
[108]. Further to this, they are also key regulators of cell death [108]. Multiple studies 
suggest that the pathology of NAFLD is linked to impairment of mitochondrial function 
[34,109–111]. In rat models, mitochondrial dysfunction precedes the development of 
hepatic steatosis, suggesting that disease pathology and progression are linked to 
impairment of mitochondrial function [32]. NAFLD is linked to structural changes in 
mitochondrial cristae and the development of crystalline inclusion bodies [112]. As 
electron transport chain (ETC) components are embedded in the cristae, structural 
changes may have a physical impact on respiration [113]. Similarly, the growth of 
inclusion bodies may also impair oxidative phosphorylation and lead to increased 
ROS production [112]. This is supported by observations of NAFLD-associated 
hepatic oxidative stress and altered levels of fatty acid beta oxidation [112,113]. 
Furthermore, in humans, once hepatic lipid content exceeds 10%, lipid export is 
compromised [82]. In tandem with altered fatty acid beta oxidation, this imbalance 
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1.3.1 Mitochondrial quality control 
Due to their central role in energy metabolism and cell death, it is important that 
damaged or dysfunctional mitochondria are regularly removed [108]. This occurs via 
a quality control process termed mitophagy, whereby damaged organelles are 
enveloped by a double-membraned structure called the autophagosome, and 
trafficked to the lysosome for degradation [114]. Mitophagy is regulated, in part, by 
the PINK1-PRKN signalling pathway, whereby the PTEN-induced putative kinase 
(PINK1) phosphorylates the E3 ubiquitin ligase Parkin (PRKN) [115]. PINK1 is located 
on the outer mitochondrial membrane, and is regulated by changes in membrane 
potential [116]. When this potential is disrupted in damaged mitochondria, it stabilises 
PINK1, which recruits PRKN, enabling the ligase to ubiquitinate the organelle and 
target it for degradation [116]. This signalling pathway also impacts on NAFLD, with 
mouse models showing that hepatic knockout of Prkn increased steatosis and 
reduced mitochondrial respiratory capacity in hepatocytes [117]. These mice also 
displayed reduced insulin sensitivity, despite no changes in weight gain following a 
high fat diet. Although it is not currently known whether this applies to human disease, 
it strongly indicates that mitochondrial integrity and function is central to maintaining 
hepatic homeostasis and protecting against the development of NAFLD.  
 
1.3.2 The TCA cycle and electron transport chain  
The TCA cycle occurs predominantly in the mitochondrial matrix, and is a central 
pathway for the metabolism of amino acids, fatty acids, and carbohydrates, to 
generate cellular energy [118]. The cycle utilises the substrate acetyl coenzyme A 
(acetyl-CoA), which is generated by b-oxidation, as well as amino acid degradation 
and glycolysis via pyruvate. Acetyl-CoA is oxidised through a series of steps (Figure 
1.3), producing nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2), which subsequently transfer electrons to the electron transport 
chain (ETC), to fuel the production of adenosine triphosphate (ATP) (Figure 1.4). 
Acetyl-CoA is generated by the oxidation of pyruvate, by pyruvate dehydrogenase 
(PDH) [119]. Pyruvate can also be carboxylated by pyruvate carboxylase (PC) to form 
oxaloacetate (OAA). Acetyl-CoA and OAA then undergo a condensation reaction to 
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form citrate, which can then progress through the TCA cycle, forming multiple 
intermediates, including alpha-ketoglutarate (αKG), succinate, fumarate, and malate. 
In addition to acetyl-CoA, the TCA cycle can also be fuelled by the deamination of 
glutamate by glutamate dehydrogenase, to produce αKG [120]. Increased influx of 
substrates into the TCA cycle can also increase cycle flux, as well as the abundance 
of the intermediates αKG, succinate, and fumarate [121].  
 
 
Figure 1.3. Schematic of the TCA cycle. Arrows indicate the direction of metabolite 
conversion under homeostatic conditions. Red text denotes processes generating 
substrates for the electron transport chain. LDH = lactate dehydrogenase; PDH = 
pyruvate dehydrogenase; PC = pyruvate carboxylase; aKG = alpha-ketoglutarate; 
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Figure 1.4. Schematic of the electron transport chain (ETC). The TCA cycle 
interfaces with the ETC at succinate dehydrogenase (complex II). Numerals indicate 
respiratory complex number. Arrows between mitochondrial matrix and 
intermembrane space indicate direction of proton (H+) flow. Q = coenzyme Q10; Cyt 
C = cytochrome C; Pi = inorganic phosphate; ADP = adenosine diphosphate; ATP = 
adenosine triphosphate.  
 
Although canonically a feature of the mitochondria, elements of the TCA cycle also 
occur in the cytoplasm [122] and the nucleus [123] (Figure 1.5). Isocitrate 
dehydrogenase and malate dehydrogenase both have cytoplasmic isozymes (IDH1 
and MDH1, respectively), and a single form of fumarate hydratase (FH) can be found 
in both the cytoplasm and the mitochondria. Furthermore, during development, 
several mitochondrial TCA cycle enzymes including PDH, PC, and isocitrate 
dehydrogenase 3 (IDH3) can translocate to the nucleus, where they ultimately 
generate αKG [123] although to date this has only been demonstrated during a time-
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Figure 1.5. Multiple compartments of the TCA cycle. The TCA cycle occurs predominantly in the mitochondrial matrix, although some 
reactions can occur beyond the mitochondria, including in the cytoplasm and nucleus. Solid arrows represent the reaction direction 
(enzymes omitted for simplicity), while dashed arrows represent the transport of metabolites into the cytoplasm (Sinton et al, 2019) [124]. 
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1.3.3 Plasticity of the TCA cycle 
Whilst the standard model of the TCA cycle describes a unidirectional process, the 
landscape is more complex than this. Instead of OAA condensing with acetyl-CoA to 
form citrate, it is possible for it to instead be converted to malate, then fumarate, and 
back to malate and OAA, in a process termed ‘backflux’ [125]. Truncation of the TCA 
cycle is also possible in certain disease states, including various cancers and 
hypoglycaemia, whereby specific steps are no longer functional and are, therefore, 
bypassed. During hypoglycaemia, for example, it is possible for glutamate to become 
the primary source of carbon, allowing OAA to be generated from αKG instead of 
citrate [126]. Loss of FH function, as found in some cancers, results in the 
accumulation of fumarate, and a corresponding decrease in NADH generation. 
However, despite these metabolic alterations these cells are viable, and resist 
hypoxia, perhaps through stabilisation of hypoxia inducible factors [127], which will be 
discussed later in this thesis. The plasticity of the TCA cycle serves to illustrate that it 
can undergo complex alterations to overcome pathological states and promote cell 
survival.  
 
There are strong indications that TCA cycle activity increases in response to NAFLD, 
in both mouse and humans, with both demonstrating increased cycle flux and 
anaplerotic influx of αKG via glutamate. Evidence for this is compelling, but the 
technical difficulties of obtaining human tissue samples mean that measurements of 
hepatic TCA cycle flux and anaplerosis in humans have been made in peripheral 
blood, and thus the results may be confounded by the release of metabolites from 
other tissues [34]. Studies of the liver of mice fed a high fat diet demonstrate increased 
TCA cycle flux associated with NAFLD, supporting findings in humans [110] although 
the use of whole tissue to examine the effects of NAFLD on metabolic function makes 
it difficult to determine which cells within a tissue are exhibiting altered TCA cycle 
activity. Supporting this, though, are nuclear magnetic resonance (NMR) studies, 
which also indicate increased hepatic TCA cycle flux and anaplerosis in humans [34]. 
A recently developed in vitro model, which uses embryonic stem (ES) cell-derived 
hepatocytes to model NAFLD, supports the assertion that intracellular lipid 
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accumulation associates with dysregulation of the TCA cycle and altered abundance 
of intermediates [128].   
 
1.3.4 The TCA cycle and NAFLD 
Satapati et al. (2012) observed increased tricarboxylic acid (TCA) cycle activity and 
anaplerosis in the livers of mice with high fat diet-induced hepatic steatosis [109]. 
They also demonstrate that increased levels of hepatic TGs induced oxidative 
metabolism, with a proportional increase in oxidative stress [129]. Indirect studies in 
humans indicate a similar effect on TCA cycle flux [34]. As TCA cycle flux generates 
NADH and FADH2, which transfer electrons to the ETC, alterations in TCA cycling 
may have a direct impact on respiration and oxidative stress. Further studies in 
humans demonstrate that NAFLD and NASH are associated with increased and 
decreased mitochondrial maximal respiration, respectively, indicating that there is a 
transition in mitochondrial function between these two disease states [130]. The 
reasons for this are unclear; such differences in maximal respiration between NAFLD 
and NASH could reflect impairment of the ETC and/or changes in baseline 
mitochondrial respiration. Furthermore, mitochondria isolated from whole tissue come 
from multiple cell types, which may differ in proportion in disease states and this may 
confound the interpretation of any results. In NASH, the decrease in maximal 
respiration which occurs despite an increase in mitochondrial mass may be a 
consequence of mitochondrial leakage resulting from decreased outer membrane 
integrity, a phenotype associated with oxidative stress and apoptosis [130,131]. 
 
1.4 The TCA cycle and the epigenome 
1.4.1 The αKG-dependent dioxygenases 
In addition to its central role in energy metabolism, the TCA cycle exerts control over 
the catalytic activity of the αKG-dependent dioxygenase family which comprises 
approximately 70 members [132]. The αKG-dependent dioxygenases are Fe(II)/O2-
dependent enzymes, which catalyse the hydroxylation of a number of substrates, 
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including DNA, histones, and proteins. The family of enzymes include prolyl-4-
hydroxylases (PHDs), Jumonji domain-containing histone demethylases (JHDMs), 
and ten-eleven translocation (TET) dioxygenases [133]. All of the enzymes within this 
family have two binding domains in their b-sheet core, which are highly specific for 
αKG - binding of αKG acts as a positive regulator of dioxygenase activity [134,135]. 
Conversely, these two binding domains can be competitively bound by succinate and 
fumarate, with subsequent inhibition of dioxygenase activity [136].  
 
The functions of the members of the dioxygenase family are numerous, but include 
epigenetic regulation, through DNA methylation, histone methylation and acetylation, 
as well as oxygen sensing through the prolyl-4-hydroxylases (PHDs) [137–139]. It is 
tempting to speculate, therefore, that the αKG-dependent dioxygenases form a 
nexus, integrating environmental signals and disseminating them to downstream 
targets, altering transcription to allow cells to maintain homeostasis. Taken together, 
it is not surprising that there is evidence indicating that JHDM, PHD, and TET enzyme 
activity may be related to the pathogenesis of NAFLD, although it is less clear whether 
these are a cause or consequence of the disease.  
 
1.4.2 Prolyl-4-hydroxylases (PHDs), HIF-1α and NAFLD 
PHDs catalyse the most prevalent post-translational modification (PTM) in humans, 
hydroxylating proline residues to form (2S,4R)-4-hydroxyproline. Whilst PHDs have 
many substrates, including Argonaut 2 [140], collagen [141], and elastin [142], one of 
the most well characterised is the hypoxia inducible factor (HIF) transcription factor 
[143]. HIF-1 is comprised of two constitutively expressed sub-units: HIF-1α and HIF-
1b [144]. Under normal oxygen conditions (normoxia), PHDs hydroxylate two proline 
residues (Pro402 and Pro 564) within the oxygen-dependent degradation domain 
(ODDD) of HIF-1α [144]. The hydroxylation of these proline residues recruits ubiquitin 
E3 ligase and leads to the polyubiquitination of HIF-1α, marking it for degradation by 
the proteasome [145]. Under hypoxic conditions, low oxygen concentrations diminish 
the ability of PHDs to hydroxylate these proline residues, and thus HIF-1α stabilises, 
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allowing it to translocate to the nucleus where it can dimerise with HIF-1b [146]. This 
allows the HIF complex to bind to hypoxia response elements (HREs), facilitating 
transcription (Figure 1.6).  
 
Despite their name, it is not only oxygen that regulates the HIFs. Since PHDs are also 
regulated by succinate, fumarate, and αKG, HIFs are able to coordinate gene 
networks in response to metabolic rewiring [147]. Indeed, hypoxia is associated with 
altered lipid homeostasis, through coordination of genes regulating lipid droplet 
formation, DNL, and fatty acid uptake [148]. Whilst there is a lack of data to directly 
link TCA cycle dysfunction in NAFLD with PHD inhibition and HIF stabilisation, there 
are limited data from rat models demonstrating altered HIF-1α mRNA and protein 
levels in steatotic whole liver [149]. A caveat to this study is that the study was 
performed in whole tissue, and perivenous regions of the liver express higher levels 
of HIF mRNA [150]. Therefore, variation in region of the liver sampled may alter 
results. However, in support of this link, there are obesity studies suggesting a 
relationship between lipid accumulation and HIF-1α stabilisation. Adipose tissue 
levels of both HIF-1α mRNA and protein levels are increased by obesity, and there is 
strong evidence that obesity provokes a hypoxia-like response in adipose tissue 
[151,152]. Tracer studies in mice, using a 13C-glucose stable isotope, demonstrated 
an increase in the abundance of αKG, succinate, and fumarate in the adipose tissue 
of obese animals [35]. Furthermore, this study found increased levels of succinate in 
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Figure 1.6. The TCA cycle and prolyl-4-hydroxylases (PHDs). TCA cycle metabolites in the cytoplasm can interact with PHDs, to 
either promote or repress activity. Repression prevents ubiquitination of HIF-1α, promoting protein stabilisation, followed by nuclear 
accumulation and transcription of target genes (Sinton et al, 2019) [124].  
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There are conflicting reports on the protective or harmful role of HIF-1α in the 
pathogenesis of fatty liver [149,153]. Using a rat model of liver steatosis, Carabelli et 
al describe increased expression of HIF-1α mRNA and suggest that this is responsible 
for an observed increase in mitochondrial biogenesis. They also speculate that this 
may form a protective mechanism, whereby hepatocytes are able to increase rates of 
b-oxidation to process excess intracellular lipids. In contrast, Mesarwi et al observed 
that HIF-1α mediates the development of hepatic fibrosis in a mouse model of NAFLD, 
suggesting a pathogenic role. The discrepancies between these studies may be 
explained by the use of different animal models. It may also be a result of NAFLD 
comprising a spectrum of pathology, whereby some molecular mechanisms may be 
protective during the early stage of disease, but eventually become chronic and 
harmful. However, there is a lack of data to suggest whether HIF-1α is important for 
the development of NAFLD in humans, and the impact of TCA cycle dysfunction on 
PHD catalytic activity.  
 
1.5 Epigenetic modifications 
The term epigenetics is commonly defined as the study of heritable phenotypic 
changes that are not related to alterations in DNA sequence, and is used to describe 
the molecular mechanisms that regulate transcription [154–156]. This can include 
histone modifications, DNA methylation, and non-coding RNAs. These modifications 
are able to persist through multiple cell divisions, but whether they are heritable 
remains a topic of debate [157,158]. It is also possible for epigenetic modifications to 
drive cell- or tissue-specific transcriptional programs [159], and to be dynamically 
influenced by diseases, such as cancer [160,161], and environmental factors [124].  
 
1.5.1 DNA packaging and chromatin accessibility 
The nucleus of a eukaryotic cell is 2-10 µm in diameter and, therefore, the several 
metres of DNA contained within must be packaged efficiently, whilst remaining 
accessible to the transcriptional machinery [162]. To facilitate both of these 
requirements, eukaryotic cells employ histone proteins. Approximately 147 base pairs 
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of DNA wrap around each histone octamer, forming nucleosome complexes, which 
then condense to form chromatin [163]. Chromatin is regulated by numerous factors, 
including chaperones, which can facilitate the deposition or eviction of histones 
[164,165]. Chromatin remodellers, which use ATP, can evict histones to regulate 
transcription [166]. It is also possible for the histones to be modified through addition 
of chemical tags, which will be discussed in the following section.  
 
1.5.2 Histone modifications 
Histone proteins form cores around which DNA can condense, allowing it to be 
packaged efficiently into nucleosomes to form chromatin [163]. These nucleosomes 
are often compacted, preventing transcription of DNA to mRNA [167]. Histones are 
also subject to many PTMs, including acetylation, methylation, phosphorylation, 
sumoylation, and ubiquitylation, with acetylation and methylation being the most well 
described [168]. Histone lysine methylation can lead to condensation of chromatin 
into a tightly compacted heterochromatin state, or can relax the chromatin into a 
euchromatic state, depending on the site of deposition [169]. Histone 3 lysine 27 
trimethylation (H3K27me3) [170], histone 3 lysine 9 di- and tri-methylation 
(H3K9me2/3) [171,172] and histone 4 lysine 20 trimethylation (H4K20me3) are 
associated with the heterochromatic state and  transcriptional silencing [173,174]. 
Conversely, histone 3 lysine 4 trimethylation (H3K4me3) and histone 3 lysine 36 
trimethylation (H3K36me3) are associated with a euchromatic state and 
transcriptional activation [175–177]. In addition to compacting or relaxing chromatin, 
there is evidence that histone modifications can act as a dock for effector proteins, 
the binding of which can elicit a transcriptional response [178,179]. However, this may 
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1.5.3 Jumonji domain-containing histone demethylase 
(JHDMs) 
The JHDMs are αKG-dependent dioxygenases, which catalyse the demethylation of 
lysine residues of histone 3 (H3) and histone 4 (H4) [181]. In general, methylation of 
H3 and H4 tails is associated with relaxation of chromatin, and increased DNA 
accessibility [182]. In contrast, demethylation by the JHDMs can increase DNA 
histone interactions, promoting chromatin compaction and transcriptional silencing 
[183]. Experimental silencing of succinate dehydrogenase results in the accumulation 
of the TCA intermediate succinate, which, in turn, results in the inhibition of the 
JHDMs, altered histone methylation patterns, and transcriptional activity [184].  
 
1.5.4 DNA methylation  
DNA methylation is a highly conserved epigenetic modification, found in plants and 
animals, and is used by the cell to modulate gene expression [185]. It is essential for 
development and is associated with repression of transposons and X-chromosome 
inactivation [186]. DNA methylation occurs at the C5 position of cytosine, and is 
deposited by DNA methyltransferases 1-3 (DNMTs) at cytosine-phosphate-guanine 
(CpG) sites within the genome, giving rise to 5-methylcytosine (5mC) [187]. The 
presence of 5mC is associated with transcriptional repression, particularly in promoter 
regions [188]. The presence of 5mC at enhancers, which are distal gene regulatory 
elements, does not appear to be related to transcriptional repression, but rather 
appears to stabilise demethylated DNA, enabling transcription factor binding [189]. It 
is possible for 5mC to influence transcription by either physically preventing 
transcriptional proteins from binding [190] or through the binding of methyl-CpG-
binding domain (MBD) proteins to 5mC. MBDs can recruit repressive proteins, such 
as histone deacetylases, to the methylated locus, generating heterochromatin [191]. 
The removal of the methyl group of 5mC can happen either passively or actively. The 
former is achieved through failure of the DNMTs to add methyl groups to the daughter 
strand of DNA during DNA replication. DNA methylation can be oxidised by the ten-
eleven translocation (TET) enzymes to sequentially produce 5-
hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), 5-carboxylcytosine (5caC), 
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before triggering base excision repair (BER) to revert the base to unmodified cytosine 
(Figure 1.7) [137].  
 
Figure 1.7. TET oxidation of 5mC through to unmodified cytosine. After the 
deposition of 5-methylcytosine by the DNMT enzymes it can be oxidised by the TETs 
to 5-hydroxymethylcytosine, 5-formylcytosine, and then 5-carboxylcytosine, before 
base excision repair resulting in unmodified cytosine. These iterative oxidation steps 
can be inhibited by the TCA cycle metabolites succinate and fumarate (Sinton et al, 
2019) [124].  
 
1.5.5 CpG islands 
In somatic cells, >80% of CpGs are methylated, except in CpG islands and other gene 
regulatory regions [192]. Approximately 10% of CpG sites are located in clusters 
termed CpG islands (CGIs), and are most commonly found in the promoters of genes 
with important developmental functions [193]. In general, these CGIs are 
unmethylated, but where methylation does occur, it is associated with transcriptional 
repression and heterochromatic regions, as DNA methylation is, in general, thought 
 
Chapter 1  40 
to prevent transcription factor binding [194]. During development, it is estimated that 
less than 30% of CpGs are methylated, in contrast to 85% in terminally differentiated 
cells, illustrating the tight control that is exerted to retain cell homeostasis and 
phenotype in differentiated cells [195].  
 
1.5.6 DNA hydroxymethylation 
Whilst initially thought to be transient, 5hmC is now accepted as a stable cytosine 
modification that is involved in transcriptional regulation [196,197]. It is between 10- 
and 100-fold more abundant than either 5fC or 5caC, and is most enriched in neurons 
and stem cells, whilst being more commonly depleted in cancer cells [198–200]. It is 
becoming increasingly evident that 5hmC is important for the maintenance of 
pluripotency and central nervous system development, as well as in tumorigenesis 
[201].  
 
Enrichment of 5hmC within gene bodies and enhancers broadly correlates with 
transcriptional activation [202,203]. In contrast, 5hmC enrichment within gene 
transcriptional start sites (TSS) is associated with transcriptional repression and the 
maintenance of CpG hypomethylation [204]. 5hmC is often present in the TSS of 
genes where promoters are marked by the bivalent, or “poised” histone modifications 
H3K27me3 and H3K4me3 [205], suggesting that 5hmC is involved in modulating 
chromatin accessibility. There is also an enrichment of 5hmC in active enhancer 
regions that are labelled with H3K4me1 and the acetylated histone 3 lysine residues 
H3K18 (H3K18ac) and H3K27ac [206]. This demonstrates that the influence of 5hmC 
on transcription is context dependent, as it is able to both promote and repress mRNA 
expression. This complex interplay is also cell type-dependent, further complicating 
the role of 5hmC in transcription [207].      
 
Altered 5hmC is also associated with different disease states or drug treatments. For 
example, induction of HCC in mice using the carcinogen phenobarbital dramatically 
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alters 5hmC at specific DNA loci. In these regions, both depletion and enrichment of 
5hmC were associated with increased mRNA expression, as well as increased levels 
of the activating histone mark H3K4me2. In a mouse model of NAFLD, steatosis was 
associated with reversible changes in 5hmC at a number of functionally relevant 
genes, including dehydrocholesterol reductase 7 (Dhcr7) and 17-beta-hydroxysteroid 
dehydrogenase (Hsd17b7) [208]. This indicates that 5hmC plays a role in 
pathogenesis of NAFLD.     
 
1.5.7 Ten-eleven translocation enzymes 
The TET enzymes are part of the αKG- and Fe2+-dependent dioxygenase family, and 
were first identified as homologues of the trypanosome J-binding proteins [137]. Like 
other members of the dioxygenase family, the TETs are allosterically regulated by 
metabolites of the TCA cycle, with αKG promoting activity, and succinate and 
fumarate inhibiting their activity [137]. Of these metabolites, αKG has the highest 
binding affinity, meaning that in the presence of all three metabolites it is highly likely 
that αKG will bind and promote TET activity [209]. To achieve this, the double-
stranded β-helix at the N-terminus of the TET enzymes brings together Fe(II), αKG, 
and 5mC to allow oxidation of the methyl group to 5hmC, 5fC, and 5caC [137]. The 
contiguous cysteine-rich domain then wraps around the double-stranded β-helix to 
stabilise the interaction between the TET enzyme and the DNA, facilitating the 
oxidation reaction [137]. The enzymes are a subset of the αKG-dependent 
dioxygenase family, comprised of TET1, TET2, and TET3, each of which can catalyse 
the iterative oxidation and demethylation of 5mC to 5hmC in vitro and in vivo 
[137,210]. However, studies indicate that TET1, which was first identified as a fusion 
partner of MLL in myeloid leukaemia [211], is responsible for demethylation of 
promoter regions, whilst TET2 is more active at CpGs located in gene bodies [212].  
 
The different TET isozymes show tissue-specific and temporal expression patterns 
[213–215]. TET1 is highly expressed in primordial germ cells and embryonic stem 
cells [137,216], suggesting a link to pluripotency. In contrast, TET2 is more highly 
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expressed in somatic cells, particularly haematopoietic cells [217]. Despite 
differences in expression of these two isozymes, they have overlapping roles in 
regulating haematopoietic homeostasis, hematopoietic stem cell maintenance, and 
leukemogenesis [218]. In contrast to TET1 and TET2, TET3 is most highly expressed 
in oocytes and zygotes, contributing to paternal global DNA demethylation [219]. 
Furthermore, the human TET1 and TET2 isozymes have higher affinities for 5mC than 
they do for 5hmC or 5fC, meaning that once 5hmC is established in genomic DNA it 
is less likely to be removed [220]. In contrast, TET3 can act as a 5caC reader during 
BER, due to the high affinity of its CXXC domain [221].   
 
In human ES cells, TET1 may orchestrate the activity of components of the epigenetic 
machinery by targeting genes for binding by the polycomb recessive complex (PRC2). 
Though they do not appear to physically interact, TET1 appears to recruit PRC2 to 
specific genes [222], possibly by maintaining a hypomethylated state, as DNA 
methylation prevents binding by PRC2 [223]. Upon binding to hypomethylated DNA, 
PRC2 can di- or trimethylate H3K27, an epigenetic mark associated with 
transcriptional repression [170,224]. This may be relevant to the pathogenesis of 
NAFLD, since genome-wide association studies have shown enrichment of PRC2 
pathways in humans with NASH [225]. In support of this, data from rat liver and human 
liver cell lines have demonstrated that downregulation of core components of PRC2 
is associated with the de-repression of inflammatory genes and intracellular lipid 
accumulation [226]. Thus, whilst TET1 may not directly control the DNA-binding 
activity of PRC2 in the pathogenesis of NAFLD, these data suggest that it may 
facilitate it. 
 
1.5.8 Post-translational regulation of TET activity 
In addition to regulation by TCA cycle metabolites, Fe(II), and oxygen, the TET 
enzymes are also regulated by PTMs, including phosphorylation and O-
GlcNAcylation. The O-GlcNAcylation PTM is deposited by O-linked N-
acetylglucosamine transferase (OGT), which attaches an N-acetyl glucosamine to 
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serine and threonine residues within target proteins [227]. Hrit et al demonstrated that 
disruption of the OGT binding site in TET1 reduced genomic 5hmC levels, with a 
concurrent reduction in gene expression [228]. This indicates that in addition to the 
other factors described here, O-GlcNAcylation also impacts on TET catalytic activity.   
   
The posttranslational addition of O-GlcNAcylation to proteins is promoted by the 
hexosamine biosynthetic pathway (HBP), which synthesises N-GlcNAc from glucose, 
linking elevated intracellular glucose to increased O-GlcNAcylation [229]. This 
generates a positive feedback loop, whereby the HBP diverts glucose away from 
glycolysis, and lowers αKG levels. This, in turn, promotes stabilisation of HIF-1α via 
PHD inhibition, and promotes increased transcription of the glucose transporter 1 
(GLUT1) gene [230], allowing more glucose to enter the cell. The reduction of αKG in 
response to elevated O-GlcNAcylation could indicate that, whilst TCA cycle 
intermediates play a direct role in TET enzyme function, they may also play an indirect 
role through the modulation of PTMs.  
 
In addition to its role in the deposition of O-GlcNAcylation PTMs on the TET enzymes, 
OGT also promotes the transition from hepatic steatosis to HCC, demonstrated 
through the use of both mouse models and human cell lines [231]. Whilst this effect 
is thought to be mediated by palmitic acid production and ER stress, other avenues 
have not been explored. OGT has been found to form a complex with TET1 or TET2 
in the nucleus, anchoring it to histones and DNA [232], and since genomic 
hypomethylation is a hallmark of HCCs [233], it is tempting to speculate that this 
complex may be involved in its development.  
 
1.5.9 Epigenetic changes in NAFLD 
There is evidence to indicate that altered TCA cycle activity, associated with obesity 
and NAFLD, results in the repression of JHDM activity [234,235]. In a mouse model 
of hepatic steatosis, the JHDMs were found to alter H3K4 and H3K9 trimethylation 
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levels at peroxisome proliferator-activated receptor alpha (PPARa) and in lipid 
catabolism networks in response to intracellular lipid accumulation [236]. Whilst there 
is no direct evidence to indicate whether this also occurs in humans, these findings 
are highly suggestive that similar mechanisms may be at play, making the JHDMs 
attractive targets to study in the context of NAFLD.   
 
Changes in hepatic DNA methylation may be associated with the development of 
steatosis, as demonstrated by Pogribny et al. Using a methionine-deficient diet (MDD) 
model of NAFLD, in mouse, they observed decreased expression of DNMT1, and a 
concurrent decrease in global levels of DNA methylation [237]. However, the authors 
do not describe in detail where in the genome these decreases occur, making it 
difficult to conclude the impact that this may have on transcriptional regulation. 
Furthermore, there are limitations to recapitulating hepatic steatosis with the MDD 
model, as shown by suppressed expression of very low density lipoprotein 
carboxylesterase mRNA [238]. In contrast, Pirola et al observed that humans with 
NASH have increased DNMT1 mRNA, and a concurrent increase in NADH 
dehydrogenase 6 methylation [239]. Whilst interesting, the findings are correlative, 
and do not describe a mechanism by which altered methylation occurs. In addition, 
the authors used bisulfite treatment to measure methylation levels, making it 
impossible to determine if they were observing changes in 5mC or its oxidised 
counterpart 5hmC. 
 
Evidence of altered nuclear DNA methylation in the liver in NAFLD is supported by a 
number of studies in humans. Differential methylation has been reported in liver 
biopsy specimens from patients with NAFLD [240,241], with some studies showing 
an inverse correlation between gene expression and DNA methylation [242]. Specific 
differentially methylated regions have been identified which may associate with 
NAFLD progression [243]. Notably, some of the changes in DNA methylation may be 
reversible with weight loss, for example following bariatric surgery [242,243]. There is 
also evidence from bariatric surgery patients suggesting that there is a correlation 
between altered DNA methylation and changes in hepatic insulin signalling [244]. A 
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recent study focused on understanding the link between NAFLD-associated liver 
fibrosis and cirrhosis and DNA methylation performed bisulfite sequencing in liver 
biopsies from female patients undergoing bariatric surgery, who had no other liver-
related pathologies [245]. The study identified differential CpG island methylation at a 
number of different genes and gene ontology analysis showed enrichment for a 
number of pathways related to NAFLD, including reactive oxygen species production 
and T2D signalling [245]. Whilst compelling, the findings in each of these studies are 
correlative and do not describe any mechanism(s) by which altered DNA methylation 
might occur. In addition, the studies again used bisulfite treatment to analyse DNA 
methylation, making it impossible to determine if they were observing changes in 5mC 
or 5hmC. 
 
There is evidence to suggest that 5hmC levels are altered in NAFLD. Patient studies 
describe a positive association between global hepatic 5hmC levels and the 
expression of peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1α 
(PPARGC1A), a gene at which DNA methylation has previously been associated with 
NAFLD and IR [239][246]. The lack of any change in global 5hmC could reflect the 
use of whole tissue, which may dilute the 5hmC signal through analysis of multiple 
cell types or alternatively may indicate that alterations in 5hmC in response to NAFLD 
occur only at specific genes. Indeed, using an in vitro model of NAFLD, it was recently 
shown that changes in 5hmC levels occur specifically at induced genes associated 
with lipid synthesis and transport [128]. Further, the study found altered expression of 
several genes encoding TCA cycle enzymes, including succinate dehydrogenase, 
isocitrate dehydrogenase, and an accumulation of the TCA cycle metabolite 
oxalosuccinate, suggesting altered cycle activity. The importance of the TET enzymes 
and 5hmC in liver disease is further supported by studies showing that aberrant TET1 
activity in HCC is associated with loss of 5hmC and a gain of 5mC, with subsequent 
transcriptional repression, suggesting that the TETs may normally prevent DNMT 
binding in these regions in the healthy liver [247]. 
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1.6 Modelling NAFLD in vitro 
Many studies have modelled NAFLD using either rodents or in vitro culture systems, 
in an attempt to understand the pathophysiology underpinning this spectrum of 
diseases. However, the multi-factorial nature of NAFLD makes it challenging to 
accurately model using these systems. For example, mouse models of NAFLD often 
induce weight gain and hepatic steatosis through feeding of a high saturated fat diet 
[248,249]. When combined with sucrose in the diet, this can recapitulate some 
elements of NASH [250]. Further to this approach, is the MDD diet, described in 
section 1.5.9, which recapitulates the inflammatory response associated with NASH, 
but not the other elements of the metabolic syndrome [238,251]. Beyond dietary 
interventions is the use of genetic manipulation to increase appetite, such as in Ob/Ob 
or Db/Db mice [252]. Alternative genetic approaches have been used to reduce VLDL 
export (MTT-/-) or fatty acid oxidation (Ppara-/-) [252]. A challenge of using rodent 
models to study metabolism of distinct cell populations is that tissue must first be 
disaggregated and then sorted, which induces oxidative stress, potentially 
confounding analysis [253].  
 
In vitro approaches commonly utilise immortalised HCC cell lines, such as HepG2s. 
However, malignant transformations, in addition to immortalisation, are known to 
induce profound changes in metabolic phenotype [254,255], limiting their utility as 
models of NAFLD. Furthermore, culturing of HCC cell lines is associated with loss of 
5hmC, making them unsuitable for studying the interplay between mitochondrial 
metabolism and modulation of the epigenome [247,256–259]. As an alternative, 
primary mouse and human hepatocytes have been used to model NAFLD [260]. 
However, these have a limited lifespan and cannot be passaged or expanded in vitro. 
Furthermore, as with rodent studies, analysis of primary cells are confounded by the 
cell sorting process [253].  
 
In recent years, limitations of these in vivo and in vitro systems has led to an increased 
interest in developing human pluripotent stem cell (hPSC)-derived hepatocyte models 
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of NAFLD, using either adult somatic cells (induced pluripotent stem cells (iPSCs)) or 
embryonically-derived stem cells (ESCs) [261–264]. Whilst iPSCs are attractive, due 
to their potential use in personalised medicine, they are challenging to derive from 
patients and require phenotyping before use [265]. Furthermore, some iPSCs exhibit 
incomplete programming and proliferative capacity [266]. The use of ESC-derived 
hPSCs to model NAFLD is more straightforward. Whilst these cells do require regular 
phenotyping, to assess pluripotency and genome integrity, they have much greater 
proliferative capacity than iPSCs and can be used for high-throughput studies [267]. 
Recently, an ESC-derived hPSC model was leveraged to model NAFLD in vitro, 
whereby human H9 cells were differentiated to hepatocyte-like cells (HLCs) and 
exposed to a cocktail of high energy substrates: lactate, pyruvate and octanoic acid 
(LPO), inducing lipid accumulation [128]. Previous studies used a similar cocktail, with 
the addition of ammonia, to induce lipid accumulation in an HCC cell line [42]. 
However, the mechanisms underpinning lipid accumulation in response to LPO 
exposure remain unclear. Exposure of HLCs to LPO induced transcriptional changes 
similar to those observed in human disease, including in genes related to the TCA 
cycle and lipid metabolism. Furthermore, untreated HLCs displayed 5hmC levels 
similar to those observed in adult human hepatocytes, which were modulated in 
response to LPO. These findings demonstrate that this model recapitulates the 
metabolic and epigenetic features of NAFLD, enabling the study of hepatocyte 
response to lipid accumulation in a single cell population. This model was refined and 
used for the studies described in this thesis.     
 
1.7 Summary, hypotheses and thesis objectives  
The study of epigenetic dysregulation in disease is fraught with difficulties and 
limitations, not least whether changes in epigenetic marks are a cause or 
consequence of the disease process itself [268]. In addition to this, many studies in 
the NAFLD field have reported changes in genome methylation but have arrived at 
their conclusions based on bisulfite sequencing data [239,242]. Since bisulfite 
sequencing cannot distinguish between 5mC and 5hmC [269], it is impossible to 
determine precisely which changes are occurring during the pathogenesis of NAFLD 
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in much of the current literature. Further to these difficulties are the inherent limitations 
of the current models of NAFLD, which make it difficult to study the interplay between 
the TCA cycle and epigenetic modifications. The aim of my thesis was to refine the 
hPSC-based model of NAFLD described above and to study the interplay between 
TCA cycle dysfunction and epigenetic regulation of gene expression in the 
pathogenesis of the disease. 
 
1.8 Hypotheses and aims 
1.8.1 Hypotheses 
1. LPO exposed HLCs are transcriptionally similar to steatotic hepatocytes 
obtained from patients with NAFLD. 
2. LPO increases TCA cycle activity, leading to increased levels of the 
metabolites αKG, succinate and fumarate. 
3. Increased αKG levels will increase TET enzyme activity, modulating levels of 
5hmC throughout the genome.  
 
1.8.2 Aims 
1. To examine the transcriptional response of LPO-treated HLCs in response to 
model refinement using an RNA-sequencing approach. 
2. To perform high-resolution analyses of mitochondrial respiratory changes 
associated with intracellular lipid accumulation.  
3. To determine whether LPO-induced changes in mitochondrial TCA cycle 
activity impact on TET enzyme activity. 
 
Chapter 2  49 
Chapter 2: Materials and Methods 
2.1 Buffers and solutions 
Reagents were purchased from Sigma Aldrich, except where stated.  
10x Western Blot Running Buffer: Tris Base 121 g, sodium dodecyl sulphate 10 g, 
HEPES 239 g were dissolved in 1 L deionised water and used at 1 x concentration. 
Western Blot Transfer Buffer: Tris Base 3 g, Glycine 14.4g , 100% methanol 100 
mL were dissolved in 1 L deionised water. 
RIPA lysis buffer with protease inhibitors: 150 mM sodium chloride, 1x Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris (pH 8.0) were dissolved 
in deionised water. 10ml aliquots were stored at -20 °C. cOmplete™ Protease Inhibitor 
Cocktail tablets were added (1/10 mL buffer; Roche, 11697498001).  
10x TBE buffer: Tris Base 108 g, boric acid 55 g and 40 mL of 0.5 M EDTA solution 
(pH 8.0) were dissolved in 1 L  deionised water. This was used at 1 x concentration. 
1M Na-Phosphate (mono and dibasic): 1 M solutions of mono and dibasic sodium 
phosphate salt were made up separately in distilled water, combined in a 39:61 ratio 
and adjusted to pH 7.0 with 4 M NaOH. 
DNA Immunoprecipitation Buffer: 100 mM Na-Phosphate pH 7.0 (mono and 
dibasic), 1.4 M NaCl, 0.5 % Triton X-100 were made up to 10 mL in deionised water 
fresh and 0.22 µm sterile filtered. 
Proteinase K digestion buffer: 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 0.5% SDS 
were prepared in 10 mL deionised water prior to each procedure and 0.22μm sterile 
filtered. 
Cold 50% trichloroacetic acid solution: 25 g of crystalline trichloroacetic acid was 
dissolved in 50 mL deionised water and stored at 4 oC. 
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1% acetic acid solution: 10 mL of 100% acetic acid was dissolved in deionised water 
to a final volume of 1 L. 
Sulforhodamine B 0.4% solution in 1% acetic acid: 0.4g of Sulforhodamine B 
powder was dissolved in 100 mL 1% acetic acid solution and stored at 4 oC. 
10mM Tris solution pH 10.5: 1.21g of Tris base was dissolved in deionised water. 
The pH of the solution was adjusted to 10.5 with HCl water added to a final volume of 
1 L before storing at 4 oC. 
LPO Treatment: Sodium L Lactate (Sigma cat. number L7022) was made up in 1 mL 
aliquots of 1 M solution and stored at -20 °C. On the day of use, 11 mg of Sodium 
Pyruvate Sigma cat. number P5280) was added to a thawed 1 mL aliquot and kept 
on ice. Octanoic Acid (Sigma cat. number C2875) 865.2mg was added to 60 mL of 
deionised water and adjusted to pH 7.0-7.9 with NaOH 4 M solution with constant 
stirring. The solution clears at this point and is stored in aliquots at -20 °C. The 
required volume of each solution was then added to media 0.22 μM filtered and added 
to the culture dish. For isotopic tracing studies, lactate was replaced with 13C3-lactate 
(CK Isotopes, CLM-1579-05). For mechanistic studies, HLCs were exposed to either 
5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5′-monophosphate (AICAR; 
1mM; Sigma-Aldrich, A1393-50MG), O-(Carboxymethyl)hydroxylamine 
hemihydrochloride (AOA; 100 µM ; Sigma-Aldrich, C13408-1G) or AICAR combined 
with monomethyl fumarate (50 µM; Sigma-Aldrich, 651419-1G) for the same duration 
as LPO.  
 
2.2 Stem cell culture and differentiation 
All cell culture reagents were GIBCO products supplied by Thermo Fisher Scientific 
unless stated otherwise. Corning (UK) supplied the plastic ware utilised throughout 
the cell culture. For high throughput imaging, specific μClear 96-well plates from 
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2.2.1 Stem cell culture 
H9 human embryonic stem cells (hESCs) were cultured on 5 μg/cm2 of Laminin 521 
(BioLamina) with mTser1 media (STEMCELL Technologies). Medium was changed 
daily. The cells were incubated at 37 °C in 5% (v/v) CO2, 95% (v/v) air, for optimal 
growth. 
 
2.2.2 Stem cell passaging 
hESC were passaged when they reached 80% confluence. Medium was aspirated 
and cells were washed with Dulbecco's phosphate-buffered saline (DPBS) (Life 
Technologies) once. Gentle Cell Dissociation reagent (STEMCELL Technologies) 
was added to the cells. For regular passaging, cells were incubated for 5 min until the 
edges of the colonies appeared rounded. The Gentle Cell Dissociation regent was 
aspirated and fresh mTser1 medium was added. Using a cell scraper, a 
homogeneous suspension of cells was formed. The cell split ratio was 1:3 for regular 
colonies maintenance. 
 
2.2.3 Stem cell freezing and thawing 
Stem-cellbanker (Amsbio) was used as a freezing solution. At 80-90% confluence, 
hESCs were dissociated and collected, cells were centrifuged at 200xg for 3 minutes 
in a 15 ml tube. Supernatant was removed and the cell pellet was resuspended in 1 
mL of freezing solution before transferring to -80 °C overnight and then storing in liquid 
nitrogen. Cells were thawed by warming the cryotube in a 37 °C water bath and then 
transferring to a 15 mL tube with 5 mL of fresh mTeSR1 medium to resuscitate the 
cells. The cells were then centrifuged at 200 x g for 3 min. The supernatant was 
removed, and the cells were resuspended in 2 mL of mTeSR1 medium supplemented 
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2.2.4 Hepatocyte-like cell differentiation 
All media used for this protocol are described in Table 2.1. For hepatocyte-like cell 
(HLC) differentiation, cells were incubated for 7-9 minutes with Gentle Cell 
Dissociation reagent until the edges of all cells were rounded, but the cells were still 
attached to the plate. Using a cell scraper, a homogeneous suspension of single cells 
was formed. Single cells, at 50,000 cells/cm2, were plated on wells coated with 5 
μg/cm2 Laminin 521. When they reached 30 - 40% confluence the differentiation 
protocol was initiated, and mTseR media was replaced with the endoderm 
differentiation medium. On day 4, the second stage, hepatoblast differentiation 
medium was added for 5 days changing the media every two days. On day 9, the 
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2.3 Stem cell characterisation 
2.3.1 Fluorescence activated cell sorting (FACS) 
Fluorescence activated cell sorting (FACS) was performed to characterise the 
expression of cell surface proteins in hESCs. hESCs were washed once with 2 mL 
DPBS and then dissociated with 1mL TrypLE. Cells were collected as single cells. 
Post centrifugation, cells were resuspended in DPBS and filtered through a 0.22 μM 
filter. The single cell suspension was then incubated for 30 min at 4 °C with the 
fluorochrome conjugated antibodies (for antibody details, see Table 2). IgG controls 
were used for antibody specificity. After incubation, cells were then washed twice with 
DPBS, and spun down at 200 x g for 5 min. Cells were then resuspended in 300 μL 
of DPBS. The analysis was carried out by using a live gate on forward scatter and 
side scatter parameters. Data for 20,000-50,000 ‘live’ events were acquired for each 
sample using a BD LSR Fortessa (4 laser) analyser. The data was analysed using 
FlowJo software. 
Antibody Fluorophore Host species Dilution Supplier 
SSEA-1 FITC Mouse 1/50 Biolegend 
SSEA-4 FITC Mouse 1/50 Biolegend 
TRA-1-60 PE Mouse 1/50 Biolegend 
TRA-1-81 PE Mouse 1/50 Biolegend 
Mouse IgG FITC/PE Rabbit 1/50 Biolegend 
Table 2.2 Antibodies used for flow cytometry  
 
2.3.2 CYP P450 activity 
CYP 3A4 activity was measured on HLCs at day 18 by using the P450-Glo™ assay 
(Promega). CYP 3A4 (1:20) substrates were diluted in hepatocyte maturation medium 
and added to the HLCs, before incubating for 5 min at 37 °C in 5% (v/v) CO2. Plain 
medium with substrate was incubated in parallel to subtract background. After 
incubation, 50 μL of supernatant was collected and mixed with 50 μL of luciferin 
detection reagent in a white 96-well plate at room temperature in the dark for 20 min. 
Luminescence was measured using a multiplex plate reader (GloMax Explorer, 
Promega) and normalised per mg of protein (RLU/ml/mg). 
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2.3.3 Protein content quantification 
The Pierce bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific) was used to 
quantify the protein content in HLCs. Protein supernatant was obtained by adding 50 
μL of RIPA buffer (Thermo Fisher Scientific) per well of a 96-well plate. 10 μL per 
samples were analysed in duplicates in a 96-well plate. A standard curve was 
generated using bovine serum albumin standards at concentrations ranging from 0-
2000 μg/mL. Reagents A and B from the kit were mixed at a 1:50 ratio for a final 
volume of 200 μL per well. Samples were incubated at room temperature in the dark 
for 30 min and absorbance was read at 562 nm using a multiplex plate reader (GloMax 
Explorer, Promega). Concentrations were then calculated using the generated 
standard curve. 
 
2.3.4 High content analysis microscopy 
Cells were stained with a cell paint assay, adapted from Lyall et al and Bray et al 
[17,19]. Cells were fixed with 50 μL/well 4% (wt/vol) paraformaldehyde (PFA; Electron 
Microscopy Sciences, 15710-S) for 15 min at room temperature. For permeabilisation, 
cells were incubated in 0.1% Triton X-100 (Sigma-Aldrich, T8787) in PBS for 15 min 
at room temperature. For lipid droplet analysis, cells were then stained with a 
combination of NucBlue Live ReadyProbes® Reagent (2 drops/mL) (Molecular 
Probes, R37605), HCS CellMask™ Red (2 μL/10 mL) (Invitrogen, H32712), and 
BODIPY™ 493/503 (1:1000) (Life Sciences, D3922), as per the manufacturer’s 
instructions. For quantification of mitochondrial fluorescence, cells were stained with 
MitoTrackerÔ Deep Red FM (1/4000; Invitrogen, M22426) prior to fixation with 50 
μL/well 4% (wt/vol) PFA (Electron Microscopy Sciences, 15710-S) for 15 min at room 
temperature. Cells were then stained with a combination of NucBlue Live 
ReadyProbes® Reagent (2 drops/mL), and Alexa FluorÔ 555 Phalloidin (Invitrogen, 
A34055), as per the manufacturer’s instructions. Following staining, images were 
acquired using an Operetta High Content Analysis microscope (Perkin Elmer, 
Buckinghamshire, UK). Lipid droplet morphology was analysed as previously 
described [17,20]. To do this, several random fields in each well were imaged before 
performing cell segmentation. Cell segmentation enables identification of features 
such as organelles and was performed by identifying nuclei followed by the cytoplasm. 
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Following this, quality control was performed and cells that were not segmented 
correctly were excluded, based on area, roundness and intensity. Finally, intensity, 
morphology and texture of cell features were quantified for each channel, for either 
lipid droplets or mitochondria.   
 
2.4 Molecular biology 
2.4.1 RNA Purification 
Plate growing surfaces were washed twice with PBS, before incubating in QIAzol 
(#79306, QIAGEN) for 5 minutes at room temperature. RNA was then purified using 
the Monarch® Total RNA Miniprep Kit (New England BioLabs, T2010) as per the 
manufacturer’s instructions. A DNase treatment step was performed, using the 
TURBO DNA-free™ Kit (#AM1907, Ambion), as per the manufacturer’s instructions. 
Samples were snap frozen on dry ice and stored at -80°C until required. 
 
2.4.2 RNA quantification and quality control 
RNA was quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific). 
For RNA-sequencing (RNA-seq), sample integrity was measured using a 2100 
Bioanalyzer (Agilent), to measure the RNA Integrity Number (RIN) and 28S/18S ratio. 
The RIN of all samples was >9.0, and the 28S/18S ratio of all samples was >1.0, 
meeting the requirements for sample submission for RNA-seq. For non-RNA-seq 
downstream analyses, A260/280 and A260/230 ratios were measured on a NanoDrop 
(Thermo Fisher Scientific). RNA integrity was assessed on a 1% agarose gel, stained 
with Gel Red (Cambridge Bioscience, Cambridge, UK) 0.005% final concentration, 
and assessing the presence of bands representing 28S and 18S ribosomal subunits.   
 
2.4.3 Reverse transcription (RT) 
For qPCR analysis, 1µg of RNA was added to nuclease-free H2O (NFH2O) to a 
volume of 10µL, which was then reverse transcribed to complementary DNA (cDNA) 
using the High Capacity cDNA Reverse Transcriptase Kit (#4368814, Applied 
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Biosystems) in accordance with the manufacturer’s guidelines. 10 µL of the 2 x master 
mix described in Table 2.3 was added to the 10 µL of diluted RNA. This was then 
reverse transcribed on a Techne Primer Thermal Cycler (Techne, UK) using the 
cycling conditions described in Table 2.4. A negative no transcriptase control was 
included. 
 
Component Volume/Sample (µL) 
10 x RT Buffer 2.0 
dNTP Mix, 100mM  0.8 
10 x RT Random Primers 2.0 
MultiScribeä Reverse Transcriptase  1.0 
RNase Inhibitor 1.0 
NFH2O 3.2 
Table 2.3. Master mix recipe for reverse transcription of RNA to cDNA 
 
Step 1 2 3 4 
Temperature 
(°C) 
25 37 85 4 
Time (min) 10 120 5 Hold 
Table 2.4. Cycling conditions for reverse transcription  
 
2.4.4 Reverse transcriction-quantitative polymerase chain 
reaction (RT-qPCR) 
2 μL of the reverse-transcribed cDNA was used in the reaction mixture shown in Table 
2.5. A list of all primer sequences used for RT-qPCR analysis of gene expression is 
shown in Table 2.6. A water and non-reverse transcriptase control were routinely 
used. All assays were carried out in triplicate. Once the mixture was pipetted into a 
384-well PCR plate (Thermo Fisher, West Sussex, UK), the plate was centrifuged for 
2 min at 563 x g to ensure all liquid was mixed at the bottom of the well. The plate 
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was inserted into the LightCycler® 480 Instrument (Roche, West Sussex, UK), and 
run on the program shown in Table 2.7. 
 
The LC480 Software (Roche, West Sussex, UK) measured fluorescence throughout 
the experiment and plotted fluorescence against PCR cycle number. The crossing 
point (Cp) was calculated as the maximum point of the second derivative of the 
amplification curve. Triplicates were considered acceptable if the standard deviation 
of the Cp was less than 0.3 cycles. Negative controls were considered acceptable if 
the Cp of any signal was greater than 10 cycles higher than that of the lowest 
standard. Each assay was considered acceptable if the reaction efficiency was 
between 1.8 and 2.1. Relative levels of mRNA of unknown samples were interpolated 
from the standard curve and expressed relative to the abundance of a reference gene. 
Student’s t-tests were carried out to ensure transcript quantities of reference genes 
were not significantly different between groups. 
 
Component Volume/Sample (µL) 
PerfeCTaÒ FastMixÒ II (#733-2110, 
Quanta Biosciences Inc.ä)  
5.0 
Forward Primer 0.4 
Reverse Primer 0.4 
NFH2O 2.1 
UPL Probe 0.1 
cDNA 2.0 
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Table 2.6 Primer pairs and probes used for qPCR. All sequences are written 5’-3’ 
 
Step Temperature (°C) Time No. Cycles 






Cool 40 30 seconds 1 
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2.4.5 RNA sequencing 
Where RNA samples had a RIN of >8.0, they were deemed suitable for RNA 
sequencing. Library preparation and RNA-seq were performed by the Beijing 
Genomics Institute (BGI, Beijing, China). RNA samples were first depleted of 
ribosomal RNA (rRNA) using the Ribo-Zero Gold rRNA Removal Kit (#MRZG12324, 
Illumina). Subsequent library preparation was performed using the TruSeqÒ Stranded 
mRNA Library Preparation Kit (#RS-122-2101, Illumina). Samples were then 
sequenced using the HiSeq 4000 PE100 platform (Illumina), to a depth of >60 million 
reads, to provide 100bp paired end reads. 
 
2.4.6 3’RNA-sequencing  
Sequencing was performed at the Wellcome Trust Clinical Research Facility 
(University of Edinburgh). Library preparation was done using the QuantSeq 3’ 
mRNA-Seq Library Prep Kit (Lexogen, Austria). The template was prepared using the 
Ion PI Hi-Q OT2 200 kit (Thermo Fisher Scientific, UK). Sequencing was performed 
using the Ion PI Chip Kit v3 (Thermo Fisher Scientific, UK).  
 
2.5 Studying mitochondrial respiration 
2.5.1 Protein Extraction 
Adherent HLCs were washed once with ice-cold PBS, before incubating in ice-cold 
RIPA Lysis and Extraction Buffer (Thermo Scientific, 89900) supplemented with 
cOmplete™ Protease Inhibitor Cocktail tablets (1/10 mL buffer; Roche, 
11697498001). The suspended HLCs were placed on ice for 30 minutes, vortexing 
every 3 minutes, before centrifuging for 20 min at 4 °C, 12,000 rpm. The 
supernatant was collected and stored at -80 °C until needed.  
 
2.5.2 Western blot analysis 
Protein quantification was performed using the Qubit™ Protein Assay Kit (Invitrogen, 
Q33211), as per the manufacturer’s instructions. Protein concentration was measured 
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using a Qubit™ Fluorometer (Invitrogen, Massachusetts, USA). Equal concentrations 
(50 μg) of HLC protein extract in 4 x Sample Loading Buffer (Li-Cor, 928-40004) were 
loaded onto NuPAGE™ 4-12% Bis-Tris Protein Gels (Invitrogen, NP0326BOX). 
Following resolution, protein was transferred to a methanol-activated polyvinylidene 
difluoride (PVDF) membrane. Protein transfer was measured using Revert 700 Total 
Protein Stain Kit (Li-Cor, 926-11010) as per the manufacturer’s instructions.  
Membranes were then blocked with Tris-buffered saline containing Tween 20 (TBST) 
and 5% skimmed milk powder, before incubating with either Pyruvate Dehydrogenase 
(C54G1) Rabbit mAb (Cell Signaling Technology, 3205) or SDHA (D6J9M) XP® 
Rabbit mAb (Cell Signaling Technology, 11998), both a 1:1000 dilution. The 
membranes were washed in TBST before incubating with the secondary antibody, 
IRDye® 680RD Donkey anti-Mouse IgG (Li-Cor, 926-68072) at a 1:10,000 dilution, for 
1 h at room temperature, in the dark, with shaking. Blots were visualised on a Li-Cor 
Odyssey® CLx (Li-Cor, Nebraska, USA), and bands normalised to the Revert 700 
Total Protein Stain, as per the manufacturer’s instructions.  
 
2.5.3 Citrate synthase activity assay 
Citrate synthase activity was assessed as a readout of mitochondrial integrity 
[270,271]. Mitochondria were isolated using the Mitochondria Isolation Kit for Cultured 
Cells (Thermo Scientific, 89874), as per the manufacturer’s instructions, selecting 
option A for isolation. Citrate synthase activity, a marker of mitochondrial integrity, 
was then measured using the Citrate Synthase Activity Colorimetric Assay Kit 
(BioVision, K318), as per the manufacturer’s instructions.  
 
2.5.4 Cell mitochondrial stress test assay 
HLCs were differentiated directly onto Seahorse XF24 V28 cell culture plates (Agilent, 
100882-004). Control and LPO groups were assigned to each well randomly, to 
ensure positioning did not impact mitochondrial respiration. The oxygen consumption 
rate (OCR) of LPO-exposed HLCs was measured using the Agilent Seahorse XF Cell 
Mito Stress Test Kit (Agilent, 103015-100) on a Seahorse XF Analyser (Agilent, 
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California, USA). Data were collected from two separate plates, representing two 
technical replicates. Analyses were performed under basal conditions and following 
treatment with oligomycin A (4 µM; an ATPase inhibitor), carbonyl-cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP; an ETC uncoupler), and combined 
rotenone (200 nM) and antimycin A (1 µM) (inhibitors of complex I and III, 
respectively). Two concentrations of FCCP (0.5 μM and 1.0 μM) were used for 
optimisation. Since replicates within each group responded similarly to each other, 
results were combined. OCR was normalised to total protein for each well, using the 
sulforhodamine B (SRB) assay.  
 
2.5.5 Sulforhodamine B (SRB) assay 
This was performed as previously described [272], but with spectrophotometric 
measurements read at 540 nm. After measuring oxygen consumption, 50 µL of 50% 
TCA solution was added to each well of the Seahorse XF24 V28 plate. Plates were 
then incubated at 4°C for 1 h. Wells were then washed 10 times with tap water and 
air dried, before adding 50 µL SRB to each well for 30 min at room temperature. 
Excess dye was removed by washing 4 times in 1% acetic acid solution. The plates 
were then air dried again. Cell-bound SRB was then dissolved using 200 µL tris 
solution, and the solution transferred to 96-well plates for spectrophotometry. 
Absorbance was then measured at 540 nm on a spectrophotometer.  
 
2.5.6 Nuclear magnetic resonance (NMR) Spectroscopy 
This protocol was previously described by Hollinshead et al [273]. NMR spectroscopy 
was performed by Christian Ludwig at the University of Birmingham (Birmingham, 
UK). At the conclusion of tracer experiments, cells were washed with 2 mL ice-cold 
0.9% saline solution and quenched with 0.3 mL pre-chilled methanol (-20 °C). After 
adding an equal volume of ice-cold HPLC-grade water containing 1 µg/mL D6-glutaric 
acid (C/D/N Isotopes Inc), cells were collected with a cell scraper and transferred to 
tubes containing 0.3 mL of chloroform (-20 °C). The extracts were shaken at 1400 
rpm for 20 min at 4 °C and centrifuged at 16,000 x g for 5 min at 4 °C. Then, 0.3 mL 
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of the upper aqueous phase was collected and evaporated in eppendorfs, under a 
vacuum using a Savantä SpeedVacä Concentrator (ThermoFisher). These samples 
were used either for NMR spectroscopy of for GC-MS. For NMR, dried samples were 
re-suspended in 60 µL of 100 mM sodium phosphate buffer (pH 7.0) containing 500 
µM DSS and 2 mM Imidazole, 10% D20, pH 7.0. Samples were vortexed, sonicated 
(5-15 min) and centrifuged briefly, before transferred to 1.7 mm NMR tubes using an 
automated Gilson. One-dimensional (1D)-1H NMR spectra and two-dimensional (2D)-
1H,13C Heteronuclear Single Quantum Coherence Spectroscopy (HSQC).  
 
NMR spectra were acquired using a 600 MHz Bruker Avance III spectrometer (Bruker 
Biospin) with an inverse cryogenic probe for 1.7 mm NMR sample tubes, fitted with a 
z-axis pulsed field gradient, at 300 K. Spectral widths were set to 13 and 160 ppm for 
the 1H and 13C dimensions, respectively. For the indirect (13C) dimension of the 2D-
1H,13C HSQC NMR spectra, 1228 out of 4096 (30%) data points were acquired using 
a non-uniform sampling scheme. 13C-13C splittings were enhanced 4-fold in the 13C 
dimension. Each sample was automatically tuned, matched and then shimmed (1D-
TopShim) to a DSS line width of <1 Hz before acquisition of the first spectrum. Total 
experiment time was ~15 min per sample for 1D-1H NMR spectra and 1 h per sample 
for 2D-1H,13C HSQC NMR spectra. 1D-1H NMR spectra were processed using the 
MATLAB-based MetaboLab software [274]. All 1D data sets were apodized using a 
0.3 Hz exponential window function and zero-filled to 131,072 data points before 
Fourier Transformation. The chemical shift was calibrated by referencing the DSS 
signal to 0 ppm. 1D-1H NMR spectra were manually phase corrected. Baseline 
correction was achieved using a spline function [274]. 1D-1H-NMR spectra were 
exported into Bruker format for metabolite identification and concentration 
determination using Chenomx 7.0 (Chenomx INC). 2D-1H,13C HSQC NMR spectra 
were reconstructed using compressed sensing in the MDDNMR and NMRpipe 
software [275–277]. The final spectrum size was 922 real data points for the 1H 
dimension and 16,384 real data points for the 13C dimension. Analysis was performed 
using MetaboLab and pyGamma software was used in multiplet simulations [278]. 
The methyl group of lactate was used to calibrate the chemical shift based on its 
assignment in the human metabolome database [279]. 
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2.5.7 Gas Chromatography-mass spectrometry (GC-MS) 
These protocols were performed by Daniel A. Tennant, Paul D. Walker or Alpesh 
Thakker at the University of Birmingham (Birmingham, UK). Dried polar metabolites 
were purified as described for NMR spectroscopy. These were derivatised by 
incubating with 40 µL 2% methoxyamine hydrochloride (Sigma Aldrich, 226904) in 
pyridine (Thermo Fisher Scientific, 25104) at 60 °C for 1 h, followed by incubation with 
60 µL N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide with 1% tert-
butyldimethylchlorosilane (MTBSTFA with 1% t-BDMCS) at 60 °C for 1 h.  
 
GC-MS analysis was performed using an Agilent 6890GC in combination with an 
Agilent 5975C MS. The MS was operated under electron impact ionization at 70 eV 
with the source held at 230 °C and the quadrupole at 150 °C. Helium was used as the 
carrier gas and maintained at a flow rate of 1 mL/min. 1 µL of derivatised sample was 
injected (splitless) with an inlet temperature of 280 °C on to a Rxi-5MS column 
(Restek) The oven temperature was held at 100 °C for 1 min then increased at a rate 
of 5 °C/min up to a maximum temperature of 330 °C. Ions were detected using 
selected ion monitoring (SIM) mode as previously described [280]. MetaboliteDetector 
software was used to correct for the natural isotope distribution and to determine the 
mass isotopomer distribution (MID) [281].  
 
2.6 Epigenome profiling  
2.6.1 DNA extraction 
DNA extraction was carried out using DNeasy® Blood and Tissue kit (Qiagen, 
Manchester, UK), according to kit protocol for use on cultured cells, using a spin-
column technique. Cell culture wells had 200μL PBS added and cells were scraped 
and transferred to microcentrifuge tubes, followed by 20 μL PureLink proteinase K 
(Qiagen, Manchester, UK). Tubes were vortexed and incubated at 56 °C for 10 min. 
Following incubation, tubes were vortexed thoroughly for 15 s, and 20 μL RNase was 
added. The tubes were incubated at room temperature for 2 minutes, before 200 μL 
Buffer AL was added, and vortexed again. 200μL 100% ethanol (Fisher Scientific, 
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Loughborough, UK) was added, before mixing thoroughly again by vortexing. This 
mixture was transferred to a DNeasy mini spin column placed in a 2 mL collection 
tube. Samples were centrifuged at 6000 x g for 1 min. Flow-through was discarded. 
500 μL Buffer AW1 was added, samples were centrifuged again, and flow-through 
discarded again. This process was repeated using Buffer AW2. Samples were then 
eluted in 100 μL Buffer AE. Once extracted, DNA was handled on ice and stored at -
4 ⁰C. 
 
2.6.2 DNA quality control 
DNA was quantified with the Qubit 2.0 Fluorometer (Invitrogen, Paisley UK) using 
DNA “broad range” standards as per manufacturer’s instructions for DNA samples. 
DNA integrity was determined by resolving extraction products on a 1.5% agarose gel 
and staining with gel red (Cambridge Bioscience, Cambridge UK) to a final 
concentration of 0.005%. 
 
2.6.3 Ultra-performance liquid chromatography (UPLC) 
Sample preparation 
2.5 μg DNA in 43 μL water, per sample, was incubated at 95 °C for 10 min. 5 μL of 
10x T7 DNA polymerase reaction buffer and 10 U T7 DNA polymerase (Thermo 
Scientific, Renfrew, UK) was then added. The reaction was incubated overnight at 37 
°C, followed by inactivation by incubation at 75 °C for 10 min. The samples were then 
centrifuged for 45 min at > 12,000 x g, the supernatant was aspirated and dried down 
using a Speed Vac and stored at -80 °C until time of analysis. 
 
UPLC 
UPLC was carried out by Dr Jimi Wills at the mass spectrometry facility, Institute for 
Genetic and Molecular Medicine, University of Edinburgh. After reconstitution, 10 μL 
polymerase-treated sample was loaded onto a HyperCarb column (Thermo Fisher 
Scientific, West Sussex, UK) and eluted using an Ultimate 3000 BioRS (Thermo 
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Fisher Scientific, West Sussex, UK) system over a 5 min gradient from 0 to 100% B, 
where A was 20 mM ammonium carbonate and B was acetonitrile. Data were 
collected using a Q Exactive (Thermo Fisher Scientific, West Sussex, UK) scanning 
in negative mode at 70k resolution and a scan range of 300-350 m/z. 
 
2.6.4 Hydroxymethylcytosine DNA immunoprecipitation 
(hMeDIP-seq) 
DNA shearing 
DNA was fragmented using the Covaris® E220 Focused-ultrasonicator (Covaris, 
Brighton, UK). 5 μg DNA was diluted in 130 μL TE buffer and was placed into a crimp 
cap microTUBE (Covaris, Brighton, UK). DNA was then sonicated in the conditions 
shown in Table 2.11. Quality of shearing was assessed by running in a 1.5% agarose 
gel in 0.5x TBE buffer for 90 min at 70 volts. Acceptable shearing was deemed as 
fragments between 100 and 600 base pair length with a mean of 200 to 300 base 
pairs and a uniform appearance between sheared samples. 
Peak Incident Power (W) 175 
Duty Factor 10% 
Cycles per burst 200 
Treatment time (s) 305 
Temperature (°C) 7 
Table 2.8 Covaris conditions for DNA shearing 
 
Hydroxymethylcystosine DNA immunoprecipitation (hMeDIP) 
2.5μg of sheared DNA was diluted up to 450 μL in TE buffer in 1.5 mL Eppendorf® 
LoBind microcentrifuge tubes (Eppendorf, UK) and then denatured by placing in 
boiling water in a heat block for 10 min. Samples were immediately cooled on ice for 
5 min. 50 μL of 10X IP buffer was then added and samples were briefly vortexed. 50 
μL ‘input’ was then removed and placed at 40 °C until the DNA clean up step below. 
1 μL of 5-Hydroxymethylcytosine (5-hmC) antibody (pAb) (Cat. No 39769; Active 
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Motif, CA, USA)  or 1 μL Normal Rabbit IgG (Cat. No 12-370, Merck, Massachusetts, 
USA) was then added to the remaining sample and incubated for 2 hours at 40 °C. 
 
40 μL of Dynabeads® Protein G for Immunoprecipitation (Invitrogen, Paisley, UK) 
were prewashed with 0.1% BSA in PBS for 5 min on a rotating wheel at room 
temperature. The beads were collected on a magnetic rack and the supernatant was 
removed. To ensure all supernatant was removed, the beads were briefly centrifuged 
at 400 x g for 5 seconds, bound to the rack and the supernatant removed again. This 
washing step was repeated twice. The beads were then resuspended in 40 μL of 1X 
IP buffer and added to the DNA/antibody mixture. This was then incubated for 1 hour 
at 4 °C on a rotating wheel. The beads were then collected again on the magnetic 
rack. The supernatant was discarded, and the tube was centrifuged again at 400 x g 
for 5 seconds, beads bound to the magnetic rack and residual supernatant removed. 
The beads were then washed three times with 1 mL of cold 1X IP buffer in the same 
manner as described above with BSA-PBS. The beads were then resuspended in 250 
μL of digestion buffer and 20 μL of proteinase K 20 mg/ml (Roche, UK) was added. 
The samples were then incubated in a thermoshaker overnight at 1000 rpm and 55 
°C. Following this, the tubes were spun at 400 x g for 5 seconds, the beads were then 
collected on a magnetic rack and the supernatant collected, containing DNA 
fragments enriched with 5hmC. Both the enriched fraction and input samples were 
then purified using the QIAquick PCR Purification Kit (Qiagen, UK) according to 
manufacturer’s protocol, with elution into 22 μL of water. 
 
qPCR of immunoprecipitated products 
Immunoprecipitated products were analysed by qPCR to determine the efficiency of 
the immunoprecipitation. Regions from the genome with known high or low 5hmC 
levels were selected as positive and negative control regions. 10 μL of the eluted DNA 
from purification was diluted 1:5 in water and was used in the reaction mixture shown 
in Table 2.9, with primer sequences for control regions shown in Table 2.10. 
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A water control was used routinely. Standard curves were created using serial 1:2 
dilutions of sonicated DNA. qPCR plates were centrifuged at 563 x g for 2 min prior 
to thermal cycling, to ensure all samples and mastermix were at the bottom of the 
well. The LightCycler® 480 Instrument (Roche, Sussex, UK) was used for 
temperature cycling (using the program shown in Table 2.11) and fluorescence 
quantifications. The LC480 Software (Roche) measured fluorescence throughout the 
experiment and data was analysed as previously described in section 2.4.4.  
Reagent Volume (μL) 
SYBR Green Master Mix (Roche, Burgess Hill, 
UK 
5.0 
Forward Primer (100 μM) 0.02 
Reverse Primer (100 μM) 0.02 
Water 1.96 
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Step Temperature (°C) Time No. cycles 














Cool 40 10 seconds 1 
Table 2.11 LightCycler 480 thermal cycling program used with SYBR Green 
assays for qPCR of hMeDIP products 
 
Whole genome amplification (WGA) 
WGA was performed using the SeqPlex Enhanced DNA Amplification Kit (SEQXE) 
(Sigma, UK), according to the manufacturer’s instructions. 10 μL of 
immunoprecipitation product and input sample were used. 15 cycles of DNA 
amplification were performed in a standard PCR machine (Techne Prime, Bibby 
Scientific, Birmingham, UK). For adaptor removal, all samples were quantified by 
nanodrop, the lowest DNA concentration was taken, and volume required for 2.1 μg 
calculated. This volume was then used for all samples in the adaptor removal step. 
Final elution was in 30 μL of water. 
 
Ion Torrent Proton sequencing 
Proton sequencing was outsourced to the Wellcome Trust Clinical Research Facility 
at the Western General Hospital, Edinburgh, UK. All kits and hardware for this 
procedure were from Life Technologies (Paisley, UK) unless specified. ). Three 
biological replicates were sequenced per group. Briefly, samples were quantified 
using the Qubit dsDNA HS kit and approximately 100 ng of DNA was used to generate 
a DNA library from each sample using the Ion Xpress Plus Fragment Library Kit. 
During this process, DNA fragments are end repaired and then ligated to Ion specific 
barcode adaptors before being amplified (8 cycles) and twice purified using the 
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Agencourt AMPure XP PCR clean up kit (Beckman Coulter, High Wycombe, UK) 
which size selects fragments approximately 100–250bp in length. Libraries were then 
quality controlled using the Agilent Bioanalyser DNA HS kit (Agilent, Santa Clara, US) 
and pooled in equimolar pairs prior to template preparation using the Ion PI™ Hi-Q™ 
OT2 200 Kit and sequencing on the Ion Torrent semiconductor sequencer using the 
Ion PI™ Hi-Q™ Sequencing kit and an Ion PI™ Chip Kit v3. For consistency, each 
sample was sequenced on a PI chip with its own input. 
 
2.7 Bioinformatic and statistical analyses  
2.7.1 Bioinformatic analysis of RNA-seq data 
RNA-seq analysis 
The generated FASTQ files were trimmed to remove adapters, using Trimmomatic 
(version 0.36) [282], before performing quality control with FastQC (version 0.11.4) 
[283]. Alignment was performed against the Homo sapiens GRCh19 assembly. The 
assembly was first indexed using STAR (version 2.5.1b) before mapping trimmed 
reads, using STAR (version 2.5.1b) in paired-end mode with default behaviour [284]. 
Duplicate reads were removed using Picard (version 2.7.11) [285], before using 
featureCounts to generate raw read counts for each gene. Differential gene 
expression (DEG) analysis was performed using DESeq2 [286]. Heatmaps were 
generated with Heatmapper [287]. Pathway enrichment analysis was performed using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) function [288–290] of the 
Database for Annotation, Visualization, and Integrated Discovery (DAVID) [291,292]. 
Transcriptomic sequencing data have been deposited on the GEO repository 
(accession number GSE138052). 
 
3’ RNA-seq analysis 
Data from 3’ RNA-sequencing were analysed using the BlueBee platform (Lexogen, 
Netherlands), which generated differential expression and principal component 
analyses (PCA). Pathway enrichment analysis was performed using the Gene 
Ontology (GO) Biological Processes function [288–290] of DAVID [291,292]. 
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2.7.2 hMeDIP-seq analysis 
Sequencing generated reads with a mean read length of 137-147 base pairs and 
21,130,039 - 31,693,844 reads per sample. Reads were aligned to the hg19 genome 
using Torrent Suite v5.2.0. Aligned reads were sorted using SAMtools, before calling 
peaks using MACS2 (v. 2.1.1) -f BAM --broad --broad-cutoff 0.05 -B -g hs, over 
corresponding inputs [293]. To detect differentially hydroxymethylated regions 
(DHRs), I used Diffbind with DESeq2 [294]. For Diffbind analysis, data were 
normalised to a pooled input for each group and an IgG control. Differentially 
hydroxymethylated regions were assigned to genes and other genomic features using 
the HOMER (v. 4.8; hg19) annotatePeaks tools [295]. Regions of interest were 
identified from the hmeDIP-sequencing dataset. Data are available through the Gene 
Expression Omnibus (GSE144955). Sliding window profiles and heatmaps were 
generated using deepTools [296], using the plotProfile and plotHeatmap functions, 
respectively, with blacklisted regions subtracted. 
 
2.7.3 Statistical testing of null hypotheses 
Statistical analysis was performed using GraphPad Prism 8 software. Datasets were 
routinely tested for normality of distribution using the Shapiro-Wilks test. When 
comparing two groups, where data were normally distributed, an unpaired Student’s 
t-test was used for analysis. Where data were not normally distributed, a non-
parametric Mann Whitney U test was used. Comparisons between two groups with 
repeated measures (e.g. different isotopomers of the same metabolite) were made 
using a two-way analysis of variance (ANOVA), with Sidak post-hoc testing to account 
for the false discovery rate. All values are represented as mean ± SD with p <0.05 
classed as significant.  
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Chapter 3: Characterising the transcriptome of 
a human pluripotent stem cell model of NAFLD 
3.1 Introduction 
In the earliest stage of NAFLD, TG accumulation in hepatocytes leads to the 
development of hepatic steatosis [17], which is characterised by the development of 
macrovesicular steatosis, whereby TGs are stored in large lipid droplets [297]. 
Understanding the changes in mRNA expression associated with development of 
these lipid droplets may be informative for the development of therapeutics in the 
future.  
 
Accurate in vitro modelling of human NAFLD is challenging, and to date many groups 
have focused on the use of whole tissues from human or mouse, HCC cell lines, or 
primary hepatocytes [42,129,298,299]. However, the use of whole tissue for 
transcriptome analysis is confounded by the presence of heterogeneous cell 
populations, each of which may have a different transcriptional profile. A limitation of 
using primary cells is that they rapidly lose their phenotype and display altered 
transcriptional signatures on purification [300,301]. I therefore set out to further 
characterise a human-relevant in vitro model of NAFLD [128], that overcomes the 
limitations of other models and determine the impact of hepatic steatosis on the 
transcriptome. To address this, I performed high content analysis microscopy to 
analyse patterns of lipid accumulation in LPO-treated HLCs, before performing an in-
depth bioinformatic analysis of the transcriptome in these cells and comparing this 
with publicly available data from NAFLD patients.  
 
3.1.1 Hypothesis 
Treatment of HLCs with LPO induces similar lipid accumulation and transcriptional 
patterns to those observed in human disease making this a suitable model for analysis 
of NAFLD-associated metabolic and epigenetic dysfunction. 
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3.1.2 Aims 
1. To determine whether HLCs differentiated on a Laminin-521 extracellular 
matrix develop a NAFLD-like phenotype upon challenge with high energy 
substrates. 
2. To assess patterns of lipid accumulation in LPO-treated HLCs, and whether 
they mirror human pathology.  
3. To characterise the transcriptomic changes that occur in LPO-treated HLCs 
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3.2 Materials and methods 
3.2.1 Differentiation and maturation of hPSC-derived 
hepatocyte-like cells 
To differentiate human female H9 cells to HLCs, I used a previously defined protocol, 
as outlined in Figure 3.1 and fully described in Chapter 2, section 2.2. H9s were 
primed to a definitive endoderm using a combination of WNT3A and Activin A, with 
daily media changes for 3 days. Next, I induced hepatoblast specification by culturing 
endodermal cells in media supplemented with Knock-Out Serum Replacement and 
DMSO. Hepatoblast specification continued for 5 days, with media changes every 
other day. To mature hepatoblasts to a hepatocyte-like phenotype, cells were then 
cultured in media containing oncostatin M, hepatocyte growth factor, and 
hydrocortisone. Maturation continued for 9 days, with media changes every other day.  
 
Figure 3.1. Schematic of the hepatocyte-like cell differentiation protocol. This 3-
stage differentiation protocol differentiates hPSCs from seeded single cells (day 0) to 
a definitive endoderm (day 3), hepatoblast specification (day 8), forming mature HLCs 
(day 17). RPMI = Roswell Park Memorial Institute (RPMI) 1640 medium; B27 = B27 
medium supplement; Knockout DMEM = Knockout Dulbecco’s Modified Eagle 
Medium; KO SR = knockout serum replacement; HGF = hepatocyte growth factor; 
OSM = oncostatin M; HCC = hydrocortisone.   
 
HLCs were cultured in a 96-well format for measurements of lipid accumulation and 
in a 6-well format for all other analyses. The luciferase-based assay to measure 
CYP3A4 activity is described full in Chapter 2, section 2.3.2. Lipid accumulation was 
RPMI 1640
+ WNT3A (50 ng/mL)
+ Activin A (100 ng/mL)
+ B27
HepatoZYME
+ HGF (10 ng/mL)
+ OSM (20 ng/mL)
+ HCC (10 µM)
Knockout DMEM
+ 20% KO SR
+ DMSO (1%)
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induced as previously described [128]. Briefly, at day 17, HLCs were exposed to a 
cocktail of sodium l-lactate (L; 10mM), sodium pyruvate (P; 1 mM) and octanoic acid 
(O; 2 mM) (Sigma, Gillingham, UK) for a period of 48 h. 
 
3.2.2 High content analysis microscopy 
Cells were stained with a cell painter assay, adapted from Lyall et al and Bray et al 
[128,302]. Cells were fixed with 50 μL/well 4% (wt/vol) paraformaldehyde (Electron 
Microscopy Sciences, 15710-S) for 15 minutes at room temperature. For 
permeabilisation, cells were incubated in 0.1% Triton X-100 (Sigma-Aldrich, T8787) 
in PBS for 15 minutes at room temperature. For lipid droplet analysis, cells were then 
stained with a combination of NucBlue Live ReadyProbes® Reagent (2 drops/mL) 
(Molecular Probes, R37605), HCS CellMask™ Red (2 μL/10 mL) (Invitrogen, H32712), 
and BODIPY™ 493/503 (1:1000) (Life Sciences, D3922), as per the manufacturer’s 
instructions. Following staining, images were acquired using an Operetta High 
Content Analysis microscope (Perkin Elmer, Buckinghamshire, UK). Lipid droplet 
morphology was analysed as described in Chapter 2, section 2.3.4.  
 
3.2.3 Gene expression 
Total RNA was extracted from HLCs using the Monarch® Total RNA Miniprep Kit (New 
England BioLabs, T2010). cDNA was generated using the High Capacity cDNA 
Reverse Transcriptase Kit (Applied Biosystems, 4368814). A master mix was 
prepared using PerfeCTa FastMix II (Quanta Biosciences, Inc., 95118-250). cDNA 
was amplified and quantified using the Universal Probe Library (Roche, Burgess Hill, 
UK) system on a Roche LightCycler 480 (Roche Diagnostics Ltd, Switzerland). Gene 
expression was measured for analysis of lipid droplet-associated markers and 
validation of transcriptomic analysis. Details of primers and Universal Probe Library 
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3.2.4 Transcriptomic and pathway analysis  
RNA library preparation and sequencing were performed by BGI (Beijing, China). The 
sequencing and bioinformatic pipelines are fully described in Chapter 2, section 2.4.7.  
 
3.2.5 Statistics 
All statistical analyses were performed using Graph Prism Version 8.0 for Windows 
or macOS, GraphPad Software, La Jolla California USA, www.graphpad.com. 
Normality of data distribution was measured using the Shapiro-Wilks test. Where 
indicated, data were analysed by unpaired Student’s t-test, Mann-Whitney test or two-
way analysis of variance (ANOVA). Data were considered to be significant where p 
<0.05. For transcriptomic analyses, changes in mRNA expression were considered 
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3.3 Results 
3.3.1 Characterisation of human pluripotent stem cells 
(hPSCs) 
Standardised and reproducible hPSC culture requires a number of quality control 
assessments to ensure maintained pluripotency of the cells, including morphological 
validation and examination of pluripotency and cell surface markers. For the studies 
described throughout this thesis, I used a female H9 hPSC line, which were cultured 
on Laminin-521-coated plates. To minimise spontaneous differentiation, cells were 
passaged regularly. Cell colonies were tightly packed and had a high nucleus to 
cytoplasm ratio (Figure 3.2).  
 
Figure 3.2. hPSC morphology in culture. Representative image of hPSCs, cultured 
in mTeSR medium, on Laminin-521-coated 6-well plates. Imaged H9 cells are at 
passage 40. Scale bar = 100 µm.  
 
Using immunohistochemistry, I showed that H9 cells, in the undifferentiated state, 
express NANOG, marking their pluripotent capacity (Figure 3.3). To assess the 
presence of pluripotent cell surface markers, I performed flow cytometry and 
measured SSEA-1, SSEA-4, TRA-1-60 and TRA-1-81. While H9s were negative for 
SSEA-1, they were positive for SSEA-4, TRA-1-60 and TRA-1-81, further supporting 
that these cells have pluripotent capacity (Figure 3.4). The capacity of these cells to 
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differentiate to hepatocyte-like cells demonstrates that they are also capable of 
forming an endodermal layer.  
 
Figure 3.3. Pluripotent marker expression in hPSCs. Pluripotent markers were 
detected by immunofluorescence in H9 hPSCs. (A) Hoechst dye was used to stain 
nuclei. (B-C) Staining was performed against a marker of pluripotency (NANOG) and 
a hepatocyte marker (HNF4A). (D) Images were merged to demonstrate localisation 
of NANOG to the cell nucleus in H9 cells. (E-H) Staining protocol was repeated in the 
absence of primary antibodies to ensure lack of non-specific binding by secondary 
antibodies. Images were taken at 40X magnification. 





A B C D
E F G H
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Figure 3.4. H9 cells express cell surface markers associated with pluripotency, which were detected by flow cytometry. Flow 
cytometry was used to determine the presence of pluripotency-associated cell surface markers in H9 cells. (A-C) Schematic of flow 
cytometry analysis methodology. H9s were negative for the expression of a marker of differentiation (E) SSEA-1. In contrast, H9s expressed 
the pluripotency markers (F) SSEA-4, (G) TRA-1-60, and (H) TRA-1-81. Figure panels show a representative distribution. n = 4 biological 
replicates.
SSEA-1 SSEA-4 TRA-1-60 TRA-1-81
A B C
E F G H
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To fully assess differentiation of hPSCs to HLCs, I performed RT-qPCR for 
pluripotency and hepatic markers, as well as measuring hepatocyte activity. NANOG 
mRNA expression was measured at each stage of differentiation, to determine 
whether cells were losing their pluripotent capacity (Figure 3.5). There was a 
decrease in NANOG expression throughout the differentiation process, which became 
undetectable once HLCs reached the end of the maturation period. In contrast, the 
hepatic markers ALB and HNF4A were undetectable in the undifferentiated H9s but 
were robustly expressed once cells reached the end of the maturation period. At this 
stage, CYP3A4 activity was analysed at the end of the differentiation process, to 
determine whether HLCs were displaying functional hepatocyte activity (Figure 3.6). 
Once fully differentiated, HLCs displayed robust CYP3A4 activity, in line with previous 
studies [128], and this was not diminished by induction of intracellular lipid 
accumulation, indicating that cells retain their hepatocyte-like phenotype upon 
challenge.  
 
Figure 3.5. Analysis of pluripotency and hepatic markers in HLCs during the 
differentiation process. RT-qPCR was used to measure mRNA expression of 
pluripotency (NANOG) and hepatic (ALB and HNF4A) markers. For each time point n 
= 3 biological replicates per gene. Data were analysed by two-way ANOVA with Sidak 
post-hoc testing and expressed as mean ± SD. ****p<0.0001. Figure taken from 
Sinton et al (2020) [303].   
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Figure 3.6. Functional analysis of hepatocyte activity in fully differentiated 
HLCs. CYP3A4 activity was measured to determine levels of functional hepatocyte 
activity. For each group n = 8 biological replicates. Data were analysed using a two-
tailed Student t-test and expressed as mean ± SD. Figure taken from Sinton et al 
(2020) [303].  
 
3.3.2 LPO treatment induces macrovesicular steatosis in 
HLCs  
It was previously reported that the high energy substrate cocktail LPO promotes 
intracellular lipid accumulation in HLCs [128] but it was unknown whether it promotes 
lipid droplet biogenesis or increased accumulation of lipids within existing droplets. To 
further assess this, mRNA expression of PLIN2, PLIN4 and PLIN5 was measured 
(Figure 3.7A-C), which showed significant increases in association with LPO 
treatment. I then performed lipid staining with BODIPY dye and assessed lipid droplet 
hyperplasia and hypertrophy. Representative images of control and LPO-treated cells 
indicated a perturbation of lipid accumulation (Figure 3.8A-B). Further analysis of lipid 
droplets using a high content microscopy system showed that LPO exposure was not 
associated with a change in the number of lipid droplets (Figure 3.8C) but did lead to 
an increase in the size of intracellular lipid droplets (Figure 3.8D), consistent with the 
development of macrovesicular steatosis.  
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Figure 3.7. RT-qPCR analysis of genes associated with lipid droplet 
membranes. RT-qPCR was used to measure mRNA expression of genes typically 
associated with formation of lipid droplet membranes. Expression of PLIN2 (A), PLIN4 
(B) and PLIN5 (C) was measured. For each group n = 3 biological replicates. Data 
were analysed using a two-tailed Student t-test and expressed as mean ± SD. 
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Figure 3.8. High content analysis of lipid droplets in LPO-treated HLCs. 
Intracellular lipid droplet number and size were measured by high content analysis 
microscopy. Hoechst dye (NucBlue) and BODIPY were used to stain nuclei or neutral 
lipids, respectively. Representative images of lipid accumulation in control (A) and 
LPO-treated (B) groups; 10x or 40x magnification. (C) Number of lipid droplets do not 
increase, (D) but intracellular lipid droplets increase in size (n = 32 biological 
replicates/group). Data were analysed using two-tailed Student t-test and expressed 
as mean ± SD. LPO = Lactate, Pyruvate, Octanoate. Figure adapted from Sinton et 
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3.3.3 Macrovesicular steatosis in HLCs is associated with 
wide-scale alterations of the transcriptome 
To examine the impact of LPO treatment on the transcriptome, mRNA sequencing 
was performed to a depth >60 million reads. Differential expression analysis identified 
853 downregulated and 826 upregulated genes, with a Log2 fold change cut-off >1.5 
(Supplementary file MCS1 – DEGs in LPO-treated HLCs ). The results of the RNA-
seq pipeline were validated by RT-qPCR analysis of key genes (Figure 3.9).  
 
Figure 3.9. Validation of RNA-seq analysis by RT-qPCR. Key genes were selected 
from the generated RNA-seq analysis and measured by RT-qPCR to confirm the 
analysis output. N = 4 biological replicates/group. Data were analysed using two-tailed 
Student t-test and expressed as mean ± SD. *p<0.05, ****p<0.0001. Figure adapted 
from Sinton et al (2020) [304].  
 
Principal component analysis (PCA) demonstrated that replicates within each of the 
control and LPO group clustered, showing minimal variation between replicates 
(Figure 3.10). Heatmap analysis of the top 1,000 dysregulated genes highlights the 
widescale transcriptomic changes that occur following LPO treatment (Figure 3.11). 
Furthermore, when applying statistical cut-offs of a Log2 fold change >1.5 and 
adjusted p value <0.05, wide-scale transcriptional changes are still present in LPO-
treated HLCs (Figure 3.12). Taken together, these findings demonstrate that LPO 
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treatment induces a transcriptional pattern that is distinct from control HLCs, and that 
this is consistent between biological replicates. 
 
 
Figure 3.10. Principal component analysis of transcriptomic data reveals 
clustering of replicates within groups following treatment of HLCs with LPO. 
PCA plot demonstrating differential clustering of each biological replicate from both 
control and LPO-treated HLCs. For each group n = 3 biological replicates. Figure 
adapted from Sinton et al (2020) [304]. 
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Figure 3.11. Heat map analysis of transcriptomic data reveals wide-spread 
transcriptomic changes following treatment of HLCs with LPO. Heap map 
representing the top 1,000 differentially expressed genes when comparing control and 
LPO-treated HLCs. Genes are clustered by Euclidean distance. For each group n = 
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Figure 3.12. Volcano plot of transcriptomic data reveals wide-spread 
transcriptomic changes following treatment of HLCs with LPO. Representation 
of differential mRNA expression in control and treatment groups. Non-significant 
expression is represented in either blue (adjusted p value >0.05) or purple (Log2 fold 
change <1.0). For each group n = 3 biological replicates. Figure adapted from Sinton 
et al (2020) [304]. 
 
Within the differentially expressed genes identified in this analysis, a number of genes 
that are typically associated with NAFLD were dysregulated upon induction of 
macrovesicular steatosis (Figure 3.13). Upregulated genes included those involved 
in lipid metabolism (PPARGC1A, PPARG, PPARA), lipid storage (PLIN2), glucose 
transport (SLC2A4, which encodes the glucose transporter type 4 GLUT4), and the 
pentose phosphate pathway (G6PD). In contrast, downregulated NAFLD-associated 
genes included those involved in cholesterol and bile acid regulation (CYP7A1), 
insulin resistance (NR0B2), ketogenesis (HMGCS1 and HMGCS2) and fatty acid 





















Adjusted p-value <0.05 Log2 fold change >1.0 Adjusted p-value <0.001
Log2 fold change >1.5
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Figure 3.13. Dysregulation of NAFLD associated genes. Differential expression 
analysis revealed dysregulation of a number of genes that are typically associated 
with NAFLD. For each group n = 3 biological replicates. Data presented here 
represent a subset of genes from the RNA-seq dataset. Data were analysed by two-
way ANOVA with Sidak post-hoc testing and expressed as mean ± SD. **p<0.01, 
****p<0.0001. Figure adapted from Sinton et al (2020) [304]. 
 
3.3.4 LPO treatment in HLCs disrupts pathways related to 
gene regulation, lipid metabolism and mitochondrial 
respiration  
I mapped genes with a log2 fold change cut-off >1.5 to the KEGG pathway database, 
identifying a number of enriched pathways. Upregulated pathways predominantly 
comprised signalling pathways, including hsa04725: cholinergic synapse, hsa04726: 
serotonergic synapse, and hsa04020: calcium signalling, and has04014: Ras 
signalling (Figure 3.14A). These pathways contained genes encoding adenylate 
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Downregulated KEGG pathways included several pathways (hsa05322: systemic 
lupus erythematosus, hsa05034: alcoholism, and hsa05202: transcriptional 
misregulation in cancer) containing a substantial number of genes encoding the 
histone structural units H1, H2A/B, H3 and H4 (Figure 3.14B; Chapter 8, Appendix 
1). In addition, there was downregulation of the pathways related to cholesterol 
(hsa00140: steroid hormone biosynthesis) and drug metabolism (hsa00982: drug 
metabolism – cytochrome P450, hsa00983: drug metabolism – other enzymes, and 
hsa00980: metabolism of xenobiotics by cytochrome P450). The cholesterol 
metabolism pathway showed downregulation of genes encoding hydroxysteroid 
dehydrogenases, cytochrome P450, and UDP-glucuronosyltransferases. Genes 
encoding cytochrome P450, and UDP-glucuronosyltransferases were also identified 
in drug metabolism pathways.  
  
When specifically comparing these transcriptomic data with the KEGG terms TCA 
Cycle and Oxidative Phosphorylation, there was extensive disruption within these 
pathways (Figure 3.15). Within the TCA Cycle pathway there were low, but 
significant, levels of transcriptomic disruption in the majority of genes encoding 
enzymes that catalyse metabolite interconversion (Chapter 8, Appendix 2). Analysis 
of the Oxidative Phosphorylation pathway revealed an overall downregulation of 
transcription of genes encoding components of respiratory complexes I (ND1, ND2, 
ND4L, NDUFS2, NDUFV1, NDUFA10, NDUFB2 NDUFA2, NDUFB10) and IV (COX1, 
COX4I1, COX8A, COX6B1), as well as ATP synthase (ATP6V1A, ATP5MF, 
ATP6V0D1, ATP6V1E1, ATP6, APT5MC2, ATP5MC1) (Chapter 8, Appendix 3). 
Previously, I observed decreased mitochondrial maximal respiration and spare 
reserve capacity in HLCs with increased intracellular lipid accumulation [303]. Taken 
together, these data suggest that NAFLD is associated with disruption of both the 
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Figure 3.14. KEGG Pathway analysis. All genes with a Log2 fold change > 1.5 
were analysed with DAVID. The top 10 pathways for up- and downregulated genes 
are represented here. Details are located in Chapter 8, Appendix 1. Figure adapted 
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Figure 3.15. Examination of the TCA Cycle and Oxidative Phosphorylation 
KEGG pathways. Heatmap representing genes identified in the TCA Cycle and 
Oxidative Phosphorylation KEGG pathways. Gene symbols are representative, and a 
full list is located in Chapter 8, appendices 2-3. Figure adapted from Sinton et al 
(2020) [304].  
 
3.3.5 Analysis of transcriptomic patterns in human NAFLD 
confirms disease heterogeneity 
As previously stated, NAFLD is a challenging disease to study in humans, due to the 
spectrum of pathologies it encompasses and the difficulty in obtaining suitable control 
samples. A recent study from Suppli et al (2019) obtained hepatic tissue samples from 
healthy adult male and female patients, alongside samples from patients with NAFLD 
[298]. To specifically compare steatotic HLCs with the transcriptome of NAFLD 
patients, I downloaded the publicly available RNA-seq datasets from GEO (accession 
number GSM3615293) and ran the RNA-seq pipeline again, this time comparing 
human control with disease samples in both males and females. The PCA revealed 
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(Figure 3.16). Further to this, pathway enrichment analysis of these data, using 
differential expression cut-offs of Log2 fold change >1.5 and adjusted p value <0.05 
did not reveal any significantly enriched pathways. These findings precluded any 
meaningful comparison between the HLC- and human-based expression datasets.  
 
Figure 3.16. PCA plot comparing human healthy control and NAFLD 
transcriptomic signatures. The analysis indicates no clustering within groups, 
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3.4 Discussion 
NAFLD is a challenging disease to study in humans, due to the difficulty of obtaining 
tissues that are not compromised by confounding conditions. Primary cells for studies 
are generally obtained from organs unsuitable for transplant [305] or non-affected 
tissue adjacent to tumours [306], potentially confounding analyses. These cells are 
technically challenging to purify and rapidly lose their phenotype in vitro [300], and 
adaptation to cell culture is demonstrated to alter their transcriptional profiles, which 
begin to resemble diseased liver tissue [301]. The Drake lab previously described a 
pluripotent stem cell-based model of NAFLD, where array-based sequencing 
revealed many transcriptomic features in common with human disease [128]. Here, I 
used a model that was further refined, whereby cells were cultured and differentiated 
on a Laminin-521 matrix instead of Matrigel. This change to the differentiation process 
was previously found to induce a more robust hepatocyte phenotype, with improved 
cell polarity and CYP4A4 activity, as well as reducing batch variation between 
differentiations [267].  
 
3.4.1 LPO treatment induces macrovesicular steatosis in 
HLCs, mirroring patterns of lipid accumulation in 
human NAFLD 
Following refinement of this model, genes related to lipid droplet formation were 
measured, and patterns of lipid accumulation were assessed. The observed changes 
in expression of genes associated with lipid droplet membrane formation (PLIN2 and 
5) are in agreement with findings from human studies: intracellular lipid accumulation 
is associated with upregulation of PLIN2 in human hepatocytes [307] and 
immunohistochemistry staining of biopsies from NAFLD patients shows increased 
accumulation of PLIN2 at the surface of macrovesicular lipid droplets [308]. In 
adipocytes, PLIN4 localises to the surface of unilocular lipid droplets, and may 
participate in their early development. Although there are no human studies 
describing perturbed expression of PLIN4 in association with NAFLD, knockout of this 
gene protects against hepatic steatosis in mice [309]. Furthermore, PLIN4 knockout 
diminishes the accumulation of triacylglycerol in lipid droplets and reduces the 
expression of PLIN5 in mouse cardiac tissue. This interplay may be important for the 
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pathology of NAFLD as in vitro studies demonstrate that PLIN5 blocks lipid droplet 
lipolysis in hepatocytes. Therefore, increases in PLIN5 expression may also 
contribute to the development of macrovesicular steatosis [310].  
 
To further understand patterns of intracellular lipid accumulations in HLCs, cells were 
stained with BODIPY 493/503 and examined using HCA microscopy. Whilst the 
number of intracellular lipid droplets did not increase following LPO treatment, their 
size increased, indicating the development of macrovesicular steatosis. NAFLD is 
typically associated with the development of macrovesicular steatosis, whereby TGs 
accumulate in single large or multiple medium-sized cytoplasmic lipid droplets 
[297,311]. Alongside analyses of PLIN2/4/5 expression patterns, these HCA data 
strongly indicate that this model recapitulates the macrovesicular steatosis observed 
in humans with NAFLD.  
 
3.4.2 Macrovesicular steatosis is associated with widescale 
transcriptomic changes  
Following refinement of the model, deep sequencing was performed to further 
understand how steatotic hepatocytes rewire their transcriptional profiles in response 
to intracellular lipid accumulation. Analysis of publicly available human NAFLD data 
[298] revealed extensive transcriptomic heterogeneity, precluding comparison with 
the transcriptomic dataset generated from steatotic HLCs. As NAFLD comprises a 
spectrum of pathologies, it is possible that samples were taken from patients at 
different disease stages. It is also possible that samples were taken from different 
locations in the liver, which may also impact analysis. Furthermore, it is possible that 
analyses were confounded by the use of bulk tissue analysis. These factors 
demonstrate the necessity of laboratory models, such as the one described here, 
which are reproducible and not excessively prone to batch variation 
 
Within the steatotic HLC transcriptomic dataset, I observed changes in the expression 
of a number of genes that were consistent with previous observations in humans 
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[298]. Pathway enrichment analysis allowed me to further interrogate transcriptional 
rewiring in steatotic HLCs and revealed disruption related to multiple metabolic 
pathways. This included pathways related to steroid hormone biosynthesis and gene 
regulation, each of which was downregulated. This is in line with other studies of 
NAFLD showing downregulation of many of the genes included in these pathways 
[298,312–318]. Whilst it has been documented that 17b-hydroxysteroid 
dehydrogenases, such as HSD17B1, are dysregulated in NAFLD [298], the 
mechanistic consequences of this are less clear. Decreased oestrogen levels in post-
menopausal women are known to increase the risk of developing NAFLD to the same 
levels as men [319]. It is possible that, in vivo, downregulation of HSD17B1 in liver 
tissue decreases oestrogen synthesis [320] and, in turn, decreases oestrogen 
signalling, raising the possibility that this enzyme is involved in NAFLD pathogenesis.  
 
Additionally, there was a downregulation of mRNA expression of a number of 
cytochrome P450 enzymes in response to LPO treatment, including CYP7A1 and 
CYP3A4. CYP7A1 is involved in the conversion of cholesterol to bile acids and 
expression is suppressed in NASH [321]. This was found to be a consequence of 
intestinal fibroblast growth factor 15 (FGF19) activity, leading to farnesoid X receptor 
(FXR) activation and suppression of CYP7A1 transcription. FGF19 expression 
increased 1.7-fold in response to LPO treatment, which may explain the suppression 
of CYP7A1 (Supplementary file MCS1 – DEGs in LPO-treated HLCs ). It may also 
indicate that, in vivo, liver-based expression of FGF19 plays an important role in 
suppression of CYP7A1. This may be of importance for NAFLD pathogenesis as 
CYP7A1 plays a central role in cholesterol metabolism, with deficiencies leading to 
hypercholesterolaemia [322]. Further to this, there was downregulation of CYP3A4 
expression in LPO-treated HLCs, which appears contradictory to the sustained 
CYP3A4 activity observed in these cells. As CYP3A4 activity is diminished in NASH 
[323], this this may indicate that LPO-treated HLCs are transitioning from a NAFLD- 
to NASH-like phenotype, with transcriptional downregulation preceding functional 
changes. However, the mechanism(s) underpinning the association between hepatic 
lipid accumulation and suppression of CYP3A4 activity remains unclear.  
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In human NAFLD, the expression of the UDP-glucuronosyltransferases (UGTs) and 
sulfotransferases (SULTs) is highly modulated depending upon disease stage 
[316,324]. UGTs and SULTs represent classes of endoplasmic reticulum-residing 
drug metabolising enzymes, the majority of which are produced in the liver [316]. 
There is little evidence to suggest why the genes encoding these enzymes are 
differentially regulated in the presence of lipid accumulation. However, their 
downregulation, alongside that of many cytochrome P450 enzymes may represent an 
obstruction, whereby cholesterol cannot be efficiently converted to bile acids or 
steroid hormones. This, in turn, could increase availability of intracellular cholesterol, 
making it available for incorporation into lipid droplets [325]. Furthermore, there was 
a decrease in expression of 5β-reductase (AKR1D1), which in human NAFLD is 
progressively downregulated with advancing disease, leading to intracellular lipid 
accumulation [315]. Together with decreased expression of cytochrome P450 
enzymes, UGTs and SULTs, these changes in mRNA expression may, in part, explain 
the development of macrovesicular steatosis in LPO-treated HLCs.  
 
In addition to these observed changes, there was a profound decrease in the 
expression of a number of histone structural units, including H1 and H2A. Histone 
depletion, such as this, has been observed extensively in yeast, where it either leads 
to transcriptional repression or de-repression [326]. More recently, in human cells, 
histone depletion was found to impact mRNA expression and cell cycle progression 
[327]. This raises the question of whether histone depletion initiates the widescale 
changes in transcription observed here of whether it is a consequence of the NAFLD 
phenotype. If it is the former, this further raises the question of what causes histone 
depletion. While it is not understood why NAFLD would impact on expression of 
histone structural units, other studies have observed similar perturbations. A variant 
of histone H2A is macroH2A1.1, which was previously found to protect against lipid 
accumulation when overexpressed in HepG2 cells, suggesting that depletion may be 
associated with lipid accumulation [328]. Similarly, induction of lipid accumulation in 
human hepatoblastoma cells results in depletion of histone structural unit H1 [42], 
indicating an interplay between intracellular lipid and histone structural units. This 
study also hypothesised that loss of histone structural units makes cells more 
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vulnerable to DNA damage from excessive reactive oxygen species (ROS) formation 
[42]. Whilst ROS was not measured directly in the study presented here, 
transcriptomic data revealed an upregulation of endoplasmic reticulum 
oxidoreductase 1b (EROB1) (Supplementary file MCS1 – DEGs in LPO-treated 
HLCs ), which is regulated by the ER unfolded protein response (UPR) [329] and 
increases ROS generation  in NAFLD [330–332]. This suggests that steatotic HLCs 
may increase ROS generation, which may lead to increased DNA damage. Further 
study within this area may be informative for understanding the causes of DNA 
mutations giving rise to NAFLD-associated HCC.  
 
Another source of excessive ROS formation in cells is respiratory complex dysfunction 
in the mitochondrial ETC [333], with complexes I, II and III producing significant levels 
when dysfunctional [334]. There is evidence from both mouse [335,336] and human 
[337] studies of defects in the ETC in NAFLD and NASH, leading to increased ROS 
production. In line with these observations, there was extensive dysregulation of 
genes associated with oxidative phosphorylation and the TCA cycle in steatotic HLCs. 
Previous mouse or indirect human studies described increases in hepatic TCA cycle 
activity associated with NAFLD [34,109,129]. Additionally, compromised ETC activity, 
with decreased mitochondrial maximal respiration, was previously observed in 
response to hepatic steatosis [130]. Significant perturbation of genes within these 
pathways suggest that steatosis may be associated with altered TCA cycle activity, 
and this will be explored further in the following chapter.  
 
3.5 Experimental limitations 
Although HLCs are morphologically and functionally similar to hepatocytes, they do 
not necessarily recapitulate the entire transcriptome of human hepatocytes [338]. 
Whilst LPO-treated HLCs express a substantial number of NAFLD-related genes, it is 
unclear how expression patterns are impacted by the lack of co-culture with other 
liver-resident cells, such as stellate or Kupffer cells. Development of co-culture 
systems, or 3D models, using pluripotent stem cell-derived stellate or Kupffer cells, 
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will facilitate further understanding of how cell-to-cell communication impacts the 
transcriptional programme of steatotic HLCs. Likewise, as with other in vitro models, 
HLCs are not exposed to the endocrine cues that they would normally receive in vivo, 
particularly those that are generated as a result of obesity.  
 
3.6 Conclusion 
Taken together, the data presented in this chapter demonstrate that LPO-treated 
HLCs not only accumulate intracellular lipid but do so in a pattern similar to that 
observed in human pathology, demonstrating the utility of this model in the study of 
NAFLD. Furthermore, transcriptional analyses reveal similarities with human disease, 
and also reveal extensive dysregulation in pathways related to mitochondrial energy 
metabolism. In light of these findings, I chose to use this model to further analyse the 
impact of NAFLD on TCA cycle metabolism and downstream effects on TET enzyme 
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Chapter 4: Understanding the link between lipid 
accumulation and mitochondrial metabolism in 
steatotic HLCs 
4.1 Introduction 
NAFLD has been linked to impaired mitochondrial respiration, with previous findings 
revealing altered electron transport chain (ETC) activity associated with steatosis 
[130]. Multiple studies suggest that the pathology of NAFLD is linked to impairment of 
mitochondrial function [34,109–111]. In rat models, mitochondrial dysfunction 
precedes the development of hepatic steatosis, suggesting that disease pathology 
and progression are linked to impairment of mitochondrial function [32]. Further, 
studies in mice indicate that hepatic steatosis is accompanied by increased 
tricarboxylic acid (TCA) cycle activity [109,129]. In support of this, limiting pyruvate 
transport into the mitochondria reduces mitochondrial flux and limits the development 
of NASH-associated inflammation [339]. Human studies also suggest that NAFLD is 
associated with increased TCA cycle activity, with increased movement of substrates 
into and out of the TCA cycle alongside increased rates of gluconeogenesis and 
lipolysis [34]. However, whilst informative, these human studies were indirect and 
used measurements of plasma metabolites to infer hepatic metabolic flux, rather than 
directly measuring levels within the liver.  
 
The use of whole tissue for metabolic flux analysis is challenging and confounded by 
the presence of heterogeneous cell populations, each of which may have a different 
metabolic phenotype [340]. Studies in primary rat hepatocytes show that modulation 
of TCA cycle anaplerosis fuels oxidative stress and enhances development of a NASH 
phenotype [299]. One limitation of primary cells is that they rapidly lose their 
phenotype and display altered transcriptional signatures on purification [300,301]. In 
these studies, we employed a renewable form of human liver tissue [341]. To my 
knowledge, high-resolution metabolomic analyses have not been performed in a 
human system, and the data presented here will provide the field with new insight into 
human liver disease.  
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4.1.1 Hypothesis 
Nutrient excess in NAFLD leads to mitochondrial dysfunction and subsequent 




1. To determine whether macrovesicular steatosis is associated with 
mitochondrial metabolic dysfunction 
2. To assess TCA cycle activity in response to macrovesicular steatosis 
3. To examine the interplay between perturbed TCA cycle activity and 
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4.2 Materials and methods 
4.2.1 Differentiation of hPSCs to HLCs and induction of lipid 
accumulation 
Human female H9 pluripotent stem cells (hPSCs) were differentiated to hepatocyte-
like cells (HLCs), and lipid accumulation induced as described in Chapter 3. For 
isotopic tracing studies, lactate was replaced with 13C3-lactate (CK Isotopes, CLM-
1579-05). For mechanistic studies, HLCs were exposed to either 5-Aminoimidazole-
4-carboxamide-1-β-D-ribofuranosyl 5′-monophosphate (AICAR; 1mM; Sigma-
Aldrich, A1393-50MG), O-(Carboxymethyl)hydroxylamine hemihydrochloride (AOA; 
100 µM ; Sigma-Aldrich, C13408-1G) or AICAR combined with monomethyl fumarate 
(50 µM; Sigma-Aldrich, 651419-1G) for the same duration as LPO.  
 
4.2.2 Mitochondrial stress test 
The oxygen consumption rate (OCR) of LPO-exposed HLCs was measured using the 
Agilent Seahorse XF Cell Mito Stress Test Kit (Agilent, 103015-100) on a Seahorse 
XF Analyser (Agilent, California, USA). The Mito Stress Test provides a readout of 
oxygen consumption in cells and uses this as a proxy for assessing mitochondrial 
ETC activity. Analysis was performed under basal conditions and following treatment 
with oligomycin A (an ATPase inhibitor), carbonyl-cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP; an ETC uncoupler), and combined rotenone and antimycin 
A (inhibitors of complex I and III, respectively). Inhibition of ATPase by oligomycin 
prevents the flow of protons from the mitochondrial intermembrane space and 
subsequent generation of ATP, revealing levels of ATP-linked respiration occurring 
within the cell. Addition of FCCP uncouples the ETC, allowing the free flow of protons 
through the inner mitochondrial membrane, helping to determine the maximum 
respiratory capacity of the mitochondria. Finally, inhibition of complexes I and III with 
combined rotenone and antimycin A is used to reveal the level of non-mitochondrial 
respiration occurring within the cell. Two concentrations of FCCP (0.5 μM and 1.0 μM) 
were used for optimisation. Since replicates within each group responded similarly to 
each other, results were combined. OCR was normalised to total protein for each well, 
using the sulforhodamine B (SRB) assay, as described in Chapter 2.  
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4.2.3 Gas chromatography-mass spectrometry and nuclear 
magnetic resonance spectroscopy 
These protocols were performed by the labs of collaborators, Dr Daniel Tennant and 
Dr Christian Ludwig, in the Institute of Metabolism and Systems Research at the 
University of Birmingham. Experimental details are outlined in Chapter 2.  
 
4.2.4 Transcriptomic analysis 
RNA was purified from HLCs that were incubated with either LPO or LPO + AICAR. 
This was sent to the Wellcome Trust Clinical Research Facility (Edinburgh, UK), 
where 3’ RNA sequencing was performed. Differential expression and principal 
component analyses were then performed using the Bluebee platform from Illumina 
(Netherlands). Heatmaps were generated with Heatmapper [287]. Pathway 
enrichment analysis was performed using DAVID [291,292].  
 
4.2.5 Statistics 
All statistical analyses were performed using Graph Prism Version 8.0 for Windows 
or macOS, GraphPad Software, La Jolla California USA, www.graphpad.com. 
Normality of data distribution was measured using the Shapiro-Wilks test. Where 
indicated, data were analysed by unpaired Student’s t-test, Mann-Whitney test or two-
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4.3 Results 
4.3.1 Macrovesicular steatosis in HLCs is associated with 
electron transport chain dysfunction 
In the previous chapter, I showed that macrovesicular steatosis in HLCs was linked 
to disruption of genes associated with the TCA cycle and oxidative phosphorylation. 
This raised the question of whether this translated into a functional impact on 
mitochondrial respiration. In order to test this further, I performed a mitochondrial 
stress test, using a Seahorse Analyser (Figure 4.1).  
 
Figure 4.1. Raw trace of oxygen consumption rate (OCR) of control or LPO-
treated HLCs.  
The basal oxygen consumption rate (OCR), representing combined mitochondrial and 
non-mitochondrial oxygen consumption, was unchanged following LPO exposure 
(Figure 4.2A). Additionally, oligomycin A, a complex V (ATPase) inhibitor decreased 
OCR equally effectively in both the control and treatment group. Firstly, this indicates 
that there were no changes in ATP-linked respiration in response to macrovesicular 
steatosis (Figure 4.2B). Secondly, when comparing oligomycin A-induced alterations 
in OCR with those following addition of rotenone/antimycin A, I detected no changes 
in proton leak between groups (Figure 4.2C). The addition of the ETC uncoupler 
FCCP revealed a decrease in maximal respiration in the steatotic HLCs (LPO treated 
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were targeted with rotenone/antimycin A, respectively, to completely inhibit oxidative 
phosphorylation, which reduced OCR to a similar level in both groups, suggesting no 
difference in non-mitochondrial sources of OCR between the control and steatotic 
HLCs. Using OCR measurements following FCCP treatment and comparing to the 
basal OCR, I calculated that there was a decrease in reserve capacity in the LPO-
treated cells, compared with control cells (Figure 4.2E). Data adapted from Sinton et 
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Figure 4.2. LPO treatment results in decreased maximal respiration in 
mitochondria but not in other aspects of oxygen consumption rate. HLCs were 
injected sequentially from ports A-C with 4 µM oligomycin, 0.5-1 µM FCCP, and 1 µM 
antimycin combined with 200 nM rotenone. (A) basal respiration; (B) ATP-linked 
respiration; (C) proton leak; (D) maximal respiration; (E) reserve capacity compared 
to control treatment (n = 18 and 16 biological replicates in the control and treatment 
group, respectively). Data analysed using two-tailed Student t-test for parametric 
data, or Mann-Whitney U test for non-parametric data, and expressed as mean ± SD. 
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4.3.2 Induction of macrovesicular steatosis is not associated 
with loss of mitochondrial integrity or alterations in 
mitochondrial number 
To analyse whether the observed changes in OCR could be due to loss of 
mitochondrial membrane integrity rather than ETC dysfunction, I measured citrate 
synthase (CS) activity. LPO treatment appears to have no impact on CS activity 
(Figure 4.3), suggesting that mitochondria remain intact following intracellular lipid 
accumulation. Although the sample size here is low, with a large spread in the data, 
it correlates with my other findings, suggesting that this is accurate. However, 
repetition of this assay, with a greater sample size, would be useful. I next measured 
abundance of specific mitochondrial proteins, succinate dehydrogenase subunit A 
(SDHA) and pyruvate dehydrogenase (PDH) a1 and a2 subunits, and observed no 
change following treatment with LPO (Figure 4.4A-B).  
 
Figure 4.3. LPO does treatment does not alter citrate synthase activity. Levels 
of citrate synthase activity were unaltered by LPO treatment. Data analysed using 
two-tailed Student t-test and expressed as mean ± SD, n = 3 biological 
replicates/group. Data adapted from Sinton et al (2020) [303]. 
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Figure 4.4 LPO treatment does not alter levels of specific mitochondrial 
proteins. There were no changes in abundance of the mitochondrial proteins 
succinate dehydrogenase subunit (SDHA) or pyruvate dehydrogenase a1 and a2 
subunits (PDH). (A) Representative blot. (B) Protein quantification. SDHA = succinate 
dehydrogenase subunit A; PDH = pyruvate dehydrogenase. Data were analysed 
using a two-tailed Student t-test and expressed as mean ± SD. Data adapted from 











Chapter 4  108 
A final question was whether changes in ETC function, as demonstrated by decreased 
cellular maximal respiration and reserve capacity, were due to decreased numbers of 
mitochondria in response to intracellular lipid accumulation. Since these were the only 
respiratory measurements to change, I hypothesised that this was not the case. In 
support of this, there were no changes in mitochondrial or nuclear DNA (Figure 4.5A) 
and no change in the ratio of nuclear to mitochondrial DNA (Figure 4.5B). Finally, 
high content microscopy was used to measure intracellular mitochondrial quantity, by 
measuring MitoTracker fluorescence, and revealed no changes following exposure to 
LPO (Figure 4.6A-B). Taken together, these data suggest that mitochondrial number 
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Figure 4.5. LPO treatment does not alter ratio of mitochondrial to nuclear DNA. 
No changes were observed in abundance of DNA in (A) mitochondrial region 2 (MT2), 
mitochondrial region 3 (MT3) or genomic region beta globulin (HBB). There were no 
significant changes in the ratio of mitochondrial to genomic DNA (B), indicating no 
alterations in the quantity of mitochondria in response to treatment. Data analysed 
using two-tailed Student t-test for parametric data, or Mann-Whitney U test for non-
parametric data, and expressed as mean ± SD, n = 4 biological replicates/group. Data 
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Figure 4.6. LPO treatment does not induce changes in the quantity of 
mitochondria. (A) Representative images of mitochondrial content in control & LPO-
treated groups 10x magnification or zoomed in on the same images. Blue staining = 
NucBlue, red staining = MitoTracker Deep Red; (B) high content microscopy revealed 
no changes in fluorescence in response to treatment (n = 4 and 6 biological replicates 
in the control and treatment group, respectively). Data analysed using two-tailed 
Student t-test for parametric data, or Mann-Whitney U test for non-parametric data, 
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4.3.3 Induction of a NAFLD-like phenotype in HLCs is 
associated with increased pyruvate carboxylase activity  
To investigate TCA cycle dynamics, lactate in the LPO cocktail was replaced with 
13C3-lactate. Lactate can enter the TCA cycle via mitochondrial pyruvate metabolism, 
through either pyruvate carboxylase (PC) or PDH. Alternatively, pyruvate can be 
transported into the cytosol and used in gluconeogenesis (Figure 4.7).  
 
Figure 4.7. Schematic showing the metabolites to which lactate can be 
converted, following conversion to pyruvate. Black circles indicate the number of 
carbons in each metabolite. OAA = oxaloacetate.  
 
LPO exposure was associated with increases in steady state levels of pyruvate, 
aspartate and citrate, but there were no changes in metabolites associated with the 
gluconeogenesis pathway (Figure 4.8). Pyruvate can be converted to alanine, or it 
can enter gluconeogenesis or the TCA cycle, and so I wanted to determine how it was 
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of alanine, there were moderate, but significant, changes in the incorporation of 13C 
into alanine (Figure 4.9), indicating sustained interconversion of alanine and 
pyruvate.  
 
Figure 4.8. Analysis of steady state metabolites shows that in steatotic HLCs, 
pyruvate is primarily converted to metabolites associated with the TCA cycle, 
indicating increased PC activity. TCA-associated metabolites: aspartate and 
citrate. Gluconeogenesis-associated metabolites: 3PG, serine and glycine. Each 
group consisted of 10 biological replicates within 2 technical replicates (n = 10 
replicates/group). Data were analysed by two-way ANOVA with Sidak post-hoc 
testing and are expressed as mean ± SD, **p<0.01, ****p<0.0001. Figure adapted 
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Figure 4.9. NMR spectroscopy analysis reveals minimal conversion of pyruvate 
to alanine in steatotic HLCs. MID (multiple ion detection mode) enables 
determination of proportions of different isotopomers in a pool. Alanine is a 3-carbon 
molecule; here each 0 represents an unlabelled carbon and each 1 represents a 13C-
labelled carbon. n = 4 biological replicates/group. Data were analysed by two-way 
ANOVA with Sidak post-hoc testing and are expressed as mean ± SD, ****p<0.0001. 
Figure adapted from Sinton et al (2020) [304]. 
 
Despite there being no increase in steady state levels of gluconeogenesis-associated 
metabolites, the increased m+2 labelling of 3-PG (Figure 4.10A), serine (Figure 
4.10B), and glycine (Figure 4.10C), suggests increased flux through the 
gluconeogenesis pathway with LPO exposure. Although pyruvate was added as part 
of the LPO cocktail, increased pyruvate generation also occurred as a result of 
increased lactate dehydrogenase activity in LPO exposed cells as shown by 
increased incorporation of 13C into the metabolite (Figure 11A). It was not possible to 
directly measure conversion of pyruvate to OAA, so I used aspartate as a surrogate 
and found increased m+3 labelling in steatotic cells. This indicates direct conversion 
of pyruvate to OAA and, therefore, increased PC activity with LPO exposure (Figure 
4.11B). Furthermore, isotopomer labelling of citrate indicated preferential synthesis 
from OAA and decreased conversion of labelled acetyl-CoA by PDH (Figure 4.11C). 
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Figure 4.10. Increased flux of m+2 isotopomers indicates sustained conversion 
of pyruvate. In steatotic HLCs there was increased incorporation of 13C into m+2 
isotopomers of (A) 3-PG, (B) serine, and (C) glycine. GC-MS data (A-B) consisted of 
10 biological replicates within 2 technical replicates (n = 10 replicates/group). For 
NMR data (C), each 0 represents an unlabelled carbon and each 1 represents a 13C-
labelled carbon; n = 4 biological replicates/group. Data were analysed by two-way 
ANOVA with Sidak post-hoc testing, and are expressed as mean ± SD, *p<0.05, 
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Figure 4.11. Steatotic HLCs display increased pyruvate carboxylase activity. 
Isotopomer labelling patterns of pyruvate (A), aspartate (B) and citrate (C) reveal that 
13C3-lactate is preferentially utilised by the TCA cycle. Data consisted of 10 biological 
replicates within 2 technical replicates (n = 10 replicates/group). Data were analysed 
by two-way ANOVA with Sidak post-hoc testing, and are expressed as mean ± SD, 
**p<0.01, ***p<0.001,  ****p<0.0001. Figure adapted from Sinton et al (2020) [304]. 
 
4.3.4 Steatosis in HLCs is associated with truncation of the 
TCA cycle  
Isotopic labelling of TCA metabolites can produce a number of different isotopomers, 
dependent on the directionality of metabolite synthesis (Figure 4.12). In steatotic 
HLCs, there was an increase in the steady state levels of akg, fumarate and malate, 
but no changes in succinate or glutamate (Figure 4.13). The lack of changes in steady 
state levels of glutamate in response to LPO indicate that there is no increase in 
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do not change and indicated the presence of more complex changes occurring in the 
TCA cycle than were previously appreciated.  
 
Figure 4.12. Schematic outlining the TCA cycle and possible 13C labelled 
isotopomers from a single cycle. Blue circles = 13C; white circles = 12C. Figure 
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Figure 4.13. Analysis of steady state metabolites by GC-MS reveals increased 
abundance of αKG, fumarate and malate, but not succinate. All Control and LPO 
group data consisted of 10 biological replicates within 2 technical replicates (n = 10 
replicates/group). Data were analysed by two-way ANOVA with Sidak post-hoc 
testing and are expressed as mean ± SD, ****p<0.0001. Figure adapted from Sinton 
et al (2020) [304]. 
 
To further interrogate these changes, 13C incorporation into TCA cycle-associated 
metabolites was measured. Whilst there was an increase of 13C incorporation into PC-
derived citrate (Figure 4.11C), this was not the case for αKG (Figure 4.14A). I then 
examined whether this was due to increased cataplerosis through glutamate. 
However, there were decreased levels of 13C incorporation into glutamate 
demonstrating that this is not the case (Figure 4.14B). Increased expression of 
OGDHL and decreased expression of SUCG1, as shown in the Chapter 3, Figure 
3.15, suggest that steatosis is associated with the generation of an increased pool of 
succinyl-CoA, with impaired conversion to succinate. This is supported by 
substantially decreased incorporation of 13C into succinate (Figure 4.14C). In 
contrast, there was increased 13C incorporation into fumarate and malate (Figure 
4.15A-B). As these metabolites can be replenished by the purine nucleotide cycle 
(PNC) or the malate-aspartate shuttle (MAS), I next wanted to investigate whether 
either of these pathways was contributing to their generation in steatotic HLCs. 
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Figure 4.14. PC-derived αKG is unchanged in the presence of steatosis, and 
PDH-derived αKG is reduced. (A) Labelling patterns of αKG are not due to 
increased cataplerosis through glutamate, as both PC- and PDH-derived glutamate 
are reduced in response to steatosis (B); each 0 represents an unlabelled carbon and 
each 1 represents a 13C-labelled carbon (C) Reduced 13C labelling of succinate 
indicates inefficient conversion from αKG. (A, C) consisted of 10 biological replicates 
within 2 technical replicates (n = 10 replicates/group). (B) n = 4 biological 
replicates/group. Data were analysed by two-way ANOVA with Sidak post-hoc testing, 
and are expressed as mean ± SD, *p<0.05, **p<0.01, ***p<0.001,  ****p<0.0001. 
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Figure 4.15. In steatotic HLCs, despite TCA cycle truncation, fumarate and 
malate continue to accumulate. Both fumarate (A) and malate (B) show increased 
PC-derived label incorporation. Each group consisted of 10 biological replicates within 
2 technical replicates (n = 10 replicates/group). Data were analysed by two-way 
ANOVA with Sidak post-hoc testing and are expressed as mean ± SD, *p<0.05, 
****p<0.0001. Figure adapted from Sinton et al (2020) [304]. 
 
4.3.5 Increased PNC and MAS activity drives NAFLD-
associated fumarate accumulation 
Next, I wanted to determine the source of fumarate accumulation in steatotic HLCs. 
Transcriptomic analysis in the previous chapter identified dysregulation of multiple 
genes associated with the MAS (Figure 4.16A) and PNC (Figure 4.16B), indicating 
that these pathways may be involved in fumarate accumulation. To investigate this 
further, HLCs incubated with 13C3-lactate-labelled LPO were co-incubated with either 
AICAR or AOA, to inhibit the PNC or MAS, respectively. Addition of AICAR increased 
the steady state levels of αKG, and neither AICAR nor AOA had a significant impact 
on the steady state levels of pyruvate, citrate, succinate or malate (Figure 4.17). 
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Figure 4.16. Transcriptomic analysis revealed disrupted expression of genes 
associated with the malate-aspartate shuttle and purine nucleotide cycle. Sample size 
n = 3/group. Data were analysed by Student’s t-test and are expressed as mean ± 
SD. *p<0.05, **p<0.01, ***p<0.001,  ****p<0.0001. MDH1 = Malate Dehydrogenase 
cytosolic isoform; MDH2 = Malate Dehydrogenase mitochondrial isoform; GOT1 = 
Glutamic-Oxaloacetic Transaminase 1; ADSL = Adenylosuccinate Lyase; AMPD2 =  
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Figure 4.17. Inhibition of the PNC and MAS reversed steatosis-induced 
accumulation of fumarate and aspartate, but not malate. All Control and LPO 
group data consisted of 10 biological replicates within 2 technical replicates (n = 10 
replicates/group), as shown in previous GC-MS figures. GC-MS LPO + AICAR and 
LPO + AOA groups consisted of 6 biological replicates/group. Data were analysed by 
two-way ANOVA with Sidak post-hoc testing and are expressed as mean ± SD, 
**p<0.01, ***p<0.001,  ****p<0.0001. Figure adapted from Sinton et al (2020) [304]. 
 
Whilst addition of AICAR did not impact the synthesis of PDH-derived citrate (Figure 
4.18A), it did result in increased accumulation of PDH-derived 13C in αKG (Figure 
4.18B), suggesting impaired conversion to succinyl-CoA or increased anaplerosis 
from glutamate. AICAR reversed LPO-induced cataplerosis of αKG through glutamate 
(Figure 4.18C) and was also able to partially restore steatosis-associated depletion 
of succinate (Figure 4.18D). This resulted in small but significant increases in PC- 
and PDH-derived succinate isotopomers (m+4 and m+2, respectively). The most 
profound effect of AICAR was on fumarate, with each isotopomer reduced to levels 
below those observed in the control group (Figure 4.19A), demonstrating that in 
steatotic HLCs fumarate accumulation is primarily driven by the PNC. Following AOA 
treatment, there was a moderate decrease in PC-derived 13C incorporation into 
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fumarate, demonstrating a small contribution from the MAS. AICAR had a moderate 
impact on incorporation of PC-derived incorporation of 13C into malate, whereas AOA 
impacted on both PC- and PDH-derived 13C incorporation, suggesting limited 
contribution of the MAS and PNC to malate accumulation (Figure 4.19B). Both AICAR 
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Figure 4.18. PNC inhibition restores glutamate cataplerosis but does not 
reverse TCA cycle truncation. PNC inhibition moderately reduced PC-derived 
citrate 13C labelling (A), but not (B) αKG. Despite this, there was a moderate increase 
in glutamate upon PNC inhibition (C). PNC inhibition did not impact on PC-derived 
succinate levels (D). All Control and LPO group data consisted of 10 biological 
replicates within 2 technical replicates (n = 10 replicates/group), as shown in previous 
GC-MS figures. GC-MS LPO + AICAR and LPO + AOA groups consisted of 6 
biological replicates/group. Data were analysed by two-way ANOVA with Sidak post-
hoc testing and are expressed as mean ± SD, *p<0.05, **p<0.01, ***p<0.001,  
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Figure 4.19. The PNC is the major contributor to fumarate in steatotic cells. 
Inhibition of the PNC, and to a lesser extent the MAS, reduced incorporation of 13C 
into fumarate in steatotic HLCs (A). PNC inhibition also reduced incorporation of 13C 
into malate and aspartate in steatotic cells (B-C). All Control and LPO group data 
consisted of 10 biological replicates within 2 technical replicates (n = 10 
replicates/group), as shown in previous GC-MS figures. GC-MS LPO + AICAR and 
LPO + AOA groups consisted of 6 biological replicates/group. Data were analysed by 
two-way ANOVA with Sidak post-hoc testing and are expressed as mean ± SD, 
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4.3.6 Fumarate accumulation is linked to widescale 
transcriptional changes in steatotic HLCs 
As exposure of HLCs to both LPO and AICAR resulted in reduction of macrovesicular 
steatosis, I questioned whether this was due to fumarate accumulation influencing 
transcription. To examine the impact of AICAR on the transcriptome, 3’-RNA 
sequencing was performed to a depth of >8.8 million reads. Differential expression 
analysis identified 437 upregulated and 918 downregulated genes, with a Log2 fold 
change cut-off >0.25 (Supplementary file MCS2 – DEGs in AICAR-treated HLCs). 
Principal component analysis (PCA) demonstrated that replicates within each of the 
control and LPO group clustered, showing minimal variation between replicates 
(Figure 4.20).  
 
Figure 4.20. Principal component analysis of transcriptomic data reveals 
clustering of replicates within groups following treatment of HLCs with either 
LPO or LPO + AICAR. PCA plot demonstrating differential clustering of each 
biological replicate from both LPO and LPO + AICAR-treated HLCs. For LPO group 
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Heatmap analysis of dysregulated genes highlights the widescale transcriptomic 
changes that occur following LPO treatment (Figure 4.21). Taken together, these 
findings demonstrate that LPO + AICAR treatment induces a transcriptional pattern 
that is distinct from LPO-treated HLCs, and that this is consistent between biological 
replicates. 
 
Figure 4.21. Heat map analysis of transcriptomic data reveals wide-spread 
transcriptomic changes following treatment of HLCs with either LPO or LPO + 
AICAR. Heap map representing the top 1,000 differentially expressed genes when 
comparing LPO and LPO + AICAR-treated HLCs. Genes are clustered by Euclidean 
distance. For LPO group n = 3 biological replicates; for LPO + AICAR group n = 4.  
 
LPO LPO + AICAR 
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4.3.7 Reduction of fumarate in steatotic HLCs disrupts 
pathways related to inflammation and iron ion 
homeostasis 
I mapped genes with a log2 fold change cut-off >0.25 to the Gene Ontology Biological 
Processes database, identifying a number of enriched pathways. These pathways 
broadly related to protein translation, immunity and response to oxidative stress 
(Figure 4.21). These pathways contained genes encoding ribosomal subunits 
(including RPL7, RPL11, RPS19 and RPS24)  components of the complement 
cascade and acute response to inflammation (including SAA4, ORM1, ORM2, C1R, 
C3, C5, C8A, C8B and C8G), as well as regulators of iron homeostasis (including 
HAMP, TFR2, CP, SOD1 and SOD2).  
 
Figure 4.22. Gene ontology (GO) pathway analysis. All genes with a Log2 fold 
change > 0.5 were analysed with DAVID. The top 15 pathways for up- and 
downregulated genes are represented here. Details are located in Appendix 4.  
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4.3.8 Fumarate accumulation drives macrovesicular steatosis 
in LPO-treated HLCs 
To further examine the relationship between macrovesicular steatosis and PNC-
driven fumarate accumulation, I examined transcriptomic data to assess how genes 
associated with lipid droplet formation respond to concurrent exposure to LPO and 
AICAR. This revealed a downregulation of the genes PLIN2, PLIN3 and CIDEC 
(Figure 4.23). Further to this, I performed further analyses of lipid droplets using high 
content analysis microscopy. This revealed that the presence of AICAR alongside 
LPO was able to prevent the development of macrovesicular steatosis (Figure 4.24). 
Furthermore, the addition of exogenous monomethyl fumarate was sufficient to 
partially restore the steatotic phenotype, in the presence of both LPO and AICAR. 
This demonstrates for the first time that fumarate accumulation drives macrovesicular 
steatosis in LPO-treated HLCs.  
 
Figure 4.23. Purine nucleotide inhibition is associated with downregulation of 
genes associated with lipid droplets. Data presented here represent a subset of 
genes from the RNA-seq dataset (Supplementary file MCS1 – DEGs in LPO-
treated HLCs). Data were analysed by two-way ANOVA and expressed as mean ± 
SD. **p<0.01, ****p<0.0001 
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Figure 4.24. Compensatory rewiring of mitochondrial metabolism, resulting in 
fumarate accumulation, drives development of macrovesicular steatosis in 
LPO-treated HLCs. (A) LPO drives development of macrovesicular lipid droplets; (B) 
Addition of AICAR to LPO-treated HLCs prevents development of macrovesicular lipid 
droplets; (C) Addition of fumarate to HLCs exposed to LPO and AICAR partially 
restores the macrovesicular steatotic phenotype. (D) Quantitative evaluation of lipid 
droplet size. LPO group n = 20, LPO + AICAR group n = 31, LPO + AICAR + Fumarate 
group n = 28. Data were analysed by one-way ANOVA with Tukey’s multiple 
comparison test and are expressed as mean ± SD, *p<0.05, ****p<0.0001. Fumarate 
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4.4 Discussion 
4.4.1 Macrovesicular steatosis is linked to impairment of 
electron transport chain function 
Using an hPSC-based model of NAFLD I was able to overcome many of the difficulties 
typically associated with studying metabolic dysfunction in this disease. In this chapter 
I aimed to determine the nature of NAFLD-associated changes in mitochondrial 
respiration, and whether these occur as a result of mitochondrial dysfunction or 
reductions in mitochondrial number. Following the establishment of relevance to 
human disease shown in Chapter 3, I wanted to understand whether macrovesicular 
steatosis was linked to dysfunctional mitochondrial respiration. Previous studies have 
shown that mitochondrial maximal respiration increases in obese humans with 
NAFLD but decreases on progression to NASH, despite an increase in mitochondrial 
mass [130]. Since NAFLD was previously shown to increase TCA cycle activity 
[34,109], I hypothesised that mitochondrial respiration would increase in response to 
LPO treatment. In contrast to this, steatotic HLCs displayed decreased maximal 
respiration and reserve capacity. This indicates that whilst mitochondria are mostly 
able to maintain respiratory integrity in LPO-exposed cells, the ETC, and therefore 
oxidative phosphorylation, may be compromised. Given that these were the only 
parameters of mitochondrial respiration to change, it suggests that LPO treatment of 
HLCs inhibits complexes I-III of the ETC. This effect may arise due to the use of 
octanoic acid, which inhibits complex I-III in rat liver, as well as increasing oxidative 
stress through reactive oxygen species production [342].  
 
I questioned whether inhibition of complex II (also named succinate dehydrogenase) 
may impact on TCA cycle activity, due to its role in converting succinyl-CoA to 
succinate.  Furthermore, I questioned whether changes in maximal respiration arose 
from loss of mitochondrial membrane integrity or resulted from decreased biogenesis. 
Given that maximal respiration was the only parameter of respiration that changed, I 
suspected this was not the case. The lack of change in the ratio of nuclear to 
mitochondrial DNA suggests that mitochondrial biogenesis was not affected by LPO 
treatment in these studies. This is supported by high content analysis of mitochondria, 
also showing no changes in mitochondrial quantity, and is consistent with human 
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studies of NAFLD which show no changes in mitochondrial mass in steatotic versus 
non-steatotic liver tissue [130]. In contrast, liver tissue from patients with NASH 
contains greater numbers of mitochondria, with a concomitant decrease in maximal 
respiration [130]. Therefore, the model of NAFLD presented here may mirror the 
transition between NAFLD and NASH, with respiratory dysfunction in the absence of 
mitochondrial biogenesis. This discrepancy may also be due to previous studies using 
isolated mitochondria from whole tissues, comprised of multiple cell types, whereas 
we examined a single cell population.  
 
Furthermore, I observed decreased mitochondrial maximal respiration, in the absence 
of altered mitochondrial biogenesis. Mitochondrial biogenesis is controlled by PPAR-
gamma coactivator 1a (PGC1A), with increased expression associated with 
increased biogenesis [343]. Transcriptomic analysis of steatotic HLCs in Chapter 3 
revealed increased expression of PPARGC1A, the gene encoding PGC1A, 
suggesting that mitochondrial biogenesis should be increased in this context and not 
unaltered as observed. This may reflect that translation of PGC1A does not strongly 
correlate to transcription of PPARGC1A. It may also support the assertion that these 
cells are at a transitional stage, where PPARGC1A expression has increased but has 
not yet induced mitochondrial biogenesis.  
 
Taken together, these data demonstrate that hepatocyte intracellular lipid 
accumulation is linked to mitochondrial dysfunction in response to the changing 
bioenergetic demands associated with NAFLD, impacting on the ETC, and limiting 
maximal respiration.  
 
4.4.2 Macrovesicular steatosis is associated with increased 
supply of pyruvate to the TCA cycle 
Typically, NAFLD is also thought to increase TCA cycle activity [34,109] but, to date, 
detailed information regarding flux dynamics has remained elusive. I utilised stable 
isotopic tracing, using 13C3-lactate which provides greater metabolite labelling than 
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other substrates [344]. In steatotic HLCs, increased lactate dehydrogenase (LDH) 
activity led to increased generation of pyruvate, a phenomenon which was previously 
predicted using an in silico model of NAFLD [345]. In the liver, flux of pyruvate into 
the TCA cycle predominantly occurs via PC [346], and there is evidence suggesting 
that PC activity increases in NAFLD [34], contributing to increased rates of 
gluconeogenesis through conversion of OAA to phosphoenolpyruvate [109]. 
However, whilst I observed sustained synthesis of gluconeogenesis-associated 
metabolites occurring in steatotic HLCs, the data presented here show no associated 
increase in gluconeogenesis. Although increased hepatic gluconeogenesis has been 
observed in association with NAFLD [347], it appears that it is linked to hepatic IR 
rather than lipid content [348]. The use of a 2D cell model, and lack of endocrine 
signalling may prevent IR from developing and explain why I did not observe 
increased gluconeogenesis in steatotic HLCs. Although studies have stated that 
NAFLD is the hepatic manifestation of the metabolic syndrome and linked to IR [349], 
there is evidence that ~50% of patients with this disease do not have IR [350], and 
the metabolic syndrome can develop in non-obese individuals [351]. Increased 
incorporation of only two 13C atoms into 3-PG, serine and glycine may suggest that 
pyruvate-derived acetyl-CoA is being converted back to pyruvate via ketogenesis 
before entering gluconeogenesis. Increased acetyl-CoA pools and disrupted 
ketogenesis have been observed in NAFLD [347], lending support to this assertion.  
 
Isotopic labelling patterns of aspartate, which is used as a surrogate for OAA, 
demonstrate that PC activity increases in steatotic HLCs. Although OAA can be 
converted to phosphoenolpyruvate for use in gluconeogenesis, increased 
incorporation of 13C3 into aspartate and citrate show that pyruvate is being 
preferentially utilised by the TCA cycle. Since malate dehydrogenase and fumarate 
hydratase readily reverse their reactions [127,352], increased incorporation of 13C into 
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4.4.3 Macrovesicular steatosis leads to TCA cycle truncation  
The increased flux of pyruvate into the TCA cycle also led to increased TCA cycle 
activity in steatotic HLCs, as previously reported in humans [34]. However, the data 
in this chapter show that changes in TCA cycle are more nuanced that was previously 
suggested. Human studies of NAFLD suggest that the disease is associated with a  
~2 fold increase in hepatic mitochondrial oxidative flux, as well as increased levels of 
gluconeogenesis and lipolysis [34]. However, these claims were made based on 
indirect studies of plasma from humans with NAFLD. Gluconeogenesis was assessed 
based on incorporation of deuterium into glucose, and then measuring plasma 
glucose levels; NAFLD-associated lipolysis was examined by measuring ketone 
levels in blood plasma. These findings were mirrored in later mouse studies [109,129]. 
These studies each used [U-13C]propionate or unlabelled propionate to study hepatic 
TCA cycle flux, due to its conversion to succinyl-CoA and incorporation into the TCA 
cycle. Importantly, propionate can be converted to pyruvate too, enabling it to enter 
the TCA cycle via either PC or PDH. Indeed, it was later revealed that administration 
of propionate increases hepatic pyruvate cycling, TCA cycle activity and 
gluconeogenesis, throwing into question its suitability as a tracer for studying hepatic 
metabolism [353]. Furthermore, this study showed that administration of 13C3-lactate, 
in rats, had no impact on plasma levels of succinate, malate or aspartate. It also had 
no significant impact on gluconeogenesis. Subsequent studies, where rats were fed 
a high fat diet and developed hepatic steatosis, show similar results when using 
lactate as a tracer, indicating its utility and that it does not act to drive carbon 
metabolism independently of other factors [354,355].  
 
Following induction of steatosis in HLCs, similarly to the aforementioned studies of 
NAFLD, I observed increased steady state levels of the core TCA cycle metabolites, 
citrate, αKG, fumarate, malate and aspartate. However, steady state levels of 
succinate were unaltered in steatotic HLCs. This was also reflected in the analysis of 
isotopomers of these metabolites, raising the question of why less 13C is being 
incorporated into succinate. Whilst this observation may be due to increased 
cataplerosis through glutamate, isotopomer analysis revealed decreased flux through 
this metabolite. Therefore, this indicates that in steatotic HLCs, there may be an 
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increased pool of succinyl-CoA. Succinyl-CoA could not be measured in this study as 
CoA profiling requires more sensitive instrumentation, such as liquid chromatography 
tandem mass spectrometry to be detected [356]. However, transcriptomic data shown 
in Chapter 3 support this hypothesis. In steatotic cells, OGDHL (2-oxoglutarate 
dehydrogenase-like), which encodes an enzyme that converts αKG to succinyl-CoA, 
was upregulated. Further to this, the same analysis revealed that SUCLG1 
(succinate-CoA ligase GDP/ADP-forming subunit alpha), which encodes a subunit of 
an enzyme converting succinyl-CoA to succinate, was downregulated. This suggests 
that αKG is continuing to be converted to succinyl-CoA in steatotic HLCs, but that 
disruption of succinate-CoA ligase is preventing further conversion to succinate. Since 
interconversion between succinyl-CoA and succinate is in near equilibrium and readily 
reversible [357], I propose that this effect could be a result of diminished succinyl-CoA 
synthetase activity. In tandem with the findings in section 4.4.1 of this chapter, this 
reveals a truncation of the TCA cycle in steatotic HLCs, preventing generation of 
increased succinate levels and preventing efficient conversion of succinate to 
fumarate. This then raised the question of how increased fumarate levels are being 
maintained under steatotic conditions.  
 
4.4.4 Mitochondria develop a metabolic shunt to compensate 
for TCA cycle truncation 
In response to truncation, I found that HLCs are able to rewire their metabolic circuitry 
to compensate for this, generating increased levels of fumarate, predominantly 
through the PNC, and to a lesser extent the MAS (Figure 4.24). A similar metabolic 
bypass has been reported in cardiac ischemic reperfusion injury [358], as well as 
human and mouse in vitro models of tumorigenesis [127]. However, this phenomenon 
has not been observed in NAFLD. In ischemic reperfusion injury, increased PNC 
activity results in fumarate overflow, driving reversal of succinate dehydrogenase 
activity and accumulation of succinate [358]. I did not observe the same phenomenon 
here, indicating inhibition of succinate dehydrogenase activity, which is supported by 
impaired conversion of succinate shown in section 4.4.3 and observed decreases in 
maximal respiration shown in section 4.4.1. In human and mouse FH-deficient cells, 
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accumulation of fumarate suppresses complex I activity [127], which may happen in 
steatotic HLCs too, as indicated by decreased maximal respiration in section 4.4.1. 
 
Figure 4.24. Model of metabolic rewiring in mitochondria of steatotic HLCs. Where 
truncation prevents conversion of succinate to fumarate, the PNC can act as a shunt 
to provide carbon to the TCA cycle. Solid red lines denote direction of metabolite 
synthesis in steatotic HLCs. Dashed red line represents TCA cycle truncation. Figure 
adapted from Sinton et al (2020) [304].   
 
Although it is possible for fumarate to be generated from reversal of fumarate 
hydratase [358], I was unable to directly manipulate the activity of this enzyme in order 
to assess its contribution to the fumarate pool. However, as FH operates at equilibrium 
[359] it is likely that low levels of fumarate, resulting from TCA cycle truncation, lead 
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Defects in complex I can diminish levels of NAD+ [360] and, therefore, regeneration 
of fumarate via the PNC may be one mechanism of increasing the NADH pool and 
maintaining the hydrogen ion gradient of the ETC. The synthesis of fumarate by the 
PNC also results in the generation of AMP, which in turn is deaminated to produce 
ammonia [361]. In rodents, hyperammonaemia is associated with the progression of 
hepatic steatosis to cirrhosis [362], and our findings may indicate that this is generated 
through increased PNC activity. This leads to the question of whether NAFLD-
associated cirrhosis is then a consequence of ammonia production or downstream 
effects of fumarate accumulation. In alcoholic liver disease, administration of 
monomethyl fumarate reverses hepatic inflammation and steatosis, and has been 
suggested as a potential therapeutic [363]. Whilst the aetiology of these diseases 
differs, this is indicative that fumarate plays a role in the progression of NAFLD. To 
this end, I questioned how inhibition of fumarate accumulation may impact on the 
development of macrovesicular steatosis.  
 
4.4.5 Inhibition of the PNC is associated with widescale 
transcriptomic changes 
As previously outlined in this chapter, fumarate is a negative regulator of the 
dioxygenase enzymes, including the TETs and JHDMs. These enzymes are thought 
to influence transcription through modulation of DNA and histone methylation. Based 
on this, I hypothesised that fumarate accumulation in steatotic HLCs would have a 
widescale impact on transcription. Within the transcriptomic dataset from LPO and 
AICAR-exposed HLCs, I observed changes in the expression of a number of genes 
associated with complement activation, and regulation of iron homeostasis, most of 
which were downregulated. It has previously been demonstrated that alterations in 
complement activation and iron homeostasis pathways are associated with NAFLD 
[364,365]. Their overall downregulation in response to AICAR treatment may suggest 
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Complement activation is known to be associated with nonalcoholic steatohepatitis 
(NASH), where complement 3 (C3) accumulates in the liver, where it activates the 
mannose-binding lectin pathway [364]. This, in turn, recruits neutrophils to the tissue, 
leading to the development of inflammation [366]. Inhibiting fumarate accumulation in 
LPO-treated HLCs led to the downregulation of genes associated with the mannose-
binding lectin pathway, suggesting prevention of complement activation. This is 
supported by the finding that DNA methylation of the C3 promoter correlates with 
transcription [367,368]. In turn, this suggests that fumarate accumulation in NAFLD 
and the subsequent modulation of dioxygenase enzyme activity can impact on DNA 
methylation at key inflammation related genes.  
 
The inhibition of fumarate accumulation in steatotic HLCs also influenced expression 
of genes associated with iron homeostasis. Previous studies suggest that, in humans, 
hepatic iron accumulation is associated with an increased risk of developing NASH 
and fibrosis [369][370], but the mechanisms underpinning this association are not yet 
understood. In NASH patients, serum hepcidin (encoded by HAMP) levels are 
commonly elevated [371], but it is unclear whether this elevation is a consequence of 
hepatic disease or associated obesity [372]. In this regard, the transcriptomic data 
here demonstrate increased expression of HAMP in response to PNC inhibition, 
indicating that these cells may be releasing iron. Furthermore, transferrin receptor 2 
(TFR2) is an iron sensor that can activate hepcidin, and its downregulation in 
response to PNC inhibition suggests that its expression may be modulated by 
fumarate in steatotic HLCs. This may indicate that in steatotic HLCs, increased PNC 
activity promotes iron accumulation. In turn, this may influence transcriptional 
regulation, as Fe2+ is a co-activator of the dioxygenase group of enzymes, including 
the TETs [137].   
 
4.4.6 Macrovesicular steatosis in HLCs is driven by PNC-
induced accumulation of fumarate  
A further consequence of fumarate accumulation is the development of 
macrovesicular steatosis. Inhibition of the PNC prevented development of 
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macrovesicular lipid droplets, which was partially restored following exposure to 
exogenous monomethyl fumarate. This correlates with findings in oligodendrocytes 
and CD8+ T cells, where exposure to exogenous fumarate perturbed lipid metabolism 
[373,374], although the mechanism by which this occurs remains unknown. However, 
my data demonstrate that fumarate is important for the development of 
macrovesicular steatosis in HLCs and that mechanisms compensating for TCA cycle 
truncation in LPO-treated HLCs cells drive intracellular lipid accumulation.  
 
4.5 Experimental limitations 
NAFLD is typically associated with obesity and IR and, therefore, the liver is exposed 
to a number of adipokines and inflammatory signals in vivo. Whilst HLCs develop 
macrovesicular steatosis, as in other in vitro systems they are not exposed to these 
signals, which may impact their metabolic response. A further limitation is that this 
study only assessed changes in polar metabolites but did not examine non-polar 
metabolites, which may give an insight into the response of b-oxidation and 
ketogenesis pathways to steatosis. This may provide valuable information in 
understanding how fumarate drives the development of macrovesicular lipid droplets. 
Furthermore, the development of mass spectrometry imaging could provide insight 
into the composition of these lipid droplets [375].  
A further limitation of the approach taken here is the use of the inhibitor AICAR, which 
is an adenylosuccinate lyase inhibitor, and blocks PNC activity, thus limiting fumarate 
accumulation [358]. However, AICAR is also an AMP-activated protein kinase 
(AMPK) agonist [376]. In human NAFLD, activation of AMPK inhibited acetyl-CoA 
carboxylase (ACC), which in turn appeared to reduce hepatic lipid storage [377]. 
However, this finding is controversial, as AMPK does not appear to impact on lipid 
storage under obesogenic conditions [378]. However, this raises the possibility that, 
the findings in this chapter, related to AICAR-driven reduction in macrovesicular 
steatosis arise from AMPK activation. The partial restoration of macrovesicular 
steatosis observed following incubation with exogenous fumarate suggests that this 
is not the case, but it is reasonable to speculate that reductions in macrovesicular 
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steatosis in response to AICAR result from combined AMPK activation and PNC 
inhibition.  
 
In addition to its impact on lipid accumulation, AMPK down-regulates the expression 
of NAD(P)H oxidase genes [379], which may alleviate oxidative stress in lipid-laden 
hepatocytes. This, in turn, could interfere with TCA cycle and ETC activity. However, 
as shown in Chapter 3, many of these genes were already downregulated, suggesting 
that AICAR-mediated AMPK activation does not impact on the isotopic tracing studies 




Taken together, I demonstrate for the first time that the development of steatosis in 
HLCs associates with truncation of the TCA cycle. I further demonstrate that following 
exposure to LPO, mitochondrial metabolic pathways are re-wired in order to maintain 
TCA cycle activity, through PNC-driven fumarate accumulation, which is associated 
with the development of macrovesicular steatosis. These findings reveal a novel 
mechanism linked to hepatic steatosis and may lead to further understanding of 
transcriptional and metabolic rewiring associated with NAFLD.   
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Chapter 5: Exploring links between altered TCA 
cycle activity and TET enzyme activity in 
steatotic cells 
5.1 Introduction 
The TCA cycle metabolites αKG, succinate and fumarate are allosteric regulators of 
the αKG-dependent dioxygenase family of enzymes; their activity is promoted by αKG 
and inhibited by succinate and fumarate [134–136]. The binding kinetics of substrates 
activating (Michaelis constant, Km)) or inhibiting (half maximal inhibitory 
concentration, IC50) TET1 and TET2 enzyme activity are outlined in Tables 5.1 and 
5.2, respectively. These values are currently unknown for TET3. This enzyme family 
include the Jumonji domain-containing histone demethylases (JHDMs), prolyl-4-
hydroxylases, and the ten-eleven translocation (TET) dioxygenases [132,133]. The 
TET enzymes can regulate the epigenome through modulation of DNA methylation, 
by oxidising 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) [137,138]. 
Dysregulation of the TET enzymes may also be important in the pathogenesis of liver 
disease. It was previously observed that in murine and human models of NAFLD, 
there are alterations in 5hmC at specific loci, suggesting a role for the TET enzymes 
[128,208]. Studies in mouse models of HCC also suggest that the TET enzymes may 
contribute to the progression of liver cancer, through perturbation of normal DNA 
demethylation events at promoters [247]. 
 
In this chapter, I aimed to understand whether there is an association between 
perturbed TCA cycle activity in steatotic HLCs and TET enzyme activity. I performed 
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Compound TET1  TET2 
Fe2+ (µM) 4.8 ± 4 125 ± 85 
aKG (µM) 55 ± 20 3.6 ± 3 
Oxygen (µM) 30 ± 10 30 ± 3 
Table 5.1. Michaelis constant (Km) values for binding of substrates promoting TET1 
and TET2 enzymatic activity. Adapted from Laukka et al (2016) [133].  
 
Compound TET1 TET2 
Succinate (µM) 540 ± 100 570 ± 90 
Fumarate (µM) 390 ± 160 400 ± 70 
Table 5.2. The IC50 values for inhibition of TET1 and TET2 enzymatic activity. 
Adapted from Laukka et al (2016) [133]. 
 
5.1.1 Hypothesis 
Steatosis-associated fumarate accumulation inhibits TET enzyme activity, leading to 
alterations in global levels of 5hmC. 
 
5.1.2 Aims 
1. To characterise changes in global levels of 5mC and 5hmC in response to 
development of steatosis in HLCs.  
2. To determine whether changes in 5hmC were associated with altered 
expression of the TET enzymes, or alteration of their function. 
3. To explore associations between altered genic 5hmC and gene transcription. 
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5.2 Materials and methods 
5.2.1 Differentiation of hPSCs to HLCs and induction of lipid 
accumulation 
Human female H9 pluripotent stem cells (hPSCs) were differentiated to hepatocyte-
like cells (HLCs), and lipid accumulation induced as described in Chapter 2, section 
2.1-2.2. 
 
5.2.2 Ultra-performance liquid chromatography (UPLC) 
analysis of global 5mC and 5hmC 
Sample preparation 
2.5μg DNA in 43μL water, per sample, was incubated at 95 °C for 10 minutes. Then, 
5μL of 10x T7 DNA polymerase reaction buffer and 10 U T7 DNA polymerase 
(Thermo Scientific, Renfrew, UK) was added. The reaction was incubated overnight 
at 37 °C, followed by incubation at 75 °C for 10 minutes. Finally, samples were 
centrifuged for 45 minutes at > 12,000 x g, before aspirating the supernatant and 
drying down using a Speed Vac. Samples were stored at -80 °C until time of analysis. 
 
UPLC  
Samples were analysed by Dr Jimi Wills at the mass spectrometry facility, Institute for 
Genetic and Molecular Medicine, University of Edinburgh, as described in Chapter 2, 
section 2.6.3. 
 
5.2.3 DNA immunoprecipitation (DIP-seq) analysis of 5hmC 
enrichment 
DNA was fragmented using a Covaris® E220 Focused-Ultrasonicator (Covaris, 
Brighton, UK), before immunoprecipitating hydroxymethylated fragments. 
Immunoprecipitated DNA was then sent to the Wellcome Trust Clinical Research 
Facility (Western General Hospital, Edinburgh), where it underwent sequencing. I 
analysed the sequencing data with the assistance of Sara Wernig-Zorc (University of 
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Regensburg, Germany), using the MACS2 and Homer pipelines. Full details of DNA 
preparation and bioinformatic analyses are located in Chapter 2, section 2.6 and 2.7. 
 
5.2.4 3D-RNA seq analysis of alternative splicing  
The RNA-seq dataset generated in Chapter 3 was re-analysed to explore alternative 
splicing events occurring in steatotic HLCs. Instead of using FeatureCounts, 
transcripts were quantified using Kallisto [380]. Transcript counts were then loaded 
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5.3 Results 
5.3.1 Macrovesicular steatosis is associated with global 
changes in 5hmC, but not in expression of the TET 
enzymes 
As fumarate is a known inhibitor of the TET enzymes, I wanted to explore whether 
increased abundance impacted on global levels of 5mC and 5hmC. UPLC analysis 
revealed a significant increase in global 5hmC (Figure 5.1) in steatotic HLCs. To 
determine whether this arose as a result of altered TET enzyme expression, I 
investigated expression of TET1, TET2, and TET3 in the RNA-seq analysis data 
generated in Chapter 3. This revealed that the presence of steatosis in HLCs is not 
associated with altered expression of these genes (Figure 5.2).  
 
 
Figure 5.1 UPLC analysis reveals increased global 5hmC in steatotic HLCs. 
Global levels of 5hmC were increased in steatotic HLCs. For each group, n = 3. Data 
were analysed using a two-tailed Student’s t-test. Data are expressed as mean ± SD.  
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Figure 5.2. TET enzyme expression is unaltered in steatotic HLCs. 
Transcriptomic analysis performed in Chapter 3 shows that TET mRNA expression is 
unaltered in steatotic HLCs. For each group, n = 3. Data were analysed using a two-
tailed Student’s t-test. Data are expressed as mean ± SD. 
 
Although expression of the TET enzymes was unchanged in steatotic HLCs, I 
questioned whether increased fumarate accumulation would have a functional impact 
on their activity, as determined by changes in 5hmC. To test this, genome-wide 5hmC 
sequencing was performed, identifying 3294 differentially hydroxymethylated regions 
(DHRs) between LPO exposed and control cells (>2-fold change). Within each group, 
samples were highly correlated, suggesting that the 5hmC patterns are stable 
between replicate samples (Figure 5.3), with the majority of changes located in 
intergenic (43%) or intronic (51%) regions (Figure 5.4). The remaining alterations in 
5hmC enrichment were located in the 3’ (0.7%) or 5’ (0.1%) UTR sites, exons (1.3%), 
intergenic regions (43%), introns (51%), non-coding regions (0.4%), promoters 
(1.7%), or TSSs (1.1%).  
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Figure 5.3 Correlation heatmap of control vs. LPO groups, following hmeDIP 
sequencing, clustered by Euclidean distance. Untreated = control group. Treated 
= LPO-treated group. For both control and LPO, n = 3 biological replicates/group. 
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Figure 5.4. Proportion of DHRs associated with different regions of the genome, 
showing the majority located in intrergenic and intronic regions. Regions were 
differentially enriched/depleted in LPO-treated HLCs compared with controls. For both 
control and LPO, n = 3 biological replicates/group. Figure is adapted from Sinton et 
al, 2020 [304] 
 
5.3.2 5hmC alterations in steatotic HLCs occurs in genic 
regions associated with tissue remodelling and 
Wnt/beta-catenin signalling  
To further explore the changes in 5hmC in response to steatosis in HLCs, I performed 
a STRING analysis. Similar to pathway enrichment, this analysis can determine 
relationships between clusters of genes that are differentially expressed and offers a 
visual representation of this. It also enables identification of putative hub genes, which 
have high connectivity to other genes. These may represent key genes that are 
involved in the disruption of pathways associated with disease [382]. Performing this 
analysis on genic regions identified in section 5.3.1 generated a map consisting of 5 
clusters of genes (Figure 5.5). Clusters related to Wnt/beta-catenin signalling 
(yellow), PI3K signalling (green), collagen deposition (aqua), or DNA damage repair 
(blue). Genes represented by red spheres did not cluster. Within the yellow cluster, I 
also identified CTNNB1, which encodes beta-catenin, as a hub gene. CTNNB1 is a 
 
Chapter 5  148 
key component of the Wnt/beta-catenin signalling pathway and is highly connected to 
other genes within this cluster, suggesting that it may play a key role in NAFLD 
pathogenesis. DIP-seq analysis revealed a 3.7-fold decrease in 5hmC in intron 33 of 
the CTNNB1 gene, correlating with a -0.6-fold decrease in mRNA expression 
(Chapter 8, Appendix 5). Within the aqua cluster are several genes related to tissue 
remodelling, including collagen, type VI, alpha 1 (COL6A1), a gene known to be 
regulated by 5mC [383]. DIP-seq analysis of COL6A1 revealed a 3.1-fold increase in 
5hmC in the gene promoter as well as a 4.1-fold increase in 5hmC in intron 3, 
concomitant with a 1.2-fold increase in mRNA expression (Supplementary file MCS1 
– DEGs in LPO-treated HLCs). STRING analysis also revealed enrichment of the 
UniProt keyword term KW0025: alternative splicing, highlighting that a significant 
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Figure 5.5. STRING analysis of DHRs in genic regions. Analysed genic regions 
were exons, introns, and transcriptional start sites, regardless of fold change in 
enrichment. Clusters were calculated using k-means clustering. Mapped genes had 
the highest confidence interaction score (0.9). Line colours represent the following: 
blue – information from curated databases; pink – interaction confirmed 
experimentally; yellow – information from text mining; black – genes known to be co-
expressed; green – genes are in the same gene neighbourhood. Dashed lines occur 
where different clusters are linked. Each sphere colour represents a cluster.  
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5.3.3 Differential 5hmC enrichment in promoter regions 
shows a moderate negative correlation with mRNA 
expression in steatotic HLCs  
It is thought that 5hmC in gene body regions may functionally relate to mRNA 
transcription [247]. Therefore, I generated heatmaps representing mean changes 
upstream of and across the TSS, with cluster 1 showing subtle increases in 5hmC 
within the upstream region (Figure 5.6). Sliding window analysis of 5hmC upstream 
of and across the gene body supports this finding, revealing subtle increases in 5hmC 
within putative promoter regions following LPO exposure (Figure 5.7).  
 
Figure 5.6. Heatmap analysis of DHRs surrounding transcriptional start sites 
highlights subtle increases in 5hmC in putative gene promoter regions. 
Heatmap was generated by k-means clustering, with an FDR of <0.05. Regions were 
differentially enriched/depleted in LPO-treated HLCs compared with controls. For both 
control and LPO, n = 3 biological replicates/group. Numbers on the y-axis represent 
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Figure 5.7. Sliding window analysis of average 5hmC levels of the 
transcriptional start site (TSS), gene body, and transcriptional end site (TES) 
shows minimal changes between control and LPO groups. Regions were 
differentially enriched/depleted in LPO-treated HLCs compared with controls. For both 
control and LPO, n = 3 biological replicates/group. Figure is adapted from Sinton et 
al, 2020 [304] 
 
In line with this, I integrated DHR and RNA-seq data to look at promoter regions 
upstream of the transcriptional start site. In doing so, I identified 12 promoter regions 
with differential enrichment of 5hmC (>2-fold) and where mRNA expression was 
altered >0.5-fold (Table 5.1). Linear regression of these regions identified a moderate 
but significant negative relationship between 5hmC enrichment and mRNA 
expression (Figure 5.8). Of these genes 7 (EPHX3, ERO1B, CSGALNACT1, DOC2A, 
COL6A1, CASP1 and TMEM88) were previously shown to be dysregulated in the 
pathogenesis of NAFLD or progression to cirrhosis [384–388]. This may indicate a 
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ENSG00000181418 DDN 3.57 -2.84 
ENSG00000105131 EPHX3 2.38 -3.82 
ENSG00000086619 ERO1B 1.65 4.05 
ENSG00000147408 CSGALNACT1 1.33 3.09 
ENSG00000149927 DOC2A 1.26 -2.49 
ENSG00000142156 COL6A1 1.24 3.13 
ENSG00000137752 CASP1 0.98 2.44 
ENSG00000119900 OGFRL1 0.71 2.21 
ENSG00000145247 OCIAD2 0.71 3.02 
ENSG00000183044 ABAT -1.26 3.04 
ENSG00000144395 CCDC150 -1.50 3.36 
ENSG00000167874 TMEM88 -2.02 3.60 
Table 5.1. Promoter regions of genes with both altered mRNA expression and 
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Figure 5.8. Steatotic HLCs show a moderate negative correlation between 
putative promoter 5hmC enrichment and mRNA expression. The cut-off for 
inclusion was: 5hmC enrichment/depletion >2.0; mRNA expression log2 fold change 
>0.5. Data were analysed by linear regression. Figure is adapted from Sinton et al, 
2020 [304] 
 
5.3.4 In steatotic HLCs, decreased 5hmC in the alternative 
promoter of PPARGC1A is associated with altered 
isoform expression  
As 5hmC deposition is thought to influence alternative splicing, [205,389], and this 
was an enriched pathway in the STRING analysis, I was interested in understanding 
whether 5hmC enrichment in genic regions in steatotic HLCs was associated with 
differential splicing events. To this end, the RNA-seq dataset generated in Chapter 3 
was reanalysed using the 3DRNA-seq analysis pipeline [381], and then integrated 
with the DIP-seq data presented in this chapter. This analysis identified that depletion 
of 5hmC in the alternative promoter of PPARg coactivator-1-a (PPARGC1A; Figure 
5.9) is associated with increased expression and differential transcript usage of 
transcript variant 2 of this gene.    
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Figure 5.9. Steatosis in HLCs is associated with depletion of 5hmC in the 
alternative promoter of PPARGC1A.  
 




Fold change -3.73 +1.52 +1.89 
Transcript Intron 2. Nearest 
promoter: NM_013621, 
transcript variant 2 
No data NM_0132621.5, 
corresponds to 
transcript variant 2 
Table 5.2 Depleted 5hmC in the alternative promoter of PPARGC1A is 
associated with increased expression of transcript variant 2.  
 
PPARGC1A can be spliced to multiple isoforms, and although the function of these 
different isoforms remains unclear, when translated they are each subject to different 
PTMs, indicating that each has a distinct function (Figure 5.10) [390].  
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Figure 5.10. Domain structures of PGC1-A (protein name for PPARGC1A). This 
schematic shows the full length PGC1-A (PRC), as well as the shorter isoforms PGC-
1b (encoded by PPARGC1A 1b), PGC-1a (encoded by PPARGC1A 1a), NT-PGC-1a 
(encoded by NT-PPARGC1A) and PGC-1a4 (encoded by PPARGC1A 1c). 
Phosphorylation, acetylation and methylation are the most common PTMs identified 
for PGC-1a and PGC-1b. AD = activation domain; RS = serine/arginine‐rich stretch; 
HCF = host factor cell; LXLL = leucine-rich motif. Figure taken from Villena (2014) 
[390].  
To further interrogate this, I performed RT-qPCR of total PPARGC1A and then of 
multiple isoforms generated from alternative splicing (Figure 5.10). This analysis 
confirmed that total PPARGC1A expression increases in steatotic HLCs, and that 
there is an increase in the intron 2-derived PPARGC1A-c, as well as the truncated 
NT-PPARGC1A isoform. Taken together, this suggests that 5hmC depletion in intron 
2 of PPARGC1A may impact alternative splicing of this gene, leading to preferential 
transcript usage of PPARGC1-c. However, the significance of this is unclear.    
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Figure 5.11. Steatosis in HLCs is associated with differential splicing of 
PPARCG1A. (A) Total PPARGC1A increased in steatotic HLCs. (B) Exon 1a derived 
transcript (PPARGC1A 1a) was unchanged in steatotic HLCs. (C) Exon 1b-derived 
transcripts (PPARGC1A 1b) decreased. In contrast, (D) exon 1c-derived transcripts 
(PPARGC1A 1c) and (E) truncated transcript (NT-PPARGC1A) expression increased. 
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5.4 Discussion 
5.4.1 Macrovesicular steatosis is linked to altered TET 
enzyme activity, leading to global changes in 
enrichment of 5hmC 
A potential consequence of fumarate accumulation in steatotic HLCs is inhibition of 
αKG-dependent dioxygenase enzyme activity. Given the previous data showing 
altered 5hmC in a mouse model of NAFLD and the potential importance of the TET 
enzymes in HCC [208,247], I used a DIP-seq approach to measure changes in 5hmC 
across the genome. 5hmC is a stable epigenetic modification that may influence 
transcription, and while the nature of this influence is unclear, studies suggest that 
5hmC enrichment at transcriptional start sites (TSSs) leads to repression of 
transcription [204]. Recent studies in mice showed that 5hmC enrichment is reversibly 
altered at specific loci in response to fat accumulation in the liver, indicating that the 
TET enzymes may play a role in NAFLD pathogenesis [208]. I observed widescale 
changes in 5hmC enrichment, predominantly in intronic and intergenic regions of the 
genome. There are studies suggesting that enrichment of intronic 5hmC may 
influence transcription in hepatocyte differentiation [391]. Furthermore, studies of 
mouse dilated cardiomyopathy demonstrated an association between the disease 
and enrichment of intronic 5hmC [392]. One possibility is that the influence of 5hmC 
within these regions is related to long range chromatin interactions, which was shown 
to have a greater impact on transcription than enhancer enrichment in differentiation 
of human CD4+ T cells [393]. Integrating the data presented here with a chromatin 
conformation capture approach, to explore interaction of 5hmC with distal regulatory 
elements may provide a clearer insight into whether intergenic or intronic 5hmC 
influences transcription in steatotic HLCs.  
 
5.4.2 Altered enrichment of 5hmC is found in genes related to 
Wnt/beta-catenin signalling and tissue remodelling in 
steatotic HLCs  
When examining 5hmC across gene bodies, STRING analysis revealed alterations in 
enrichment in genes related to tissue remodelling, and Wnt/beta-catenin signalling. 
As Wnt/beta-catenin signalling is known to induce expression of genes related to 
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tissue repair and remodelling [394], it is notable that both of these pathways were 
enriched in this analysis. Wnt/beta-catenin signalling is increased in ~50% of patients 
who present with NAFLD-associated HCC [395]. Furthermore, a significant proportion 
of these patients do not have mutations in CTNNB1, the gene encoding beta-catenin, 
suggesting that expression may be modulated by the epigenome [396]. Previous 
studies in mouse models of HCC have shown a gain of 5mC with a concomitant loss 
of 5hmC in the promoter core of CTNNB1 [247]. Further to this, histone deacetylase 
8 (HDAC8) regulates CTNNB1 in NAFLD-associated HCC [397]. However, it is 
unclear which loci in CTNNB1 undergo HDAC8-mediated deacetylation. The 
presence of either 5mC or 5hmC can recruit MeCP2 [398], which, in turn, can recruit 
HDACs [399] or histone methyltransferases [400] to the DNA. In steatotic HLCs it is 
unclear whether loss of 5hmC in CTNNB1 influences transcription of the gene, 
particularly given the location of the depletion. Furthermore, it is unclear whether 
depletion of 5hmC here is a result of increased TET enzyme activity, further oxidising 
it to downstream derivatives, or whether there is decreased activity, leading to 
increased levels of 5mC.  
 
In addition to these changes, a number of genes related to tissue remodelling 
displayed altered enrichment of 5hmC, with changes mostly occurring in intronic 
regions. These included collagen, type VI, alpha 1 (COL6A1) and collagen, type XII, 
alpha 1 (COL12A1). Upregulation of these genes in NAFLD is typically associated 
with stellate cell activation in response to inflammation, leading to development of 
hepatic fibrosis [387]. In steatotic HLCs, there was an upregulation of COL6A1 and 
COL12A1, which are known to be involved in development of NAFLD-related cirrhosis 
in humans [387,401]. Previous studies have shown that 5mC in the promoter of 
COL6A1 can influence transcription of the gene [383]. However, this was determined 
using bisulphite sequencing, which is unable to discriminate between 5mC and 5hmC 
[402]. Therefore, it is unclear which of these DNA modifications, in this context, 
influences transcription. Whereas it appears that COL6A1 expression may be 
influenced by TET activity, this is less clear in the case of COL12A1, where increased 
levels of 5hmC occur in a late intron within the gene body. As both Wnt/beta-catenin 
signalling and collagen deposition are associated in NAFLD, the data presented here 
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suggest that altered enrichment of genic 5hmC may play a role in disruption of these 
pathways. However, further studies are required to confirm or refute this.  
 
5.4.3 There is a moderate negative correlation between 5hmC 
and mRNA expression associated with steatosis in 
HLCs 
Changes in 5hmC at specific loci did not, in general, correlate with transcriptional 
changes in steatotic cells. However, as gene promoter 5hmC has previously been 
correlated with transcriptional perturbation [247], I went on to explore this relationship 
in steatotic HLCs. This analysis revealed a moderate negative correlation between 
5hmC enrichment and mRNA expression in 12 genes, 7 of which were previously 
shown to be associated with NAFLD: EPHX3, ERO1B, CSGALNACT1, DOC2A, 
COL6A1, CASP1 and TMEM88 [384–388].  
 
ERO1B is an endoplasmic reticulum (ER) oxidoreductase, which catalyses the 
formation of sulphide bonds [403]. Under ER stress, the unfolded protein response 
(UPR) is activated, which can induce increased expression of ERO1B [404]. There is 
evidence to suggest that LPO may induce ER stress [42], a known contributor to 
NAFLD [44]. Further to this, the UPR can induce activation of the NLRP3 (NOD-, LRR- 
and pyrin domain-containing protein 3) inflammasome [405], and downstream 
activation of CASP1 (caspase-1), leading to apoptosis [406]. Upregulation of both 
ERO1B and CASP1 suggests that steatotic HLCs are undergoing increasing levels of 
apoptosis, which is thought to be involved in the progression of benign steatosis to 
NASH [407].  
 
Upregulation of EPHX3 (epoxide hydrolase 3) mRNA expression correlated with a 
loss of 5hmC in the promoter of this gene. Whilst the precise role of EPHX3 in NAFLD 
has not been described, activation of this enzyme is thought to be beneficial for the 
treatment of NASH, and has been shown to improve lipid homeostasis in hepatocytes 
[408]. However, this study was performed in mice using a methionine-choline-
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deficient diet model of NASH, which is poorly representative of the disease in humans 
[238]. Upregulation of EPHX3 in steatotic HLCs may be a protective mechanism, 
assisting in maintenance of lipid homeostasis. However, knockout and 
overexpression studies would be required to further interrogate this.  
 
In steatotic HLCs, TMEM88 (transmembrane protein 88) mRNA expression was 
downregulated, with a concomitant increase in promoter 5hmC. TMEM88 is known to 
inhibit Wnt/beta-catenin signalling [409] and, therefore, its downregulation in steatotic 
HLCs may de-repress this signalling pathway. As discussed in section 5.4.2, 
Wnt/beta-catenin signalling is increased in ~50% of patients who present with NAFLD-
associated HCC [395]. Previous studies have characterised methylation of the 
TMEM88 promoter, associating it with unfavourable prognosis in non-small cell lung 
cancer [410]. This study used bisulphite sequencing to determine the presence of 
methylation in the TMEM88 promoter, which, as discussed in section 5.4.2 is unable 
to discriminate between 5mC and 5hmC [402]. Therefore, the authors of this study 
may have been observing enrichment of promoter 5hmC rather than 5mC, as 
observed in this study. Taken together, repression of TMEM88 expression by 
promoter 5hmC enrichment may de-repress Wnt/beta-catenin signalling in steatotic 
HLCs and may be an indicator of downstream development of NAFLD-related HCC.   
 
5.4.4 Depletion of 5hmC in the PPARGC1A alternative 
promoter correlates with increased expression of 
specific isoforms 
Steatosis in HLCs was associated with depletion of 5hmC in the promoter of 
PPARGC1A, with corresponding increases in mRNA expression of exon 1c-derived 
transcripts (PPARGC1A 1c) and truncated PPARGC1A (NT-PPARGC1A). The 
canonical PPARGC1A promoter is known to be subject to epigenetic modification, 
with studies showing increased enrichment of 5hmC in response to exercise in mice 
[411]. However, the same study observed no changes in 5hmC in the alternative 
promoter, suggesting that hydroxymethylation of this promoter is context dependent. 
Whilst changes in canonical promoter methylation corresponds with changes in gene 
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transcription, it is unknown whether this is the case for the alternative promoter, and 
further studies are required to determine this. A similar study showed increased 
expression of alternative promoter-derived PPARGC1A isoforms and found that 
PPARGC1A 1c had a similar function to canonical promoter-derived isoforms [412]. 
Therefore, further studies are required to understand whether preferential expression 
of alternative promoter-derived isoforms of PPARGC1A is of functional importance in 
NAFLD.   
 
5.5 Experimental limitations 
Although this study focused on promoter 5hmC enrichment, it possible that differential 
5hmC enrichment is occurring in regions associated with expression of enhancers, 
non-coding RNAs, or microRNAs, which in turn may influence mRNA transcription 
[413–415]. Further to this, the DIP-seq approach utilised here does not provide base-
pair resolution. Using combined bisulphite and oxidative bisulphite sequencing would 
provide this level of resolution, and may give additional insight into the interplay 
between 5hmC enrichment and transcriptional regulation [416].   
 
I hypothesised that steatosis-associated fumarate accumulation would influence TET 
enzyme activity, as demonstrated by altered 5hmC enrichment. However, as 
previously mentioned, fumarate is an allosteric inhibitor of the whole dioxygenase 
family of enzymes, which may impact on transcriptional regulation in NAFLD, 
including effects on HIF1α or the histone demethylase enzymes [417,418]. Further to 
this, in steatotic HLCs there was also an increase in αKG, which is an activator of the 
TET enzymes [137]. It is suggested that as αKG has a higher binding affinity for the 
dioxygenases that it will always outcompete fumarate for binding [209]. From the data 
presented here, it is unclear whether changes in 5hmC arise from inhibition of TET 
activity, leading to decreased conversion of 5mC to 5hmC, or increased activity, 
leading to increased oxidation of 5hmC to 5fC.  
 
 
Chapter 5  162 
It is important to note that the data presented in this chapter are correlative, and do 
not show a direct link between 5hmC and mRNA expression. In this regard, the 
negative correlation between promoter 5hmC and mRNA expression was based on a 
very limited number of genes raising the question of whether this is functionally 
relevant. Further mechanistic studies, including knockout and overexpression 
experiments, may provide further insight into the functional relevance of correlations 
between 5hmC and mRNA expression in steatosis.   
 
5.6 Conclusion 
This genome-wide study of 5hmC enrichment in steatotic HLCs provides a novel 
insight into the epigenetic regulation of NAFLD-related genes. Here, I reveal genome-
wide alterations in 5hmC, and a potential correlation between promoter 5hmC 
enrichment and transcription of genes relevant to NAFLD. Furthermore, this study 
further supports that Wnt/beta-catenin signalling is important in NAFLD and suggests 
that it is influenced by overnutrition-mediated epigenetic regulation. This study opens 
the door to further exploration of how environmental cues influence the epigenome 
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Chapter 6: Discussion 
6.1 Summary 
NAFLD is the most prevalent form of hepatic disease globally, representing an 
extraordinary burden on healthcare systems. There is currently a lack of non-invasive 
diagnostics or therapeutics available to reverse pathology, which is a reflection of the 
complexity of this disease [15]. As global obesity rates soar, with concurrent increases 
in the prevalence of NAFLD, the need for easy diagnostics and therapeutic 
interventions is becoming ever more urgent. The work in this thesis explores, at high 
resolution, the impact that overnutrition has on hepatic mitochondrial metabolism in a 
human-relevant hPSC model of NAFLD. In this thesis I show, for the first time, that 
rewiring of the TCA cycle directly impacts on lipid accumulation in hepatocytes, 
presenting a possible area of interest for the development of novel therapeutics. 
Further to this, I also demonstrate that these changes are associated with 
transcriptomic and epigenomic changes, which may be important in the development 
of NAFLD.  
 
6.2 Novel findings 
6.2.1 Hepatic steatosis is associated with impaired 
mitochondrial respiration 
Previous studies have demonstrated alterations in mitochondrial respiration 
associated with NAFLD [34,130]. In 2015, Koliaki et al showed that hepatic 
mitochondria from NAFLD patients displayed increased maximal respiration in the 
absence of changes in mitochondrial content [130]. In contrast, they identified 
increased hepatic mitochondrial content in NASH patients, which was associated with 
decreased maximal respiration. Based on these findings they hypothesised that 
mitochondria in steatotic hepatocytes can adapt to cellular stress but that this is lost 
when the disease progresses to NASH. However, there were a number of limitations 
to this study, potentially confounding their findings. The authors studied whole tissue 
and the study, therefore, does not account for cell type-specific changes in 
mitochondrial respiration. Different cell types have varying metabolic profiles 
depending on their energetic needs. For example, activated Kupffer cells, which are 
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found in the liver during NASH, are more glycolytic [419], whereas steatotic 
hepatocytes appear to rely more on oxidative metabolism [34]. Whilst this could be 
overcome by using a cell sorting approach, the metabolome is very sensitive to 
changing environmental stimuli, and this process has been shown to alter cellular 
redox status [253]. The use of a single cell type, as described in this thesis, overcomes 
these challenges, enables the study of the metabolome without introducing 
environmental stressors or the confounding effects of multiple cell populations with 
varying metabolic profiles.  
 
In addition to this, the authors of this study used isolated mitochondria to examine the 
respiratory response to NAFLD. Mitochondrial isolation is understood to impact on 
organelle function as it can result in fragmentation, impairing respiratory function 
[420]. By culturing and differentiating hPSCs in situ, I was able to measure 
mitochondrial respiration without this confounding effect. Another limitation of the 
Koliaki study was that the authors only analysed expression of genes associated with 
mitochondrial biogenesis and did not perform transcriptomic analyses to determine 
whether there were NAFLD-associated changes in transcripts encoding respiratory 
complexes. The transcriptomic analyses performed in the studies presented here 
demonstrate that hepatic steatosis is associated with decreased expression of genes 
related to the TCA cycle and ETC. Whilst this does not demonstrate cause, it suggests 
that downregulation of these genes plays a role in the impairment of mitochondrial 
respiration.  
 
In this thesis, I demonstrate that steatotic HLCs have decreased maximal respiration 
capacity, but in the absence of changing mitochondrial content. This suggests that 
this model may reflect a transition phase, falling between the NAFLD and NASH 
phenotypes, and that impaired respiratory function may precede increased 
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6.2.2 Rewiring of the TCA cycle and subsequent fumarate 
accumulation drives macrovesicular steatosis 
It was previously observed by Burgess et al that NAFLD in both rodents and humans 
appears to be associated with mitochondrial dysfunction and increased TCA cycle 
activity [34,109,129,421]. Whilst informative, studies in humans have been indirect, 
using blood plasma metabolites as a readout of TCA cycle activity [34]. However, the 
finding of increased TCA cycle activity in rodents, with increased levels of all TCA-
cycle associated metabolites, support the findings in humans. This strongly indicates 
that hepatic TCA cycle function is disrupted in association with NAFLD.  
 
Using the hPSC-based model of NAFLD described in this thesis, I was able to 
determine whether hepatic steatosis is indeed associated with TCA cycle disruption. 
Using stable isotope tracing studies, I found that steatosis is associated with TCA 
cycle truncation, inhibiting the conversion of succinate to fumarate. This correlates 
with the findings of Chapter 3, where I observed dysfunction in the ETC. This 
dysfunction most likely arises from inhibition of respiratory complex I, II, or III, but I 
was unable to determine which of these was responsible for decreased maximal 
respiration in mitochondria. Inhibited conversion of succinate to fumarate suggests 
that this is, in part, due to dysfunction of complex II, also known as succinate 
dehydrogenase. Further respirometry studies may provide further insight into this.  
 
Steatotic HLCs were able to compensate for TCA cycle truncation by increasing 
purine nucleotide cycle (PNC) activity, leading to increased generation of fumarate. A 
similar compensatory mechanism was previously observed in cardiac ischaemia 
reperfusion injury [358], demonstrating that the TCA cycle is plastic and can adapt to 
changing metabolic demands. Further supporting this are studies of fumarate 
hydratase (FH), showing that knocking out the enzyme causes respiratory dysfunction 
but is not lethal, due to compensatory rewiring [127]. Notably, FH knockout resulted 
in fumarate accumulation, which, in turn, inhibited complex II activity. This raises the 
question of whether, in hepatic steatosis, increased PNC activity is compensating for 
TCA cycle truncation, or whether the truncation arises as a result of increased PNC 
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activity. Furthermore, this opens the question of whether the TCA cycle exhibits 
plasticity under homeostatic conditions or whether this is more generally associated 
with disease pathogenesis.  
 
6.2.3 Macrovesicular steatosis is associated with moderate 
changes in enrichment of 5hmC in gene promoters  
The association between transcriptional activity and 5hmC levels have previously 
been documented [206,212,222]. Furthermore, two studies reveal that changes in 
hepatic 5hmC are dynamic and can be induced by toxicological insults, with 
subsequent reversal upon withdrawal of the insult [422][423]. Studies of NAFLD have 
also identified dynamic changes in hepatic 5hmC, suggesting that it may play a role 
in the transcriptional changes observed in association with this disease [208]. As 
5hmC levels are modulated by the TET enzymes, and the activity of these enzymes 
is inhibited by fumarate, I questioned whether increased fumarate would inhibit TET 
activity. Sequencing analyses revealed widespread changes in 5hmC enrichment in 
steatotic HLCs, with the majority located in intergenic or intronic regions. Whilst these 
regions could act as regulatory elements and influence the expression of distal genes, 
the data presented in this thesis do not provide evidence of this, and further studies 
are required. I also observed a moderate negative correlation between promoter 
5hmC and gene transcription in 12 genes, as well as in the alternative promoter of 
PPARGC1A.  
 
The data presented in this thesis support the idea that generation of 5hmC is highly 
dynamic and that the TET enzymes can respond rapidly to changing environmental 
cues, an essential property for transcriptional regulators. However, whether 5hmC is 
functionally important in the regulation of transcription and altered transcriptional 
programme associated with NAFLD remains unclear. The findings that 5hmC profiles 
are highly conserved, precisely regulated and tissue specific suggests a functional 
role [67,196,206,215]. Genetic manipulation of the TET enzymes in the model of 
NAFLD used in this thesis may provide further insight into their influence on the 
pathogenesis of this disease.    
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6.3 Limitations 
This model of NAFLD utilises a single cell type cultured and differentiated in a 
monolayer. Whilst the model recapitulates the features of NAFLD that I aimed to study 
in this thesis, the model has limitations. As with many in vitro culture systems, these 
include the lack of other cell types and endocrine signals that cells receive in vivo. As 
described in Chapter 1, a major feature of NAFLD is the activation of Kupffer and 
stellate cells, which contribute to steatosis-associated inflammation and fibrosis. 
Furthermore, NAFLD in humans is generally associated with IR [424], which is not a 
feature of this model. However, it is also important to note that these limitations apply 
to other in vitro models of NAFLD and it is, therefore, important to interpret the work 
in the context of the considerable biological and technical limitations implicit in the 
field.  
 
A further limitation of the studies is related to the study of 5hmC in steatotic HLCs. 
The use of DNA immunoprecipitation sequencing (DIP-seq) provides a highly 
reproducible method of profiling, and correlates well with qPCR analysis. However, 
despite the accuracy of sequencing in identifying regions of enrichment, it is unclear 
how well this methodology can detect smaller changes at occurring at typically highly 
enriched loci. Furthermore, this type of sequencing does not offer base-pair 
resolution. There are alternative techniques that offer this level of resolution, including 
oxidative bisulphite or TET-assisted bisulfite sequencing. These techniques have 
enormous potential but remain prohibitively expensive. Another advantage of 
bisulphite-based sequencing is the uniformity of bioinformatic pipelines used to 
analyses them. This is a further limitation of DIP-seq, where pipelines are variable, 
and generally based around the use of tools built for ChIP-seq. The lack of 
standardised pipelines makes it challenging to compare studies directly. Further to 
this, the studies presented here do not clarify whether NAFLD-associated changes in 
5hmC enrichment arise from fumarate-induced inhibition of TET activity. It is possible 
that the changes observed arise because TET activity is inhibited and that 5mC 
cannot be oxidised to 5hmC and downstream derivatives. Alternatively, increased 
levels of αKG may promote increased TET activity, leading to increased conversion 
of 5mC to 5hmC and downstream derivatives. Future studies involving genetic 
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manipulation of individual TET enzymes, or their inhibition, will allow us to draw 
conclusions related to how altered mitochondrial metabolism influences their activity.  
 
6.4 Future directions 
The work in this thesis opens the door to a number of avenues of exploration. Delving 
further into the findings presented in this thesis, the next steps would include 
determining the mechanism by which fumarate accumulation induces macrovesicular 
steatosis. A number of approaches could help to address these questions, including 
further isotopic tracing analyses of non-polar metabolites to determine how TCA cycle 
metabolites and LPO are utilised to synthesise lipids. A further approach is to use 
mass spectrometry imaging, which can reveal the lipid species composition of lipid 
droplets at single-cell resolution [375].  
 
A further question raised in this thesis is whether fumarate accumulation impacts TET 
enzyme activity. This is challenging as the TET enzymes are involved in differentiation 
[425], and as hPSCs differentiate they reach confluence, making them difficult to 
transfect. One strategy for knocking out TET function is to create a Cas9 knock-in, 
under a constitutive promoter, alongside guide RNAs under an albumin promoter. 
Overexpression is made more challenging by the length of the sequences encoding 
the TET enzymes, which are >12 Kb in length. However, a similar strategy could be 
employed, whereby the TET enzyme of interest is introduced as a knock-in under an 
albumin promoter and is, therefore, only expressed as the cells mature and acquire a 
hepatocyte-like phenotype. An alternative to genetic manipulation is the use of small 
molecule inhibitors of TET function. One compound, Bobcat339, was recently 
described and shown to inhibit TET1 and TET2 in vitro [426]. Although a more 
straightforward approach than genetic manipulation, the off-target effects of 
Bobcat339 have not been described, and it is unclear whether it also inhibits activity 
of other dioxygenase enzymes.   
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The use of the monolayer population of HLCs to model NAFLD offers the opportunity 
to study mitochondrial dysfunction and lipid accumulation in the absence of the 
confounding effects created by other cell types. Taking this forward, the next logical 
step would be to use hPSC-based spheroids, which are then differentiated to HLCs 
within a 3D structure [427]. Compared with the monolayer-based model used here, 
these spheroids display a more organised architecture and make it easier to 
extrapolate findings to in vivo organs. Furthermore, these spheroids maintain function 
for up to a year, making them suitable for much longer-term studies than monolayer 
HLCs [428]. They can also be grafted into mice, where they support liver function of 
the animal. This offers the opportunity to continue studying a single cell population 
but in vivo, where the cells will receive endocrine signals and interact with other cell 
populations. Further to this is the option of using liver organoids, which offers the 
opportunity to study the impact of cellular interactions on the pathology of NAFLD. As 
well as hepatocyte-like cells, these organoids also contain stellate-like cells and 
Kupffer-like cell [429]. Recently it was shown that where the iPSCs used to generate 
these organoids were derived from patients with NASH that the organoids developed 
a NASH-like phenotype, and transcriptomes that were distinct from those derived from 
healthy donors [430]. As with spheroid models, it is also possible to graft liver 
organoids into rodents, to assess their function in vivo. These organoid models offer 
the opportunity to further study genetic susceptibility to progressing from benign 
steatosis to NASH, as well as opening the door to personalised medicine.   
 
Whilst there is still work to be done, hPSC-derived liver tissues have the potential to 
be used in clinical settings in the future. Firstly, hPSCs can be differentiated to HLCs 
in 96-well plates, as demonstrated in this thesis, which opens the door to high 
throughput screenings of potential therapeutic compounds to treat liver disease. 
These screenings can be used to measure the impact of these compounds on disease 
pathology as well as toxicity. Building upon this, once putative therapeutic compounds 
have been assessed, they can be tested in vivo, through grafting of human hepatocyte 
spheroids into mice [428]. This will enable closer approximations of the effects of 
these compounds in a clinical setting. Furthermore, drugs such as metformin, appear 
to exert a beneficial effect on NAFLD [431], but in-depth studies are required to 
determine the mechanisms underpinning these effects. Using in vitro systems such 
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as the one utilised in this thesis may enable more in-depth mechanistic studies of 
drugs such as these, which, in turn, may enable the development of more targeted 
therapeutics. With further development of iPSC-based hepatocytes, this may also 
enable the development of personalised drug therapies, whereby clinicians administer 
drugs that patients are most likely to respond favourably to.  
 
6.5 Conclusions 
In conclusion, this thesis provides insights into the mitochondrial dysfunction that 
occurs in association with hepatic steatosis and how rewiring of respiratory pathways 
induces macrovesicular steatosis. These findings open the door to understanding 
precisely how increased fumarate synthesis induces intracellular lipid accumulation. 
Although manipulation of fumarate levels is an unlikely therapeutic strategy, 
exploration of downstream pathways affected by its accumulation may reveal 
therapeutic targets. Until a strategy is identified to reverse the accelerating global 
rates of obesity, targeting NAFLD directly, and preventing disease progression will 
limit the burden on healthcare systems.      
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Chapter 8: Appendices 
8.1 Appendix 1: Up and downregulated KEGG 
pathways 






4.20 ADCY4, ADCY2, CACNA1I, GRIN1, 
GRIA3, PRKG1, PRKCB, KCNJ5, 
PLCB4, GRIN2D, CACNA1G, RYR1, 
GNG2, PER3, GNG4, MTNR1A 
hsa04724: Glutamatergic 
synapse 
4.15 ADCY4, DLGAP1, ADCY2, GRIK2, 
GRIN1, GRIK5, GRIN3B, GRIA3, 
SHANK1, PRKCB, SLC17A7, GLS2, 
GRM4, PLCB4, GRIN2D, PLA2G4F, 
GNG2, GNG4, PLA2G4D 
hsa04725: Cholinergic 
synapse 
3.59 ADCY4, ACHE, ADCY2, KCNJ12, 
KCNJ14, PRKCB, KCNJ4, KCNQ4, 
KCNQ3, CHRM4, PLCB4, GNG2, 
PIK3R5, GNG4, KCNQ1, CHRNA3 
hsa04750: Inflammatory 
mediator regulation of 
TRP channels 
3.31 ADCY4, ADCY2, TRPM8, TRPV2, 
ASIC3, ASIC1, PRKCB, PLCB4, 




3.26 ADCY4, ADCY2, ADRB1, SGCG, 
CACNG8, ITGA8, ITGA7, CACNB1, 
CACNB4, TNNI3, ITGA2B 
hsa04911: Insulin 
secretion 
3.23 TRPM4, ADCY4, ADCY2, PLCB4, 
KCNN1, KCNN3, ATP1A3, RIMS2, 
PCLO, KCNJ11, PRKCB 
hsa04726: Serotonergic 
synapse 
3.14 GABRB2, PRKCB, KCNJ5, PLCB4, 
ALOX15B, HTR7, SLC18A2, PLA2G4F, 
GNG2, HTR1D, HTR3A, GNG4, 
ALOX12, PLA2G4D 
hsa04514: Cell adhesion 
molecules (CAMs) 
2.81 ICAM1, NTNG1, NTNG2, CLDN10, 
CD40, HLA-DMB, CDH4, HLA-G, 
NCAM2, ITGA8, NLGN4X, PECAM1, 
CNTN1, HLA-DOA, CD6, ICOSLG 
hsa04921: Oxytocin 
signalling pathway 
2.66 ADCY4, ADCY2, CACNG8, CACNB1, 
CACNB4, KCNJ12, TRPM2, KCNJ14, 
PRKCB, KCNJ5, KCNJ4, PLCB4, 
RYR1, PLA2G4F, NFATC1, PLA2G4D 
 




2.43 F2RL2, C5AR1, GABRB2, GRIK2, 
GRIN1, GABBR1, GRIK5, LPAR3, 
GRIA3, GRIN3B, P2RX5, GRM4, 
SSTR2, ADRB1, S1PR1, CHRM4, 
CHRNA9, SSTR1, GRIN2D, HTR7, 
CHRNA5, ADRA1A, CALCRL, HTR1D, 
CHRNA3, GRID1, MTNR1A 
hsa04024: cAMP 
signalling pathway 
2.39 ADCY4, HCN2, ADCY2, GRIN1, 
GABBR1, ATP1A3, GRIN3B, GRIA3, 
TNNI3, GLI1, SSTR2, ADRB1, SSTR1, 




2.37 SLC8A3, ADCY4, SLC8A2, ADCY2, 
CACNA1I, GRIN1, PRKCB, P2RX5, 
PLCB4, ADRB1, ATP2A3, GRIN2D, 
HTR7, CACNA1G, RYR1, ADRA1A, 
PLCD1 
hsa04014: Ras signalling 
pathway 
2.32 FGF19, FGF5, FLT4, FGF17, EFNA3, 
GRIN1, FGF11, PRKCB, RASAL1, 
HTR7, RASGRP2, PLA2G4F, PLA1A, 
GNG2, PIK3R5, NGFR, SYNGAP1, 
GNG4, RASA4, PLA2G4D, NGF 






6.65 HIST1H2AB, C7, HIST1H4L, 
HIST1H2AG, C6, HIST1H2AE, 
HIST1H2BO, HIST2H2AB, 
HIST1H2BM, HIST1H4A, HIST1H2BL, 
HIST1H2BI, HIST2H2AC, HIST1H2BJ, 
H2AFX, HIST3H2BB, HIST1H4I, 
HIST1H4J, HIST2H3A, HIST1H3J, 
HIST1H2BB, HIST1H2BC, HIST1H2BE, 
HIST1H2BF, HIST1H2BG, HIST1H2BH, 
ACTN2, HIST2H3C, HIST2H3D, 
HIST2H2BF, HIST1H3A, HIST1H3B, 
HIST1H2AI, HIST1H2AH, HIST1H3C, 
HIST1H3E, HIST1H2AJ, HIST1H3F, 




6.43 HSD3B2, CYP3A4, CYP3A5, CYP3A7, 
HSD3B1, CYP11A1, HSD17B1, 
UGT1A9, CYP7A1, UGT2B11, 
UGT2B4, HSD17B6, UGT2B10, 
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UGT2A3, SULT1E1, UGT2B15, 
AKR1D1, CYP19A1 
hsa00053: Ascorbate and 
aldarate metabolism 
5.37 UGT1A9, UGT2B11, RGN, UGT2B4, 




5.10 KNG1, F11, PLAT, MBL2, C7, MASP2, 
F13A1, C6, F9, C4BPB, C4BPA, F13B, 
F3, KLKB1, SERPINA5, SERPIND1, 
CPB2 
hsa00040: Pentose and 
glucuronate 
interconversions 
5.02 UGT1A9, KL, AKR1B10, UGT2B11, 
UGT2B4, UGT2B10, UGT2A3, 
UGT2B15 
hsa05034: Alcoholism 4.92 HIST1H2AB, HIST1H4L, HIST1H2AG, 
HIST1H2AE, HIST1H2BO, HIST2H2AB, 
HIST1H2BM, HIST1H4A, HIST1H2BL, 
HIST1H2BI, HIST2H2AC, HIST1H2BJ, 
H2AFX, HIST3H2BB, HIST1H4I, 
HIST1H4J, HIST2H3A, HIST1H3J, 
HIST1H2BB, HIST1H2BC, HIST1H2BE, 
HIST1H2BF, HIST1H2BG, HIST1H2BH, 
FOSB, HIST2H3C, HIST2H3D, 
HIST2H2BF, NTRK2, HIST1H3A, 
HIST1H3B, HIST1H2AI, HIST1H2AH, 
HIST1H3C, HIST1H3E, HIST1H2AJ, 
HIST1H3F, HIST1H2AM, HIST1H3G, 
HIST1H2AL, HIST1H3H, HIST1H3I 
hsa00982: Drug 
metabolism - cytochrome 
P450 
4.88 GSTA1, CYP3A4, GSTA2, CYP3A5, 
ALDH3B2, ADH1B, ADH1A, FMO5, 
UGT1A9, FMO1, ADH4, UGT2B11, 




4.86 CYP3A4, CYP3A5, UGT1A9, CYP3A7, 
ADH4, UGT2B11, ADH1B, UGT2B4, 
CYP26A1, HSD17B6, ADH1A, 
UGT2B10, UGT2A3, UGT2B15, RDH5 
hsa05204: Chemical 
carcinogenesis 
4.40 GSTA1, CYP3A4, GSTA2, CYP3A5, 
CYP3A7, NAT2, ADH1B, ALDH3B2, 
ADH1A, CYP3A43, UGT1A9, ADH4, 
UGT2B11, UGT2B4, UGT2A3, 
UGT2B10, UGT2B15 
hsa00983: Drug 
metabolism - other 
enzymes 
4.05 CYP3A4, UGT1A9, NAT2, UGT2B11, 
UGT2B4, UGT2B10, UGT2A3, 
UGT2B15, TK1 
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hsa00980: Metabolism of 
xenobiotics by 
cytochrome P450 
3.92 GSTA1, CYP3A4, CYP3A5, GSTA2, 
ALDH3B2, ADH1B, ADH1A, UGT1A9, 
ADH4, UGT2B11, UGT2B4, UGT2A3, 
UGT2B10, UGT2B15 
hsa04110: Cell cycle 3.01 CDC6, CDK1, PKMYT1, TTK, CDC20, 
ESPL1, PTTG1, MCM2, CDC25C, 
CCNB1, CDKN1C, MAD2L1, CCNB2, 




2.61 CCNB1, CDK1, MAD2L1, CCNB2, 
PLK1, SGO1, BUB1, FBXO43, 




misregulation in cancer 
2.36 PLAT, HIST2H3A, NFKBIZ, HIST1H3J, 
MMP9, MMP3, HIST2H3C, HIST2H3D, 
HHEX, EYA1, CDKN2C, HIST1H3A, 
HIST1H3B, HIST1H3C, HIST1H3E, 
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8.2 Appendix 2: Dysregulated genes in the TCA Cycle 
KEGG pathway 
Ensembl ID Gene Log2FC padj 
ENSG00000197444 OGDHL 1.08547769 3.29E-30 
ENSG00000166411 IDH3A 0.74709247 7.70E-20 
ENSG00000204370 SDHD 0.3777972 0.0003 
ENSG00000100412 ACO2 0.26021698 0.002 
ENSG00000146701 MDH2 0.23945724 0.0009 
ENSG00000073578 SDHA -0.1593416 0.03 
ENSG00000138413 IDH1 -0.1812103 0.03 
ENSG00000168291 PDHB -0.2026402 0.02 
ENSG00000131828 PDHA1 -0.2107741 0.01 
ENSG00000163541 SUCLG1 -0.2111892 0.006 
ENSG00000143252 SDHC -0.2414483 0.02 
ENSG00000150768 DLAT -0.2619025 0.0003 
ENSG00000091483 FH -0.4936542 1.01E-12 
ENSG00000014641 MDH1 -0.5085681 3.36E-13 
ENSG00000101365 IDH3B -0.5405112 5.07E-13 
ENSG00000067829 IDH3G -0.5829934 1.14E-09 
ENSG00000100889 PCK2 -0.5852916 3.07E-18 
ENSG00000131473 ACLY -0.6074454 9.80E-24 
ENSG00000173599 PC -0.9409933 3.13E-37 










Chapter 8  201 
8.3 Appendix 3: Dysregulated genes in the Oxidative 
Phosphorylation KEGG pathway 
Ensembl ID Gene Log2FC padj 
ENSG00000147614 ATP6V0D2 3.973933876 9.35E-140 
ENSG00000198763 ND2 1.473526224 2.53E-06 
ENSG00000198888 ND1 1.363322749 6.19E-05 
ENSG00000198840 ND3 1.217622162 2.54E-33 
ENSG00000212907 ND4L 1.095495883 0.0001 
ENSG00000198886 ND4 0.866690501 0.002 
ENSG00000114573 ATP6V1A 0.803262336 2.80E-32 
ENSG00000198804 COX1 0.656245362 1.17E-09 
ENSG00000198899 ATP6 0.634543196 0.009 
ENSG00000198938 COX3 0.632275024 2.80E-10 
ENSG00000171130 ATP6V0E2 0.589272395 2.52E-11 
ENSG00000198727 CYTB 0.557687429 0.02 
ENSG00000047249 ATP6V1H 0.506014583 5.94E-13 
ENSG00000117410 ATP6V0B 0.479535962 2.58E-11 
ENSG00000147416 ATP6V1B2 0.437789019 5.51E-09 
ENSG00000128609 NDUFA5 0.381648881 0.0008 
ENSG00000204370 SDHD 0.377797199 0.0003 
ENSG00000198712 COX2 0.322901415 0.005 
ENSG00000073578   SDHA -0.159341647 0.04 
ENSG00000023228 NDUFS1 -0.210017339 0.002 
ENSG00000112695 COX7A2 -0.211631763 0.02 
ENSG00000156467 UQCRB -0.2162753 0.03 
ENSG00000167792 NDUFV1 -0.222597617 0.007 
ENSG00000135390 ATP5MC2 -0.222831627 0.002 
ENSG00000143252 SDHC -0.24144827 0.02 
ENSG00000160194 NDUFV3 -0.242343108 0.004 
ENSG00000131100 ATP6V1E1 -0.274149444 2.61E-05 
ENSG00000189043 NDUFA4 -0.277227615 0.0001 
ENSG00000176340 COX8A -0.278696825 0.001 
ENSG00000165264 NDUFB6 -0.28300413 0.005 
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ENSG00000213619 NDUFS3 -0.29075047 0.001 
ENSG00000178741 COX5A -0.297956503 9.27E-05 
ENSG00000110719 TCIRG1 -0.300385483 0.002 
ENSG00000090266 NDUFB2 -0.301527793 0.001 
ENSG00000174886 NDUFA11 -0.318594422 0.001 
ENSG00000169021 UQCRFS1 -0.319382279 2.33E-05 
ENSG00000130414 NDUFA10 -0.320916351 3.89E-05 
ENSG00000131143 COX4I1 -0.336149045 2.75E-07 
ENSG00000158864 NDUFS2 -0.343567449 4.23E-06 
ENSG00000139180 NDUFA9 -0.357605693 0.0006 
ENSG00000004779 NDUFAB1 -0.360587197 2.52E-05 
ENSG00000184076 UQCR10 -0.375287362 3.00E-06 
ENSG00000116459 ATP5PB -0.379803823 9.50E-08 
ENSG00000126267 COX6B1 -0.388197692 3.84E-08 
ENSG00000100554 ATP6V1D -0.405728961 7.75E-08 
ENSG00000131495 NDUFA2 -0.419069805 1.65E-06 
ENSG00000115286 NDUFS7 -0.422028053 0.0002 
ENSG00000136888 ATP6V1G1 -0.428892928 2.02E-09 
ENSG00000183648 NDUFB1 -0.432392964 0.0003 
ENSG00000154518 ATP5MC3 -0.445435152 1.00E-08 
ENSG00000125356 NDUFA1 -0.459056555 2.84E-07 
ENSG00000179091 CYC1 -0.468189203 1.54E-09 
ENSG00000127540 UQCR11 -0.475454692 4.04E-09 
ENSG00000110955 ATP5F1B -0.49393262 1.83E-16 
ENSG00000099795 NDUFB7 -0.509075592 1.10E-09 
ENSG00000168653 NDUFS5 -0.520875625 8.23E-11 
ENSG00000159720 ATP6V0D1 -0.540902137 6.67E-12 
ENSG00000147123 NDUFB11 -0.542107011 1.51E-08 
ENSG00000178127 NDUFV2 -0.542969651 0.006 
ENSG00000124172 ATP5F1E -0.574462256 1.96E-13 
ENSG00000152234 ATP5F1A -0.606022757 1.10E-17 
ENSG00000140990 NDUFB10 -0.613088113 6.15E-12 
ENSG00000119013 NDUFB3 -0.65837698 2.66E-11 
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ENSG00000169020 ATP5ME -0.663226048 5.18E-18 
ENSG00000159199 ATP5MC1 -0.712677613 1.05E-19 
ENSG00000241468 ATP5MF -0.735984185 1.21E-15 
ENSG00000099624 ATP5F1D -0.737422752 3.56E-17 
ENSG00000169429 CXCL8 -0.820462236 3.09E-17 
ENSG00000164405 UQCRQ -0.860634282 1.66E-38 
ENSG00000198695 ND6 -0.979723775 1.42E-08 
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8.4 Appendix 4: GO analysis of 3’ RNA-seq data 
Pathway P value Genes 
GO:0042273~ribosomal 
large subunit biogenesis 
1.39E-06 RPL35A, RPL14, RPL7, NPM1, 
RPL26, RPL5, RPL11, RPL24 
GO:0042274~ribosomal 
small subunit biogenesis 
6.22E-05 RPS19, RPS16, RPS17, RPS14, 
NPM1, RPS6, RPS24 
GO:0006414~translational 
elongation 
3.59E-40 RPL18, RPL36A, RPL19, RPL14, 
RPL13, RPS2, RPS3, RPLP0, RPL10, 
FAU, RPL11, RPL12, RPS27A, 
RPL35A, RPS18, RPS19, RPS16, 
RPS17, RPS14, RPS12, RPS13, 
RPS11, EEF1D, EEF1B2, RPL27A, 
RPL35, RPL37, RPL38, RPL30, 
RPS27, RPL32, RPS29, RPL7, RPL6, 
RPL9, RPL34, RPL8, RPL3, RPL5, 
RPL10A, RPL7A, RPL4, RPS20, 
RPS23, RPS24, EEF1A1, EEF1A2, 
RPL26, RPL27, RPL23A, RPL24, 
RPS6, RPS5, RPS8, RPL23, 




2.23E-05 HAGH, GGT5, GPX1, CTH, GCLC, 






C8A, C8B, MBL2, CD55, C3, CLU, 
C5, C1R, C1S, CFI, C8G 
GO:0034599~cellular 
response to oxidative 
stress 
1.86E-06 EPAS1, DUOX2, DUOX1, PRDX5, 
SOD1, TPM1, SOD2, APOA4, 
PYCR1, GPX1, LONP1, HIF1A, 
HMOX1, GPX4, ETV5 
GO:0006956~complement 
activation 
8.15E-06 MBL2, MASP1, C3, C5, CLU, C1R, 




4.64E-05 TTC7A, HAMP, HPX, HMOX1, TFR2, 




4.48E-10 MBL2, YWHAZ, MASP1, C3, CLU, 
C5, C1R, C1S, AHSG, CFHR1, 
APOA2, ITIH4, CFH, CFI, FN1, F12, 
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EPHX2, SAA4, IGF2, IL6R, SIGIRR, 
C8G, C8A, ORM1, C8B, CD55, F3, 
F2, ORM2 
GO:0009896~positive 
regulation of catabolic 
process 
5.09E-05 APOA4, PPARA, APOA2, HIF1A, 
GCLC, APOA5, NDFIP1, MDM2, 




1.09E-06 ARHGEF2, LIMA1, ACTC1, ACTN4, 
CALD1, FSCN1, NEDD9, ACTN1, 
TTN, PROX1, FLNA, PPP1R9A, 
RND1, PAK2, CFL1, RHOA, RHOF, 
DBN1, PLS3, LCP1 
GO:0002449~lymphocyte 
mediated immunity 
3.13E-06 MSH6, MBL2, ICAM1, C3, CEBPG, 
CLU, C5, C1R, C1S, C8G, C8A, C8B, 




5.42E-05 MBL2, MSH6, C3, CLU, C5, C1R, 
C1S, C8G, C8A, C8B, CD55, BCL3, 
HSPD1, CFI, FAS 
GO:0006412~translation 1.99E-21 EIF6, RPL18, RPL36A, RPL19, 
RPL14, RPL13, RBM3, EIF2A, 
RPS27L, RPL22L1, RPS2, RPS3, 
EIF4EBP2, RPLP0, RPL10, FAU, 
RPL11, RPL12, POLG2, EIF2B2, 
RPS27A, RPL35A, RSL1D1, RPS18, 
RPS19, RPS16, DHX29, RPS17, 
RPS14, RPS12, RPS13, RPS11, 
EEF1D, NACA, EEF1B2, RPL27A, 
RPL35, RPL37, IGF2BP3, RPL38, 
DTD1, EIF3D, RPS27, RPL30, RPL7, 
RPL32, RPS29, EIF3H, MRPL14, 
RPL6, RPL34, RPL9, RPL8, RPL3, 
RPL5, RPL4, RPL10A, RPL7A, 
RSL24D1, RPS20, RPS23, RPS24, 
EEF1A1, EEF1A2, RPL26, RPL27, 
RPL24, RPL23A, ETF1, RPS6, RPS5, 
RPS8, EIF4B, MRPL24, RPL23, 




4.86E-06 MSH6, MBL2, ICAM1, YWHAZ, C3, 
CEBPG, CLU, C5, C1R, IL6R, C1S, 
C8G, C8A, C8B, CD55, TUBB, BCL3, 
FAS, HSPD1, CFI, RAB27A 
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8.5 Appendix 5: Promoter regions of genes with both 
altered mRNA expression and enrichment of 
5hmC 





ENSG00000181418 DDN 3.57 -2.84 
ENSG00000105131 EPHX3 2.38 -3.82 
ENSG00000086619 ERO1B 1.65 4.05 
ENSG00000147408 CSGALNACT1 1.33 3.09 
ENSG00000149927 DOC2A 1.26 -2.49 
ENSG00000142156 COL6A1 1.24 3.13 
ENSG00000137752 CASP1 0.98 2.44 
ENSG00000119900 OGFRL1 0.71 2.21 
ENSG00000145247 OCIAD2 0.71 3.02 
ENSG00000183044 ABAT -1.26 3.04 
ENSG00000144395 CCDC150 -1.50 3.36 
ENSG00000167874 TMEM88 -2.02 3.60 
 
